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N-glycosylation plays an important role in Envelope (Env) function and may be involved in 
the modulation of the immune response to HIV-1 infection. In this study, we hypothesized that 
Env N-glycosylation may affect viral pathogenesis by influencing Env structure and function. 
Furthermore, we also postulated that differences in Env glycosylation could affect interactions 
between Env and DC-SIGN of dendritic cells (DCs), activating alternative signalling pathways 
which stimulate the release of different immune modulators. We generated pseudovirus of 
eighteen Env clones (PSVs) with variable number and position of potential N-glycan sites 
(PNGs) and compared their ability to infect TZM-bl cells, bind to Raji+ DC-SIGN cells, trans-
infect TZM-bl cells when captured by either Raji-DC-SIGN cells or monocyte-derived 
dendritic cells (MDDCs) and modulate MDDC signaling by investigating the release of 
Interleukin-10 (IL-10) and other immune modulatory cytokines and MAPK activation. Entry 
efficiency, DC-SIGN binding and trans-infection varied widely across all clones. The level of 
IL-10 secreted by MDDCs in response to PSV stimulation varied 32-fold. The induction of IL-
10 secretion by purified gp140 confirmed that Env was the viral component that stimulated the 
secretion of IL-10 via interaction with DC-SIGN and potentially other undefined receptors. 
PSV and purified gp140 stimulated MDDC signaling via ERK and JNK phosphorylation, while 
p38 was not activated. The addition of recombinant DC-SIGN lowered the levels of secreted 
IL-10 and ERK /JNK phosphorylation, suggesting that DC-SIGN plays a role in these 
responses. As Env mannosylation correlated with DC-SIGN binding, five highly conserved 
Env PNGs (241, 262, 386, 392, and 448) previously identified to carry high mannose type N-
glycans and hence thought to be involved in DC-SIGN binding were deleted in two Env clones 
by site-directed mutagenesis to confirm their importance in Env function.  The potential role 
of these PNGs in Env entry efficiency, DC-SIGN binding, trans-infection, induction of MDDC 
IL-10 secretion and activation of MAPK phosphorylation was determined. Deletion of these 
sites significantly affected the entry efficiency, DC-SIGN binding, trans-infection and MDDC 
IL-10 secretion, with one Env clone proving to be more sensitive to mutation than the other. 
This suggests that PNGs influence Env function in a clone-specific manner. As deletion of 
highly conserved PNGs abrogated Env function we used sequence analysis to identify PNGs 
involved in binding DC-SIGN and inducing MDDC IL-10 secretion. We grouped PSVs based 
on the presence or absence of specific PNGs in Env sequences and compared entry efficiency, 
DC-SIGN binding, trans-infection, stimulation of MDDC IL-10 secretion and induction of 
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MAPK phosphorylation. Three Env PNGs were significantly associated with entry efficiency 
(N356, N392, and N674), and three sites (N289, N356 and 674) were significantly associated 
with trans-infection while N674 also influenced DCSIGN binding. The majority of MDDC 
donors secreted higher levels of IL-10 when stimulated with PSVs that carried PNGS at N130 
(p = 0.0016) and N332 (p = 0.0039) and lacked N674 (p = 0.033). When Envs were graded on 
whether they had 0, 1, 2 or 3 of the PNGs (e.g. -130, -332, +674; -130, +332 and +674, etc.) 
those that carried either one of the PNGs or the entire induction motif (N130+ N332+ N674-) 
significantly stimulated MDDCs to secrete higher levels of IL-10 than those that completely 
lacked the motif (p = 0.0335 and p = 0.0304, respectively). As the presence of N674 was linked 
to reduction in all functions of Env, it is likely that the presence of an N-glycan at this site 
affected Env structure and could skew the analysis. Excluding N674 indicated that the presence 
of PNGs at position 130 and 332 was sufficient to induce significantly higher IL-10 release 
than those that had either none or one of these sites (p = 0.0053). When we determined whether 
N130 and N332 were enriched in subtype C acute infection Envs, these sequences were not 
enriched with PNGs at either N130 or N332 compared to chronic infection viruses. However, 
when IL-10 levels were compared between MDDC donors stimulated with PSV of either acute 
or chronic infection clones, those from early infection significantly enhanced MDDC secretion 
of IL-10 (p = 0.0039). This suggests that even though PNGs at 130 and N332 could be involved 
in inducing MDDC IL-10 secretion, it is not the only requirement for enhanced stimulation. 
Although Env differentially activated ERK and JNK phosphorylation, ERK phosphorylation 
did not correlate with IL-10 secretion, suggesting that this MAPK signaling pathway was not 
solely responsible for triggering the release of MDDC IL-10 and other regulatory cytokines. 
PSVs also stimulated the release of TNFα, IL-1β, IL-6, IL-8, MIP-1a, and MIP-1b while having 
no effect on IL-12 levels. This suggests that HIV-1 binding to DCs in the genital tract could 
change the dynamics of DC immune responses, deregulating their cytokines secretion and 
destabilising the Th0 cell differentiation to facilitate viral survival and thus productive clinical 
infection. We therefore conclude that HIV-1 variants differentially stimulate MDDCs to release 
immunosuppressive IL-10 and that transmitted founders could be better at modulating immune 
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Chapter 1 Literature review 
1.1 Introduction 
Although the global burden of HIV-1 seems to have stabilized in terms of global prevalence, 
the total number of new cases continues to increase. Despite increased availability of 
antiretroviral therapy (ART), ART treatment remains accessible to less than half of the 37 
million infected people. Only 30 – 40% of people living with HIV in low and middle income 
countries had access to ART in 2014 (WHO, 2014; Deblonde et al., 2015; UNAIDS, 2015). 
More so, poor ART adherence and associated drug resistance are critical issues which need to 
be addressed in the development of better treatment options. More options are needed to reach 
the 2030 WHO goal of ending AIDS or making the AIDS pandemic less of a global public 
health problem (UNAIDS, 2016). Sub-Saharan Africa has the highest prevalence of HIV and 
with women in some communities still unable to negotiate safe sex, the situation might take 
longer than expected to improve. Unfortunately, the pandemic affects mostly women of child-
bearing age with 56 % of new infections in Sub-Saharan Africa in 2015 due to heterosexual 
transmission in young women  (UNAIDS, 2016).  
Despite successful programs for prevention of mother to child transmission (MTCT), about 
240 000 children born to HIV positive mothers were diagnosed globally in 2013 (United 
Nations Children’s Fund (UNICEF), 2013; UNICEF, 2014). This calls for enhanced efforts to 
find new therapeutic options to control infection and more importantly, the identification of 
novel interventions to prevent HIV transmission. New strategies to combine treatment with 
prevention are needed globally to control the growing pandemic (Hladik & Doncel, 2010). 
Although the rate per coital act is said to be as low as 0,001%, heterosexual transmission still 
accounts for most HIV-1 infections (Royce A. Rachel et al., 1997; Wawer et al., 2005; Hladik 
& McElrath, 2008; Boily et al., 2009; Gray & Wawer, 2012). Developing effective strategies 
to reduce HIV-1 transmission requires proper understanding of the initial events that take place 
at the genital mucosa during transmission.  
Attempts to decrease HIV transmission through a vaccine or microbicide are limited by an 
incomplete understanding of how HIV-1 penetrates the mucosal barriers and subsequently 
spreads to the lymphoid tissues. The virus and/or infected cells are believed to cross the 
epithelium shortly after exposure in the genital tract to infect target cell (Pope & Haase, 2003; 




However, the mechanism(s) by which the transmitted variants interact with host cells and the 
type of cells first encountered are still debated (Spira et al., 1996; Hu, Gardner & Miller, 2000; 
Zhang, Wietgrefe, et al., 2004; Hladik et al., 2007). 
The virus seems to have multiple challenges to overcome in order to infect target cells 
especially in a healthy genital mucosa. In most cases, only a single or a few variants from the 
donor’s quasispecies  succeed in establishing infection (Keele et al., 2008; Abrahams et al., 
2009; Keele & Estes, 2014), leading to a genetically homogenous viral population during the 
first weeks post infection. Variants that successfully establish infection might have biological 
properties that enable them to do so.  
Dendritic cells (DCs) have been postulated to play a role in the establishment of infection as 
they possess C-type lectin receptors (CLR) like DC specific intracellular adhesion molecule 
(ICAM)-3 non-integrin (DC-SIGN) and CD4+ as well as co-receptors required for HIV 
infection (Hong et al., 2007; Liao et al., 2011; Shen, Kappes, et al., 2014). Upon HIV binding to 
DC-SIGN, DCs translocate to the lymph nodes where they then trans-infect CD4+ T cells 
facilitating systemic infection (Geijtenbeek, Torensma, et al., 2000; Geijtenbeek et al., 2002; 
Shen, Kappes, et al., 2014).  
Previous studies have found that specific Env potential N-glycan sites (PNGs) interact with 
DC-SIGN ( Hong et al., 2007, Liao et al., 2011)  on DCs  and that myeloid DCs facilitate HIV 
transmission (Shen et al., 2014). Furthermore, studies that showed that subtype C and A 
transmitted founder (TF) Env PNG numbers were lower than those from chronic infection (CI) 
(Derdeyn et al, 2004; Chohan et al., 2005) and that site-specific PNGs of TFs were  enriched 
with high mannose (HM) N-glycans (Go et al., 2011), suggested that Env N-glycosylation 
could play a role in HIV transmission. The role of specific/combination of PNGs in interacting 
with cellular receptors at transmission is not fully understood.  
Moreover, interaction of Env with DC-SIGN on monocyte derived dendritic cells (MDDCs) 
was found to induce the secretion of IL-10, an immune suppressive cytokine (Shan et al., 2007).  
IL-10 production has also been found to enhance HIV infection (Sozzani et al., 1998; Stylianou 
et al., 1999) suggesting that HIV Env N-glycosylation could modulate DC function. A number 
of PNGs have recently been shown to form epitopes for neutralising antibodies (Scanlan et al., 
2002; Moore et al., 2012; Pritchard, Spencer, et al., 2015), suggesting that the inclusion of Env 
N-glycans in vaccine immunogens could induce neutralising adaptive immune responses. 




could lead to unwanted immune responses that reduces vaccine efficacy.  Understanding the 
role of specific/combination of Env PNGs in interacting with DC-SIGN and how this 
interaction modulates DC function to facilitate HIV transmission or disease progression will 
provide important information for the design of new strategies to prevent HIV transmission.  
An overview of the structure of the HIV virus particle, the infection process, the role of DCs 
and mechanisms of infection and the role of Env and its N-glycosylation in HIV pathogenesis 
is explored in more detail in the next sections. 
1.2 Structure of HIV 
HIV-1 is a positive stranded RNA lentivirus of the family Retroviridae. The HIV genome 
consists of two identical single stranded RNA molecules, each 9.2 kb in length, which encode 
all the structural and regulatory proteins required for the life cycle of the virus. A total of 9 
genes are encoded by the RNA. Three of these (gag, pol and env) are structural genes which 
encode for structural proteins; Gag (matrix, capsid and nucleocapsid), Pol (protease, reverse 
transcriptase) and Env proteins, all of which are found in all lentiviruses. The remaining six 
genes; vif, vpr, tat, rev, vpu and nef encode viral accessory proteins. The packaged RNA is 
tightly bound to the nucleocapsid protein, p7, a sub-protein of Gag. The enzymes required for 
virus replication such as reverse transcriptase, integrase and protease are encoded by the pol 
gene and together with the nucleocapsid are bound within the viral capsid. The capsid protein, 
p24, together with the matrix, p17, the p6 protein and the nucleocapsid are encoded by the gag 
gene. They are initially synthesized as the Gag-p55 precursor that is cleaved following 
processing into the matrix protein that stays bound to the viral membrane and the capsid which 
encloses the viral core (Mervis et al., 1988; Veronese et al., 1988; Goto, Nakai & Ikuta, 1998) 
(Figure 1.1). The outermost surface of the viral particle is composed of the spherical lipid 






A.         B. 
Figure 1.1 Structure of HIV and Envelope on the surface of the virus.  A) Adapted from 
Thomas Splettstoesser (www.scistyle.com), CC BY-SA 4.0, 
https://commons.wikimedia.org/w/index.php.curid=38751738  
B) Quaternary structure of trimeric gp120 and gp41 in unliganded form on the surface of the virion 
(Audray K. Harris et al. 2013 J. Virol. ;87:7191-7196)(Harris et al., 2013). 
 
1.3 Envelope  
Env comprises of gp120 and gp41 generated by cleavage of gp160 encoded by the env gene. 
As gp120 and gp41 units are exposed at the viral surface and make first contact with host cells, 
they are considered important HIV-1 immunogens for the generation of protective immunity 
(Goto, Nakai & Ikuta, 1998; Sierra, Kupfer & Kaiser, 2005). However, thus far, vaccines designed 
to elicit an immune response to gp120 have failed due to high variability in env  (Reviewed in 
Araujo and Almeida, 2013)(Araújo & Almeida, 2013). Env diversity is caused, most especially 
high replication rate of HIV, error prone reverse transcriptase (Araújo & Almeida, 2013) and 
the probably the pressure imposed by the large population size, but also by post translational 
modifications like N-glycosylation (Binley et al., 2002; Banerjee et al., 2009).  
Env is one of the most heavily glycosylated proteins (Zhang, Gaschen, et al., 2004) and N-glycan 
modifications are important for interaction with receptors on target cells (Ly & Stamatatos, 2000; Hong 
et al., 2007; Liao et al., 2011) and may play other roles in infection  (Wang et al., 2013), which are not 
yet known. N-glycans also mask conserved epitopes from  the immune system, and are involved in 




1.3.1 Env Biosynthesis 
Env is synthesized from bicistronic vpu/env mRNA as an unprocessed gp160 polyprotein 
precursor in the rough endoplasmic retriculum (RER). Cellular signal peptidases then cleave 
and remove the RER signal peptide co-translationally but the hydrophobic transmembrane 
domain of the gp41 prevents its complete release from the cytoplasm into the lumen of the ER 
(Reviewed in Checkley, Lutge and Freed, 2011). This is followed by addition of high mannose 
(HM) N-linked and O-linked oligosaccharide side chains during translation (Leonard et al., 
1990). Monomers of gp160 oligomerize into trimers (Poignard et al., 2001), although  some 
dimers and tetramers are also formed, and translocate to the Golgi (Earl, Koenig & Moss, 
1991). HM sugars are trimmed and complex type carbohydrates added as the Env passes 
through the Golgi  to the trans-Golgi network (TGN) (Scanlan, Offer, et al., 2007). During this 
time, Vpu remains bound to CD4 receptors to down-regulate expression and to prevent it from 
binding prematurely to the newly oligomerized Env (Fujita, Omura & Silver, 1997; Schubert 
et al., 1998; Gomez et al., 2005; Hill et al., 2008). The gp160 is then proteolytically cleaved at 
a conserved Arg-X-Lys/Arg-Arg (R-E-K/R-R) motif by furin-like proteases to give rise to the 
gp120 surface unit (SU) and the gp41 trans-membrane (TM) protein (Moulard & Decroly, 
2000; Binley et al., 2002). The two Env subunits, remain non-covalently associated, with 3 
molecules each of gp120 and gp41 forming a heterotrimer (Freed, Myers & Risser, 1989; 
Kantanen, Leinikki & Kuismanen, 1995; Staropoli et al., 2000; Harris et al., 2013), which is 
transferred and incorporated into the plasma membrane (Willey et al., 1988) (Figure 1.1 B). 
Some of the gp120 is shed upon arrival at the membrane (Egan et al., 1996; Zhu et al., 2003; 
Yang et al., 2005) due to the weak non-covalent bonds between gp120 and gp41, leaving the 
virions with few Env spikes (Bachrach et al., 2005). 
1.3.2 Env structure 
Env consist of five variable regions (V1 – V5) interspaced by five conserved regions (C1-C5) 
(Willey et al., 1986) ( Figure 1.2). Variants infecting a single donor can differ up to 20 % due 
to diversity within V1-V5 because of recombination, insertions and deletions and also point 
mutations introduced during reverse transcription. The variability is highest in the V1-V2 
regions due to differences in length and number of PNGs which were suggested to change with 
disease state (Chohan et al., 2005; Sagar et al., 2006). Predominantly, C1, C2, C3 and the V3 
regions are involved in interaction with CD4 receptor and co-receptors (Lasky et al., 1987). 




antibodies (nAbs) discovered thus far (Walker et al., 2011; Garces et al., 2014; Doores, 2015; 
Pritchard, Spencer, et al., 2015)  
 
Figure 1.2 Schematic representation of gp120 structural features The amino acids are 
illustrated by connected circles and the five variable (V1 - V5) and five constant (C1 – C5) regions are 
indicated, separated by disulphide bridges shown by short connecting lines. N-glycans are indicated by 
ц for complex type N-glycans and џ for high mannose/ hybrid types whereas Ѱ represent unknown 
glycan types (McCaffrey et al., 2004, Leonard et al., 1990).  
 
Env has about 20 cysteine residues that are covalently linked to form 10 disulphide bridges 
necessary for folding Env into its native structure (Leonard et al., 1990). Almost half of the 
molecular weight of gp120 is made up of N-glycans (Leonard et al., 1990), with about 20 – 35 
N-linked glycans in gp120 and 3 – 5 in gp41. These N-linked glycans play a critical role in 
protecting the conserved epitopes on the protein backbone from immune recognition,  folding 
of the protein and forming receptor binding sites (Montefiori, Robinson Jr. & Mitchell, 1988; 
Binley et al., 1998; Li, Chien  Jr., et al., 2008; Raska et al., 2014). Based on the orientation in 
its trimeric form, gp120 consist of an inner and an outer domain linked by bridging sheets 




Gp41 is required for trimerizeration of Env and mediates viral fusion with host cells during 
infection. It is organized into the ectodomain, TM and cytoplasmic tail (CT) (Freed, Myers & 
Risser, 1990). The ectodomain has a fusion peptide which is usually hidden within the 
gp120/gp41 core and only becomes exposed following interaction with the CD4 receptor and 
co-receptor and is inserted into the host cell membrane. The ectodomain also comprises of the 
heptad-repeat regions (HR1 and HR2) that form α-helical coiled coils, a polar region and a 
membrane proximal external region (MPER), whose interaction drives the fusion process 
(Freed, Myers & Risser, 1990; Munoz-Barroso et al., 1999). One of the driving aims of vaccine 
design is generating a form of Env expressed in high amounts that reflects the structure of 
native, functional trimers to elicit broadly neutralising immune responses. As gp41ectodomain 
is required for trimerisation, soluble gp140 was constructed lacking the TM either with or 
without cleavage sites and in some cases, stabilised by a disulphide bond. However, successful 
trimerisation required cleavage and correct N-glycosylation whereas the presence of a 
disulphide bond linking gp120 and gp41 resulted in mostly oligomeric Env (Schülke et al., 
2002; Forsell, Schief & Wyatt, 2009; AlSalmi et al., 2015). Thus gp41 plays an important role 
in the formation of functional Env trimers. 
1.3.3 Envelope processing 
Disulphide bonds form as gp160 folds in the RER and it is generally accepted that native 
trimers and soluble gp120 carry nine canonical disulphide bonds whereas gp41 has only one 
(Julien et al., 2013; Lyumkis et al., 2013; Kwon et al., 2015). However, it has also been shown 
that recombinant gp120 and gp140 have aberrant disulphide bonding patterns based on the 
exchange of bonds between different cysteine residues during folding (Go, Zhang, et al., 2011; 
Ringe et al., 2015). Native trimers carry canonical disulphide linkages because the process of 
trimerisation excludes heterodimers that are incorrectly disulphide linked. As trimerisation also 
influences N-glycosylation, there is an interdependence between native structure, disulphide bonding 
and N-glycosylation of Env (Go et al., 2016).  
The N-glycosylation of Env is very important for proper processing and folding into the correct 
conformation required for interaction with cellular receptors (Fenouillet et al., 1989; Fenouillet, 
Gluckman & Jones, 1994; Fenouillet & Jones, 1995; Land, Zonneveld & Braakman, 2003). It 
may also assist in the transport of the protein from the RER to the Golgi as well as cleavage of 
gp160 into gp120 and gp41 (Fenouillet & Jones, 1995). N-glycosylation involves the addition 




and Threonine while X  is any amino acid except Proline (Gavel & Heijne, 1990; Apweiler, 
Hermjakob & Sharon, 1999). The biosynthetic machinery of the host cell determines the 
composition and type of N-glycans added at each PNG (Go et al., 2013). This process starts in 
the ER, with the transfer of a pre-assembled oligosaccharide group (five mannose residues and 
two N-acetyl-glucosamine [GlcNAc] residues) linked to a membrane carrier lipid dolichol 
pyrophosphate to the Asparagine residue of the N-X-S/T sequon of the newly synthesized 
growing polypeptide by a series of glucosyltransferases (Yan & Lennarz, 2005; Kelleher & 
Gilmore, 2006). The oligosaccharide and dolichol complex is subsequently translocated to the 
lumen of the ER by the help of transmembrane lipid transporter enzymes, flippases (Helenius 
et al., 2002; Sanyal & Menon, 2009). Glycosyltransferases subsequently add mannose and 
glucose residues forming the Glc3Man9GlcNAc2 core (Helenius et al., 2002). Removal of 
three α-1,2 linked terminal glucose residues serve to ensure proper folding (Hebert, Garman & 
Molinari, 2005) followed by removal of mannose residues, which prepares the protein for 
proper folding and transport to the Golgi (Kornfeld & Kornfeld, 1985). 
On arrival at the cis-Golgi, more mannose moieties are trimmed off to form the Man3GlcNAc2 
molecule, which serves as a substrate for formation of complex or hybrid type N-glycans. The 
protein is then transported to the medial Golgi, where there is addition of GlcNAc to form 
hybrid N-glycans (Choi, Bobrowicz, et al., 2003; Nett et al., 2010). At times, an α 1-6 linked 
fucose residue is added to the oligosaccharide core at GlcNAc of the hybrid N-glycans formed  
of (Stein & Engleman, 1990; Crispin et al., 2006; Scanlan, Ritchie, et al., 2007). The process 
moves on to the trans-Golgi, where the N-acetyl glucosaminyl transferase (GnT) family of 
enzymes add more GlcNac moieties to the growing GlcNAcMan5GlcNAc to form complex N-
glycans. Galactose and sialic acid are subsequently added  at the terminals  to form complex 
type N-glycans (Kim, Lee & Jeong, 2009). When fully processed, Env is heterogeneously N-
glycosylated with a mixture of high mannose, hybrid and complex N-glycans and is transported 
to the plasma membrane for incorporation into the virus during budding.  
1.3.4 Function of Env N-Glycans 
1.3.4.1 Role of N-glycosylation in structure and function of Env  
Monomeric gp120 and uncleaved gp140 oligomers have been shown to carry more processed, 
complex-type N-glycans than native trimers enriched with oligomannose (Bonomelli et al., in 
press; Pritchard, Vasiljevic, et al., 2015). However, N-glycan processing only happens after the 




oligomannose or more processed N-glycans is likely a consequence of whether Env forms 
monomers or trimers. Env proteins synthesized in the presence of tunicamycin, a drug that 
inhibits N-glycosylation, led to misfolded aggregates that were biologically inactive, 
confirming that N-glycans help fold Env into its functional conformation (Fenouillet, 
Gluckman & Jones, 1994; Land, Zonneveld & Braakman, 2003) (Montefiori, Robinson Jr. & 
Mitchell, 1988). PNGs at specific regions of Env were associated with  DC-SIGN binding 
(Hong et al., 2007; Liao et al., 2011).  Mutational studies suggested that N262 and N386 form 
conformational epitopes as deletion resulted in reduced binding to antibodies like b12 and 17b 
(Pritchard, Spencer, et al., 2015) and to loss of function in other studies (Wang et al., 2013; 
Mathys et al., 2014). Some PNGs help determine viral tropism as the PNG at N301 was 
suggested to prevent CXCR4 usage favouring R5 or dual tropism (Clevestig et al., 2006), while 
N334/335 was suggested to help in CCR5 interaction (Clevestig et al., 2006). Further, a PNG 
at position 616 in gp41 was essential for incorporation of Envs into viral particles for some 
clones but not for others (Mathys & Balzarini, 2014). Therefore, the role of PNGs in Env 
function is highly variable and differs from one variant to another. 
Table 1.1 Potential N-glycan sites that play a role in Envelope phenotype  
Presence of potential N-
glycosylation site 
Envelope Phenotype Reference 
N262 and N386 Env function Wang et al., 2013; 
Mathys et al., 2014 
N301 Favours R5 and dual tropism Clevestig et al., 2006 
N334/335 Involved in binding to CCR5 Clevestig et al., 2006 
N616 Incorporation of Envs into viral 
particles 
Mathys & Balzarini, 
2014 
N230, N295, N674 Loss of Env function Mathys & Balzarini, 
2014, 2014, 2015 
N295, N332, N339, N386 
and N392; N160 and N156 or 
N173;  
Form epitopes for 2G12; PG9 and 
PG16; PGT127 and PGT128 
Scanlan et al., 2002; 
Calarese,2003; 




Pejchal et al., 2011; 
Walker et al., 2011; 
Moore et al., 2012 
N448 and N230; N301 and 
N386 
N332 
Escape from antibodies: Li, Chien  Jr., et al., 
2008; Koch et al, 
2003 
Moore et al., 2012 
 
1.3.4.2 N-glycosylation and pathogenicity 
As N-glycosylation was shown to impact Env function, by extrapolation, it will also influence 
the replicative fitness of the virus and thus HIV pathogenicity. Deletion of some conserved 
PNGs like at N262 and N386 abrogated infectivity of these PSV mutants (Wang et al., 2013; 
Mathys et al., 2014) whereas PSVs produced in the presence of  tunicamycin were non-
infectious (Montefiori, Robinson Jr. & Mitchell, 1988). In some instances, deletion of PNGs 
lead to increased infectivity as they could sterically hinder Env native structure, and impair 
viral fitness. PNGs at N230, N295 (Mathys & Balzarini, 2015) and N674 reduced infectivity 
while present but enhanced replication once deleted (Mathys & Balzarini, 2014). PNGs could 
be important for the modulation of host responses to HIV infection  as a switch in PNG position 
from N332 to N334 at six months post-infection helped subtype C Env escape neutralizing Ab 
recognition and thus enhanced virus fitness (Moore et al., 2012).  
1.3.4.3 N-glycans protect important epitopes from immune recognition 
Many studies have suggested that N-glycosylation helps the virus to escape immune pressure 
(Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006) as they shield or mask conserved 
epitopes from neutralizing antibodies as shown when deglycosylation of Env led to enhanced 
neutralization (Binley et al., 1998; Koch et al., 2003; Wei et al., 2003; McCaffrey et al., 2004; 
Li, Cleveland, et al., 2008; Walker et al., 2011) Masking of epitopes recognized by broadly 
neutralizing antibodies might have contributed to the poor immunogenicity of most Env 
immunogens (Shan et al., 2007; Banerjee et al., 2009). Examples of these are N386, which was 
found to mask the b12 epitope by steric hindrance (in some subtypes) and N301 whose deletion 




2003). PNGs at N448 and N230 have also been shown to affect proteolytic cleavage of CD4 T 
cell epitopes preventing presentation and thus activation of CD4+ and CD8+ T cells (Li, 
Chien  Jr., et al., 2008). Lastly, the reduced Env PNG number of transmitted founders  
compared to variants from chronic infection (Subtypes A and C) suggested that N-
glycosylation could  also be involved in the selection of variants for transmission (Derdeyn et 
al., 2004; Chohan et al., 2005; Sagar et al., 2006). 
1.3.4.4 N-glycosylation enhances immune recognition 
Despite protection of some epitopes by PNGs, some PNGs have however been found to be 
epitopes for broad and potent neutralizing antibodies. The 2G12 antibody recognizes  an N-
glycan epitope in the C2-C4 region, that includes PNGs at N295, N332, N339, N386 and N392 
(Scanlan et al., 2002; Calarese, 2003). Most of these PNGs  were profiled as high mannose 
type N-glycans and 2G12 was suggested to recognise α1-2 linked mannose residues (Scanlan 
et al., 2002; Calarese et al., 2003). Other classes of broadly neutralizing antibodies (bnAbs)  
including PG9 and PG16 that recognize high mannose N-glycans at N160 and N156 or N173 
and PGT127 and PGT128 that recognize epitopes linked to PNGs at N301 and N332 in the V3 
loop  were identified (McLellan et al., 2011; Pejchal et al., 2011; Walker et al., 2011; Moore 
et al., 2012). These bnAbs recognize mainly Man8 and Man9 N-glycans and were found to 
neutralize a vast array of isolates across clades.  Most recently, the mannose patch around N332 
and the V3 loop of gp120 was described as the “supersite of immune vulnerability” as they 
were recognized by the PG128 class of bnAbs. The N-glycans around this area form glycan-
glycan interactions or glycan-protein interactions that form a thick fence of N-glycans that 
prevent access of mannosidases, leading to poor/incomplete processing of the N-glycans. This 
leaves an oligomannose “patch” which cannot be processed to hybrid and complex N-glycans, 
and identifies them as non-self to the immune system. It was also found that some antibodies 
are able to extend their variable regions to penetrate the glycan shield around this area thus 
enabling binding to epitopes below the glycan shield (Pejchal et al., 2011; Pritchard, Spencer, 
et al., 2015).  
1.3.4.5 N-glycosylation and receptor interactions. 
N-glycosylation has been linked to the switch from R5 to X4 tropism (Clevestig et al., 2006), 
suggesting that N-glycans determine Env interactions with co-receptors on CD4 T cells. 




SIGN (Hong et al., 2002). The DC-SIGN binding site overlapped with 2G12 binding, 
suggesting that DC-SIGN interaction with Env gp120 might involve PNGs N295, N301 and 
N386 (Hong et al., 2002). Furthermore, this same group and later Liao et al. (2011) identified 
PNGs by deletion mutagenesis named the DC-SIGN interactive domains which included N276, 
N295, N356, N386 and N392, as they were involved in binding to DC-SIGN. Liao et al did not 
test functionality of the deletion mutants and loss of PNGs could have abrogated Env function 
and thus likely structure, as in the case of N386 (Wang et al., 2013; Mathys et al., 2014). In 
addition, the interaction was suggested to favour mostly high mannose type N-glycans. Env 
expressed in cells that add mostly mannose type N-glycans were found to enhance the 
interaction between Env and DC-SIGN (Lin et al., 2003; Eggink et al., 2010; van Montfort et 
al., 2011). This suggested that high mannose type N-glycans were important to bind DC-SIGN. 
Interaction with DC-SIGN also leads to the release of the immune suppressor, IL-10 by 
MDDCs (Shan et al., 2007). DC-SIGN-initiated immunosuppressive responses raises the 
concern that poor immunogenicity of past vaccine candidates may be due to gp120 N-glycans. 
Therefore, further research into the effects of N-glycosylation on the regulation of the immune 
response by DCs could be very important for future vaccine design.  
1.4 HIV transmission 
1.4.1 Mechanisms of HIV transmission 
Infection of HIV is a multi-step process, whereby the Env mediates attachment of the virus to 
the host cell by sequential binding to the CD4 receptor and then to co-receptors, CCR5 or 
CXCR4. This is followed by conformational changes that leads to fusion of the viral and host 
cell membranes and then transfer of the viral components into the host cell (Maddon et al., 
1986; McDougal et al., 1986, 1991; Jones, Korte & Blumenthal, 1998; Sullivan et al., 1998). 
Although HIV infection occurs via multiple routes: parenteral, intra-partum, homosexual and 
heterosexual intercourse, heterosexual transmission accounts for about 70% of HIV infections, 
despite the low per coital transmission rate (Wawer et al., 2005; Hladik & McElrath, 2008; 
Boily et al., 2009; Gray & Wawer, 2012).  
Multiple mechanisms have been proposed to explain the low per coital infection rate of HIV. 
Firstly, physically protective barriers such as the genital mucosa and the stratified squamous 
epithelial (SSE) layer of cells are protection against incoming pathogens (Haase, 2011). There  




Miller, 2000; Hladik et al., 2007) and are found mostly in the lamina propria, to which the virus 
has poor access. However, some authors hold that HIV directly infects T cells in the genital 
mucosa, resulting in systemic, productive infection  (Zhang, Wietgrefe, et al., 2004).  
There are also local immune responses from cells in the female genital tract (FGT) (Reis 
Machado et al., 2014) from DCs and other innate immune cells of monocyte lineage. DCs are 
expected to bind HIV via pathogen capture receptors including DC-SIGN and other C-type 
lectins expressed on the cell surface, undergo maturation and present antigens to CD4 T cells 
in the lymph nodes, triggering an adaptive immune response (Steinman, 1991; Banchereau & 
Steinman, 1998; Steinman & Hemmi, 2006). It has been suggested, however, that HIV is able 
to hijack this process, facilitating its transmission and sustained replication (Geijtenbeek, 
Kwon, et al., 2000; Kwon et al., 2002; Parrish et al., 2013; Shen, Kappes, et al., 2014) 
1.4.2 Biological features of transmitted viruses  
Highly homogenous variants are transmitted during mucosal HIV-1 transmission in healthy 
individuals (Wolfs et al., 1992; Zhang et al., 1993). Typically, heterosexual transmission has 
been characterized by a genetic bottleneck, whereby 80% of productive infections are initiated 
by a single variant despite the  diverse quasi-species circulating in the infected donor (Keele et 
al., 2008; Abrahams et al., 2009; Keele & Estes, 2014). This was further confirmed in non-
human primates models (Rhesus Macaques) inoculated with diverse SIVmac251 or 
SIVsmmE660 where only one or few variants  established productive infection 1 - 5 weeks 
post inoculation (Keele & Derdeyn, 2009). This is unlike transmission in the presence of 
sexually transmitted infections (STI’s), where the mucosal barrier is compromised and 
infection with more than one variant takes place (Haaland et al., 2009). Whether transmission 
of a single variant happens randomly or whether the transmitted founders (TFs) possess specific 
biological properties (Shaw & Hunter, 2012) that give them an advantage over those not 
transmitted has been a subject of research for some time now.  
1.4.3 The role of Env in HIV transmission 
1.4.3.1 Phenotypic properties of HIV-1 transmitted founder Envs 
Previous studies have attempted to characterize TF Envs and the properties that could influence 
their likelihood of transmission (Table1.1). A common characteristic of TFs is their ability to 
use CCR5 for entry and it was previously suggested that R5 tropism was due to the availability 




are not macrophage-tropic, require high CCR5 density and are more sensitive to CCR5 
inhibitors (Berger, Murphy & Farber, 1999; Parker et al., 2012; Ping et al., 2013). Furthermore, 
when Etemad et al. (2009) took the V1-V5 region from early and chronic variants and cloned 
it into an isogenic HIV backbone to generate chimeric infectious molecular clones (IMCs), the 
chronic infection variants replicated to higher titers in cells with lower CCR5 levels compared 
to those from early infection, suggesting that TF variants might require higher levels of CCR5 
for infection (Etemad et al., 2009). 
On the contrary, when 8 transmission pairs were evaluated for differences in co-receptor 
utilization, it was shown that both TFs and chronic infection viruses had a requirement for high 
CD4 and CCR5 levels and utilized alternative receptors similarly (Isaac-Beck et al., 2009).This 
was supported when Willen et al. (2011) compared the Env from 24 transmitted/founder 
viruses to 17 from chronic infection in a pseudotyped assay for their ability to utilize CCR5, 
CD4+ subset cell tropism, fusion kinetics and dendritic cell trans-infection. They found that 
the TFs were only marginally more sensitive to CD4 binding site antibodies than those from 
chronic infection. TFs had increased sensitivity to neutralizing antibodies (like b12 and 
VRC01) and pooled HIV hyper-immune immunoglobulin [HIVIG] (Wilen et al., 2011), or 
preferentially bound a subset of CD4+ T cells with increased α4β7 integrin levels (Arthos et 
al., 2008; Cicala, Arthos & Fauci, 2011; Nawaz et al., 2011). However when this was tested 
using a panel of SGA derived env clones from 20 acute and 20 chronic infection variants from 
different participants, there was no difference in 47 reactivity, utilisation of CD4 and CCR5 
nor sensitivity to CD4 binding antibodies (Parrish et al., 2013). These variants were also  
suggested to replicate more efficiently  in CD4+ T cells while others were found to have  
enhanced binding to DC-SIGN receptor relative to chronic infection clones (Parrish et al., 
2013; Ping et al., 2013). These conflicting results (table 1.1) could suggest that different 
approaches that include the use of pseudoviruses and IMC’s and transmitted founder and 




Table 1.2 Phenotypic characterisation of transmitted founder HIV-1 variants. 




Sensitivity to CD4 binding 
site Abs (b12, VRC01 and 
pooled HIV IgG  
B Increased *Wilen et al., 2011; Parker et al., 
2012; Parrish et al., 2013) 
Sensitivity to neutralization 
by autologous Abs, but not 
heterologous 
C Increased (Derdeyn et al., 2004) 
Sensitivity to CCR5 inhibitor 
(Maraviroc) 
C, B Increased #Parker et al., 2012; Ping et al., 
2013) 
Receptor tropism C More CD4  
dependence, enhanced 
replication in CD4+ 
cells 
Ping et al., 2013  
Parrish et al., 2013 
PNG at position 415 involved 
in escape from autologous 
Abs 
B PNG at 415 
underrepresented in 
T/F 
Gnanakaran et al., 2011 
 PNGs at N234,  N442, N611 
and N625 associated with 
sensitivity to Ab 
C Less represented in 
T/F 
Ping et al., 2013 
 
Replication in primary CD4+ 
T cells 
B Similar kinetics Parrish et al., 2013 
MDDC capture & enhanced 
interaction with vaginal 
myeloid DCs and transfer to 
CD4+ cells 
B, C Enhanced de Witte, Nabatov & Geijtenbeek, 
2008; Parrish et al., 2013; Shen, 
Kappes, et al., 2014 
Concentration of Env particles 
per virus 
B, C Increased (Parrish et al., 2013) 
IFN resistance B More resistant (Parrish et al., 2013) 
Interaction with Langerin on 
LCs/infection of LCs 
 Both (Kawamura et al., 2005; Hladik et 
al., 2007; de Witte, Nabatov & 
Geijtenbeek, 2008) 




(Arthos et al., 2008; Cicala, Arthos 
& Fauci, 2011; Nawaz et al., 2011) 
Parrish et al, 2013 
#Parrish et al., 2013, used infectious molecular clones (IMC), not paired samples while Parker et al., 
2012 samples were not paired but used IMC.  





1.4.3.2 Genotypic properties of early founder viruses 
Genotypic properties identified in subtypes A, C and D early founder viruses included shorter 
variable loop length with fewer PNGs (Chohan et al., 2005; Sagar et al., 2006) but this was not 
apparent for subtype B TFs (Frost et al., 2005). PNG numbers increased during the course of 
infection with insertions/deletions and shifting of PNG positions likely due to escape from 
immune pressure as TFs have increased sensitivity to neutralizing antibodies (Derdeyn et al., 
2004; Sagar et al., 2006). Whereas previous studies found that early founder viruses encode 
Env sequences closer to the ancestral sequence (Herbeck et al., 2006; Sagar et al., 2009), 
variants from chronic infection were generally more diverse. In subtype B variants, a Histidine 
or basic amino acid was more frequent at position 12 of the signal peptide of early founder 
variants, which enhanced Env expression, incorporation into viral particles and infectivity. 
Lack of or underrepresentation of a PNG at N234,  N442, N611 and N625 (Ping et al., 2013) 
and  N415 (Asmal et al., 2011; Gnanakaran et al., 2011) compared to chronic infection clones 
was also identified in subtype B TFs.  Furthermore, PNGs at positions N241, N262, N386, 
N392 and N448 of subtypes B and C Envs were specifically enriched with high mannose type 
N-glycans in TFs, unlike Envs isolated at chronic infection (Go, Hewawasam, et al., 2011). 
These findings coupled with the change in number and reshuffling of PNGs and  the importance 
of mannose N glycans in interaction with DC-SIGN (Lin et al., 2003; Eggink et al., 2010; van 
Montfort et al., 2011) led to the suggestion that Env N-glycosylation might play a role in the 
selective interaction of some variants with genital mucosal DCs for transmission and 
productive infection. 
1.5 The Genital mucosa barrier 
The vaginal epithelium is composed of many layers of SSE with a thickness ranging from 200 
to 300 µm of tightly packed cells separating the mucus membrane from the lamina propria and 
an underlying vascular sub-mucosa. The mucus membrane, epithelium and lamina propria 
comprise the mucosa. SSE is made up of four zones: basal, squamous, granular and cornified 
layers (Miller & Shattock, 2003; Haynes & Shattock, 2008). The cells of the epithelium as well 
as the more fragile single cell layer epithelium of the endocervix, are held together by proteins 
that form desmosomes, tight junctions, and adherens junctions, whose permeability fluctuates 




Trauma during sexual intercourse and co-STI-infections could lead to tears in the epithelial 
layers that allow passage of HIV despite mucus covering the endo-cervical epithelium  
(Haaland et al., 2009). Ecto- and endo-cervical epithelial and endometrial mucosae have been 
suggested to be involved in HIV transmission through transcytosis of the virus across tight 
junctions. Some studies suggested that endocytosed virus was stored prior to transfer to target 
cells (Wu, Chen & Philips, 2003; de Witte, Bobardt, et al., 2007; Kinlock et al., 2014). It was 
also suggested that DCs and Langerhans cells (LCs) are interspersed within the vaginal lumen 
and the lamina propria (Figure 1.3). DCs and LCs  extend their dendrites  into the mucosa to 
sense pathogens, trap virus and can either return to the epithelium or travel  with bound virus 
to the sub-epithelium to infect target cells (Hu, Gardner & Miller, 2000; Miller & Shattock, 
2003; Miller et al., 2005). Studies in rhesus macaques showed that DCs and LCs were the 
predominant target cell type infected within 24 – 72 hours post intravaginal inoculation (Haase, 
2011). Using vaginal tissues explants, DCs were also the major cell type infected following 
inoculation (Shen et al., 2014) although Zhang et al. (1999) detected viral RNA (vRNA) mostly  
in CD4+ T cells in the endocervix (Zhang et al., 1999) following inoculation. The latter study 
did indicate that breaks in the single epithelial layer lining the cervix might have compromised 
the genital tract barrier, leading to infection of CD4+ T cells present at higher numbers in this 
region (Zhang et al., 1999) which could explain why vRNA was detected in very few DCs and 
macrophages (Zhang et al., 1999). In non-human primates, foci of productively infected cells 
have been found in the endocervix early in infection, (Li, Estes, et al., 2009; Haase, 2010) 
although they did not specify if virus was captured by other cell types before delivery to CD4+ 
T cells.  
Bobardt et al. (2007) further suggested that primary genital epithelial cells expressed  
galactosyl ceramide (GalCer) and proteoglycans such as chondroitin sulfate proteoglycans 
(CSPGs) and heparan sulfate proteoglycans (HSPGs) that promote HIV attachment to these 
primary epithelial cells (Bobardt et al., 2007; Magerus-Chatinet et al., 2007). Furthermore, it 
was suggested that epithelial cells in this area are capable of producing chemokines which help 
recruit plasmatoid (pDC)  to the basolateral surface of the cervical epithelium  (Li, Estes, et al., 
2009; Nazli et al., 2010). Nazli et al. (2010) found, using genital and intestinal epithelial cell 
line models that HIV induced a chemokine concentration gradient, opening up tight junctions 
and allowing target cells from underlying layers to gain access to virus (Nazli et al., 2010) . 




layers were exposed to virus, gp120 attracted DC-SIGN-expressing cells that made contact 
with the virus (Cavarelli et al., 2013).  
1.6 Mechanism of Dendritic Cell mediated transmission 
DCs and macrophages are frequently present at the sub-epithelium of the genital mucosa (Spira 
et al., 1996; Hu, Gardner & Miller, 2000; Hladik et al., 2007) and are permissive to HIV 
infection although with poor efficiency (Lee et al., 1999; Wu & KewalRamani, 2006).  
However, other studies have suggested that despite their limited susceptibility to infection 
(Smed-sörensen et al., 2005), DCs play a facilitating role by binding HIV in the genital mucosa 
and transferring virus to CD4+ T cells in the sub-epithelium or lamina propria, and/or  
translocate to the proximal lymph nodes and trans-infect  CD4+ T cells (Curtis, Scharnowske 
& Watson, 1992; Geijtenbeek, Torensma, et al., 2000; Wu & KewalRamani, 2006) (Figure 
1.3).  
 
Figure 1.3 Structure and arrangement of genital tract tissues. Normal vaginal epithelium 
comprises a multi-cellular layer of stratified squamous epithelial cells. Intra-epithelial dendritic cells 
(DCs) or Langerhans cells (LCs) extend processes into the vaginal lumen, bind virus and infect CD4+ 
T cells in the sub-epithelium. Within hours after exposure, CD4+ T cells in the sub-epithelium are 
infected as well as sub-epithelial DCs and macrophages expressing mannose-binding C-type lectins. 
Shortly thereafter, the virus can be found in nearby lymphoid tissues (Lederman, Offord & Hartley, 




Alternatively, studies in non-human primate models suggested that DCs took up and protected 
virus until inflammation attracted increasing numbers of activated CD4+ T cells to the mucosa 
for local amplification before dissemination to lymphoid tissues (Hu, Gardner & Miller, 2000; 
Miller & Shattock, 2003; Miller et al., 2005; Hladik et al., 2007). 
1.6.1 DCs and their contribution to HIV infection 
DCs are located in all peripheral tissues and function in immune surveillance as professional 
antigen presenting cells (APCs). They possess multiple pattern recognition receptors (PRR) 
[toll like receptors (TLR) and CLRs] for capturing antigens, including HIV. They are able to 
initiate both innate and adaptive immune responses upon pathogen encounter, and modulate 
the immune response. Upon antigen capture, they traffic to secondary lymphoid tissues to 
present antigens to naïve T cells to initiate an adaptive immune response (Banchereau & 
Steinman, 1998; Banchereau et al., 2000; Pulendran, 2001). Once they recognize a pathogen, 
DCs mature and induce the expression of pro-inflammatory cytokines (Janeway & Medzhitov, 
2002; Iwasaki & Medzhitov, 2004; Medzhitov, 2007)(Huppa JB and Davis MM, 2003) during 
antigen (Ag) presentation to T cells via MHC-T cell receptor (TCR) complexes. They also up-
regulate co-stimulatory molecules to enhance T cell priming and produce cytokines to initiate 
and maintain the adaptive immune response (Banchereau & Steinman, 1998; Banchereau et al., 
2000). During Ag presentation, an immunological synapse forms that HIV uses as a 
“virological/infectious synapse” that aids efficient transfer of virus to CD4+ T cells 
(McDonald, 2003). In vitro studies found this method led to enhanced infection levels 
(Cameron et al., 1992; Kwon et al., 2002; Wu & KewalRamani, 2006; Piguet & Steinman, 
2007; Reyes-Rodriguez, Reuter & McDonald, 2016).  
1.6.1.1 DC subtypes and roles in HIV transmission 
DCs include myeloid (mDCs), pDCs and LCs. Although mDCs and pDCs are involved in HIV 
infection the role of LCs is still debated (Kawamura, 2000; Kawamura et al., 2005; de Witte, 
Nabatov, et al., 2007). Although both are involved in HIV transmission, mDCs which are 
located in mucosal surfaces are more susceptible to HIV infection than pDCs (located mostly 
in tissues but also in blood). pDCs play more often an antiviral role as they secrete antiviral 
interferons (Granelli-Piperno et al., 2004; Smed-sörensen et al., 2005).  
 As LCs are located in the sub-epithelium (Figure 1.3) and extend their processes to sample 




Hu, Gardner & Miller, 2000). They  capture the virus using langerin, a CLR and target virus to 
the Birbeck granules, a special organelle/compartment for degradation (de Witte, Nabatov, et 
al., 2007). Since they also possess CD4 and CCR5, some authors argue that LCs become 
infected when high viral loads lead to saturation of langerin.  It has been suggested that this 
could be one mechanism to explain why TFs are R5 tropic as LCs do not express CXCR4 
(Sozzani et al., 2000; Kawamura et al., 2005; de Witte, Nabatov & Geijtenbeek, 2008). Other 
studies suggest  LCs are not infected by HIV but instead bind virus in the vaginal lumen and 
infect CD4+ T cells in the sub-mucosa (Kawamura et al., 2005; Hladik et al., 2007) because of 
their strategic location (de Witte, Nabatov & Geijtenbeek, 2008). Studies conducted in vitro on 
mDCs, pDCs and MDDCs suggested that DCs are infected with HIV as well as sequester 
infectious virus in endosomal compartments for transfer to CD4+ T cells (Loré et al., 2005; 
Nobile et al., 2005). The consistency between findings using mDCs, pDCs and MDDCs 
suggests that these cells have similar properties and morphology. This is important as mDCs 
and pDCs are difficult to isolate and most experiments utilise MDDCs differentiated from 
CD14+ monocytes to mDCs (Sallusto & Lanzavecchia, 1994).  
1.6.1.2 Cis- and trans-infection 
1.6.1.2.1 Cis- infection 
DCs facilitate HIV transmission and have been found to play a critical role in dissemination at 
local mucosal sites and systemic spread (Wu & KewalRamani, 2006; Piguet & Steinman, 2007; 
Rinaldo, 2013; Ahmed et al., 2015). All subsets of DCs are poorly infected most likely due to 
low levels of CD4 and CCR5 expression  (Lee et al., 1999). MDDCs express 10- to 100-fold 
lower levels compared to CD4+ T cells (Wu & KewalRamani, 2006). Furthermore, DCs have 
interferon (IFN) dependent and independent restriction factors like apolipoprotein B mRNA-
editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), a Cytidine deaminase human 
enzyme which introduces G-A mutations in the HIV genome. APOBEC3G is found in DCs 
and CD4+ T cells and was upregulated after SIV inoculation in a macaque study (Pido-Lopez 
et al., 2007). Other HIV restriction factors include Sterile A motif and HD-domain containing 
1 (SAMHDI) which has RNAse activity and hydrolyzes deoxyribonucleotides in cells, thus 
limiting nucleotide availability for reverse transcription (Pion et al., 2006), Tripartite motif 5α 
(TRIM5α) and tetherin. These limit viral replication in DC subsets, macrophages and 
sometimes T cells (Pion et al., 2006; Huthoff & Towers, 2008).  SAMHDI is specific for 




inhibition is reduced by high SAMHDI levels (Bloch et al., 2014).  Poor replication in DCs 
however could still produce sufficient virus (de novo virus) to infect T cells in trans. In 
addition, apart from helping virus dissemination, viral uptake by DCs could lead to latent viral 
reservoirs (Kwon et al., 2002; Reyes-Rodriguez, Reuter & McDonald, 2016). 
1.6.1..2.2 CLR dependent trans-infection 
The binding and transfer of HIV to T cells by DCs without being infected themselves is termed 
trans-infection and involves cell to cell contact (Geijtenbeek, Torensma, et al., 2000; Kwon et 
al., 2002). Trans-infection was suggested to play a key role in virus spread and dissemination 
as the virus needs to reach the lymphoid tissues to replicate to high levels to establish systematic 
infection (Geijtenbeek, Kwon, et al., 2000). When T cells were co-cultured with HIV-1 pulsed 
DCs, infection was higher than when T cells were directly infected with the same amount of 
virus (Cameron et al., 1992). Curtis et al. (1992) found that the binding and transfer of HIV by 
DCs was via interaction with gp120 in a CD4 independent mechanism, but via an unidentified 
CLR (Curtis, Scharnowske & Watson, 1992). Further studies by Geijtenbeek et al. (2000) 
found that HIV gp120 bound MDDCs through a mannose binding CLR (MCLR), DC-SIGN 
(Geijtenbeek, Kwon, et al., 2000; Geijtenbeek, Torensma, et al., 2000).  It was suggested that 
DCs take up the virus, sequester and protect it in an infectious form before  transferring to T 
cells across an infectious synapse (Geijtenbeek, Kwon, et al., 2000; Kwon et al., 2002). Once 
virus is taken up into the endosomal compartment, Env stays bound to DC-SIGN, which helps 
recycle the virus to the surface upon encounter with a T cell. The Env-DC-SIGN complex is 
concentrated at sites in contact with the T cells, which then recruit CD4 and co-receptors 
forming the infectious/virological synapse (Figure 1.4 A). Hence, both DC-SIGN and T cell 
receptors are required for formation of the adhesive junction between the two cells (McDonald, 
2003). Adhesion molecules: ICAM-1, ICAM-3 and LFA-1, enhance the strength of the synapse 
and ensure efficient transfer of the virus to the T cells.  
Trans-infection was initially demonstrated in MDDCs, but was also later shown in mucosal 
and dermal DCs, which also express DC-SIGN. However, the fate of virus taken up by DCs 
remains debatable (Gummuluru, KewalRamani & Emerman, 2002; Wu & KewalRamani, 
2006). While some studies suggested that immature DCs can retain infectious virus for up to 
six days following exposure (Figure 1.4, A) (Geijtenbeek, Kwon, et al., 2000; Kwon et al., 
2002; McDonald, 2003), other studies found that virus taken up by MDDCs is degraded within 




(Figure 1.4, C). Turville et al. (2004) then suggested a “two phase” mechanism of DC-mediated 
HIV transfer. The first phase occurs within 24 hours when endosomally recycled virus are 
transferred to T cells (Figure 1.4, A) and the second phase involves the transfer of de novo R5 
viruses after 24 hours (Turville et al., 2004). This was supported by studies conducted with 
mDCs and pDCs (Loré et al., 2005; Nobile et al., 2005).  
Other studies found that following binding of Env to DC-SIGN on DCs, some of the virus was 
taken up into multivesicular bodies (MVB) (Figure 1.4 B) rich in tetraspannins (CD81). These 
variants were translocated by formation of DC vacuoles (Gummuluru, KewalRamani & 
Emerman, 2002) that budded into T cells upon contact with DCs in a gp120 independent 
manner, transferring the virus by exocytosis. The virus taken up into MVB escapes degradation 
and survives in acidic, non-lysosomal compartments and binding to DC-SIGN helps in the 
uptake process (Gummuluru, KewalRamani & Emerman, 2002)..  
DCs express other CLRs able to bind HIV and trans-infect T cells, including Mannose receptor 
(MR) and DC immunoreceptor (DCIR) (Turville et al., 2001; Lambert et al., 2008).   
Irrespective of the mechanism, transfer of HIV to CD4+ T cells by DCs is in conflict with its 
role as immune sentinels (Steinman, 1991, 2000; Banchereau & Steinman, 1998). Instead, DCs 
are hijacked by HIV which subverts their function to get access to T cell rich areas. How this 





Figure 1.4 Mechanisms of DC-mediated HIV-1 transmissions. Incoming HIV-1 can be 
transmitted from DCs to CD4+ T cells by three distinct mechanisms. A: trans-infection via the 
virological synapse: HIV-1 binds to DC-SIGN on the DC surface and taken up into endosomal 
compartments. When DCs make contact with CD4+ T cells, a virological synapse is formed stabilized 
by interactions between ICAM-1 and LFA-1. The CD4+ T cell extends a filipodium, by actin 
cytoskeleton rearrangements, into the pocket on the DC surface to capture the HIV-1 while 
concentrating its CD4 and co-receptors at the surface. B: trans-infection via the exosome secretory 
pathway where endocytosed virus form multi-vesicular bodies and is released in association with 
exosomes to infect nearby CD4+ T cells. C: cis-infection where following binding to DC-SIGN and 
CD4/co-receptors, HIV-1 enters DCs by fusion with CD4 and co-receptors and replicate to generate de 
novo infectious HIV-1 that infect nearby CD4+ T cells (Coleman, St Gelais & Wu, 2013) Adv. Exp. 
Med. Biol. 2013; 762: 109–130.  doi:  10.1007/978-1-4614-4433-6_4 
1.6.1.3 CLR-independent transfer of HIV by DCS  
Besides CLR-mediated DC transfer of virus to T cells, there are other Env-CLR independent 
attachment factors on some DCs subsets. These include Syndecan-3, a DC-specific heparin 
sulfate (HS) proteoglycan that binds to Env via charged basic interactions and stabilizes virus-
DC interaction to favour cis-infection (de Witte, Bobardt, et al., 2007).   Glycosylphospholipids 
(GSLs) are Env independent methods of virus transfer by MDDCs. 
Trisialotetrahexosylganglioside (GM3) (and also GM1) are incorporated into virions as it buds  







Contreras, et al., 2012). Gangliosides are highly sialylated GSLs, with terminal α-2, 3 sialic-
acid residues that bind to CD169, a sialoadhesin (also called Siglec-1) on mature MDDCs 
(Puryear et al., 2012) that enable transfer of captured virus to T cells. CD169 capture of HIV 
has two mechanisms: 1) a gp120-independent one which uses GSLs on mature MDDCs and  
2) a gp120-dependent mechanism observed in macrophages (Puryear et al., 2012; Kijewski & 
Gummurulu, 2015). Galactosyl ceramide (GalCer) is another receptor expressed on immature 
MDDCs (iMDDCs) and primary DCs isolated from human blood, mucosal tissue and epithelial 
cells. GalCers capture HIV-1 through gp41 and mediate transfer of virus to CD4+ cells 
(Magerus-Chatinet et al., 2007).  
1.7 DC-SIGN-mediated regulation of DC immune responses  
To facilitate their survival pathogens  have evolved to use DC-SIGN or other CLRs  to activate 
a DC-specific signaling mechanism to sabotage TLR-dependent responses (Geijtenbeek et al., 
2003; Van Kooyk, Appelmelk & Geijtenbeek, 2003). HIV-stimulated DC-SIGN-mediated 
signaling in conjunction with TLR8 activation, recruited pTEF (transcription elongation factor) 
to the NF-KB promoter, which led to full-length HIV transcripts (Gringhuis et al., 2010). 
Furthermore, HIV-DC-SIGN stimulated signaling increased Rho-GTPase activity required for 
the formation of DC-SIGN-mediated virological synapses (Hodges et al., 2007). The 
immunological consequences of HIV-induced DC signalling are not fully understood. 
It has been suggested that pathogens or pathogenic products that induce IL-10 expression could 
to subvert DC function to favour immune suppression and thus pathogen survival (Geijtenbeek 
et al., 2003; van Kooyk & Geijtenbeek, 2003; Geijtenbeek & Gringhuis, 2009). The interaction 
of DC MCLR  with gp120 was suggested to induce the secretion of immunosuppressive 
cytokines like IL-10 (Shan et al., 2007), while impairing DC maturation and IL-12 secretion 
(Fantuzzi et al., 2004; Granelli-Piperno et al., 2004). This was accompanied by impaired up-
regulation of co-stimulatory and MHC class II molecules. Env-DC-SIGN induced IL-10 
secretion resulted from activation and phosphorylation of ERK (Shan et al., 2007) while DC-
SIGN-mediated  modulation of the TLR-dependent activation of NF-kB for inflammatory gene 
expression  also enhanced IL-10 expression (Geijtenbeek & Gringhuis, 2009). Understanding 
how HIV-1 modulates DC-SIGN-meditated modulation of DC IL-10 production and ERK 
phosphorylation is important for the development of a vaccine that does not result in immune 




Enhanced IL-10 production  was due to DC-SIGN-mediated activation of NF-KB via Raf-1 
(Gringhuis et al., 2007). Raf-1 activation was influenced by the type of carbohydrate on the 
PAMP/pathogen as mannose-containing pathogens induced responses different from those that 
carried fucose (Gringhuis et al., 2009). MAPKs are well known downstream effectors of Raf-
1 (Wellbrock, Karasarides & Marais, 2004) (Figure 1.6), but Raf-1 activation by ManLAM in 
the absence of other TLR ligands did not lead to ERK activation (Gringhuis et al., 2007). 
However, other DC-SIGN ligands have been found to activate ERK. Capparos et al. (2006) 
found that ERK was phosphorylated in response to an anti-DC-SIGN antibody (MR-1) binding 
to DC-SIGN of MDDCs, ThP-1 and Jurkat cells (Caparros et al., 2006). Furthermore, studies 
by Shreffler et al. (2006) found that ligation of DC-SIGN by Schistosoma mansoni egg antigen 
led to activation of ERK. Zhao et al (2013) also found that the ligation of DC-SIGN by E2 of 
hepatitis C Env activated ERK. Moreover, Hsu  et al (2010) found that a Bermuda  grass 
protein, BG60 also activated ERK together with Raf-1 following binding to DC-SIGN 
(Caparros et al., 2006; Shreffler et al., 2006; Hsu et al., 2010; Zhao et al., 2013).  Further studies 
by Gringhuis et al. (2009) found that DC-SIGN ligation led to the activation of Raf-1 kinase 
and to the modulation of TLR induced production of cytokines (Gringhuis et al., 2007; 
Geijtenbeek & Gringhuis, 2009) as well as acetylation of the p65 subunit of NF-кB. Modulation 
of TLR activation of inflammatory cytokine expression depends on the type of carbohydrate 
on the PAMP/ligand. While HIV and Mycobacterium tuberculosis, which carry mostly 
mannose type N-glycans induced Raf-1, Helicobacter pylori, which carry Fucose did not 
induce Raf-1 phosphorylation (Geijtenbeek & Gringhuis, 2009; Gringhuis et al., 2009), 
although both pathogens lead to enhanced IL-10 expression. As Shan et al. (2007) also found 
that HIV-1 Env mannose type N-glycans activated MDDC ERK leading to IL-10 production, 
(Shan et al., 2007) signaling downstream of Raf-1 could differ depending on variation in Env 
N-glycosylation. Taken together, these studies suggest that PAMPs with different 
carbohydrates may differentially influence the activation of signaling pathways via binding 
DC-SIGN and modulating TLR-mediated signaling via Raf-1. The impact of differential HIV-
1 Env N-glycosylation on mitogen activated protein kinases (MAPK) activation is not known.  
Dysregulation of DC-SIGN-activated immune responses was also shown to tilt the Th1/Th2 
balance in favour of Th2 and regulatory T cell phenotypes (Clerici & Shearer, 1993; Clerici et 
al., 1993; Chehimi et al., 1994), but the impact of N-glycosylation on Th0 polarization is not 
well understood. Given that activation of DC-SIGN signaling could impact adaptive immune 




cytokines by MDDCs. In view of the role of carbohydrates in DC DC-SIGN-mediated-
signaling, we hypothesized that HIV Env N-glycosylation may have a role in modulating DC 
responses given that DC-SIGN binds gp120 N-glycans. 
1.8 Cytokines regulate DC function 
Cytokines are soluble mediators, which together with other inflammatory mediators like 
chemokines represent the effector phase of the innate immune response. They are secreted 
following ligand binding to pattern recognition receptors (PRR) such as TLRs and CLRs on 
DCs. Cytokine production is considered very important in HIV infection as cytokines produced 
by the innate immune system determines the strength of an adaptive immune response (Borish 
& Steinke, 2003). The types of cytokines produced following PAMP signaling depend on the 
pathogen so that the appropriate immune responses are initiated. PRRs are differentially 
distributed on inflammatory cells so that immune cells recognize different classes of PAMPs 
and induce similar but not identical patterns of soluble mediators. The response to pathogens 
thus varies according to the PAMP (Trinchieri, 2003), but also the PRR triggered. Both the 
innate and the adaptive immune responses regulate each other through the cytokines they 
produce, which sets the stage for pathogen clearance.   
1.8.1 Cytokine storm in HIV infection 
In HIV infection, inflammation meant to initiate an effective host immune response is often 
exploited by the virus (Deeks, Tracy & Douek, 2013). Inflammatory mediators cause the influx 
of immune cells to sites of infection, which contrary to fighting infection provide target cells 
for robust replication (Hladik & McElrath, 2008; Li, Estes, et al., 2009). Cytokine deregulation 
has been found in plasma of HIV infected patients: concentrations of pro-inflammatory 
cytokines, IL-8, IL-1 and TNF-α, and pleiotropic cytokines such as  IL-10 and IL-6 were 
increased, while there was a decrease in IL-2, IL-12 and IFN-γ (Breen et al., 1990; Matsumoto 
et al., 1993; Chehimi et al., 1994; Daftarian et al., 1995; Taoufik et al., 1997; Marshall et al., 
1999; Stylianou et al., 1999; Jennes et al., 2004; Roberts et al., 2010; Borges et al., 2014, 2015). 
Cytokine deregulation intensified with disease progression and was partially resolved with 
antiretroviral (ARV) treatment, suggesting a relationship between viral replication and 
inflammation (Stylianou et al., 1999). Further research found that combinations of certain 
cytokines enhanced HIV replication and disease progression (Breen, 2002), while HIV 
infection resulted in a switch from a Th1 to Th2 response (Clerici & Shearer, 1993; Buisson et 




(Borghi et al., 1995; Ji et al., 2005). Deregulation was initially thought to be caused by  
replication of the virus in APCs (Poli et al., 1990; Hewson et al., 1999). However, later studies 
found that the mere interaction of gp120 N-glycans with DC-SIGN was sufficient to induce 
IL-10 secretion by MDDCs (Borghi et al., 1995; Shan et al., 2007) although other cell types 
may also contribute to the “cytokine storm”. IL-10 release was accompanied by poor 
maturation of DCs and lack of up-regulation of co-stimulatory markers. 
Buisson and colleagues further found that treatment of MDDCs with HIV-1 not only enhanced 
IL-10 secretion, but also inhibited the release of IL-12 and their capacity to stimulate T cell 
proliferation. HIV-induced IL-10 suppressive effects on DCs could thus have negative 
consequences on T cell responses to HIV infection (Buisson et al., 2009).  
1.8.1.1 Anti-inflammatory cytokine IL-10 
IL-10 is produced by multiple cell types including T cells, B cells, DCs and macrophages 
(Brockman et al., 2009; Hedrich & Bream, 2010). It is an anti-inflammatory cytokine that 
down-regulates the expression of inflammatory cytokines (IL-12, IL-1α, IL-1β, IL-18, TNF-α, 
IL-6, MCP-1, IL-8, IP10 and MIP-2α). It influences the outcome of Signal 1 and Signal 2 
(Figure 1.5) by regulating MHC class II and co-stimulatory molecules in both an autocrine  
(Moore et al., 2001; Couper, Blount & Riley, 2008) and paracrine manner which can limit 
cellular immunity. It also inhibits the production of mononuclear phagocytes and NK cells and 
also alters Th1 and Th2 cytokine production (Clerici & Shearer, 1993; Buisson et al., 2009; 
Alter et al., 2010).   
It is a multifunctional cytokine with both protective and regulatory roles. It protects against 
excessive tissue damage due to Th1, CD8+ and NK cell responses, especially in infections like 
Toxoplasma, Trepanosoma, Mycobacterium and some Plasmodium spp. that cause excessive 
production of IFN-γ and TNF-α (Moore et al., 2001). However, in viral and other intracellular 
bacterial infections, its inhibitory and anti-inflammatory functions/effects tend to suppress the 
innate and adaptive responses of DCs, macrophages and T cells respectively, inducing immune 
tolerance and thus survival of the pathogens and establishment of infection (de Waal Malefyt, 
Haanen, et al., 1991; Taoufik et al., 1997; Moore et al., 2001). This was recently demonstrated 
in experimental mouse models of Lymphocytic choriomeningitis virus infection (LCMV) and 




blocking IL-10 receptors led to clearance of persistent infection (Brooks et al., 2006; Ejrnaes 
et al., 2006; Wilson & Brooks, 2011).   
1.8.1.2 Role of IL-10 in HIV infection 
In HIV infection, there is increased serum IL-10 levels, which increase with disease 
progression, impair IL-12 production and tilt the Th1/Th2 polarization in favour of Th2 
phenotypes (Clerici & Shearer, 1993; Taoufik et al., 1997; Stylianou et al., 1999). IL-10 
production occurred very early in infection (Stylianou et al., 1999; Norris et al., 2006; Liu et 
al., 2014), increased with viral load  suggesting that viral replication was the cause of IL-10 
production (Stylianou et al., 1999). Further investigations found that IL-10  was not only 
induced by virus but that gp120 also influenced IL-10 secretion (Ameglio et al., 1994; Borghi 
et al., 1995). Additionally, HIV-induced IL-10 production leads to DC dysfunction in HIV 
infected subjects as IL-10 and IL-4 specific antibodies could reverse the Th1- Th2 switch in 
HIV infected lymphocytes from HIV infected donors (Clerici et al., 1993). Cells from healthy 
donors also became dysfunctional when exposed to HIV or gp120  (Borghi et al., 1995; 
Fantuzzi et al., 2004; Granelli-Piperno et al., 2004; Chougnet & Gessani, 2006; Shan et al., 
2007; Alter et al., 2010).. However, Shan et al. (2007) found that only some gp120 variants 
stimulated MDDC IL-10 secretion independently of MDDC donor. They also suggested that 
gp120 N-glycans, specifically the mannose type glycans contributed significantly to the 
induction of IL-10 production in healthy MDDCs through their interaction with mannose CLRs 
(Shan et al., 2007). This was shown when removal of mannose residues significantly reduced 
gp120-stimulated IL-10 secretion and prevented loss of DC maturation and function (Shan et 
al., 2007; Banerjee et al., 2009, 2012).  
1.8.1.3 IL-12 production and its role in infection  
Bioactive IL-12p70, commonly known as IL-12 is a heterodimer of IL-12p40 and IL-12p35 
subunits (Abdi, 2002). Not only is the secretion of the heterodimer highly modulated, the 
subunits are encoded by genes on separate chromosomes that are independently regulated at 
transcriptional and post-translational levels (Abdi, 2002). Therefore, the expression of IL-12 is 
carefully regulated and influenced by multiple factors (Carra, Gerosa & Trinchieri, 2000). It 
has been shown that the production of IL-12p70 and IL-12p40 by cells is significantly 
correlated, suggesting that secretion of IL-12p40 could be a surrogate marker for the 




form IL-12p80 and with IL-12p19 to form IL-12p23, with each playing a different role in 
immune responses. IL-12p40 and IL-12p80 were found to act as agonists of IL-12 by 
competing for binding to the IL-12R and preventing IFN-γ expression and thus inhibiting the 
initiation of a Th1 response in both murine and human cell models. However, knock-out 
experiments showed that mice lacking IL-12p35 but not IL-12p40 were resistant to infection 
and the authors suggested that IL-12p40 might form heterodimers with other molecules that  
initiate Th1 responses (Hölscher, 2004). It is also involved in stimulating the migration of DCs 
to the lymphoid tissues  (Khader et al., 2006). Therefore, it has been suggested that the function 
of IL-12p40 is much more complex and that it might also act independently of IL-12 (Piccotti 
et al., 1997; Hölscher, 2004). The predominant function of IL-12 is to regulate the adaptive 
immune response. IL-12, IL-10 and the other regulatory cytokines play a very important role 
in the development of naıve CD4+ T cells into either Th1, Th2 cells or regulatory T cell subsets, 
respectively, which are essential for an effective adaptive immune response (de Waal Malefyt, 
Haanen, et al., 1991; Fiorentino et al., 1991; D’Andrea et al., 1993; Chehimi et al., 1994; 
Trinchieri, 1994, 2003; Biron & Gazzinelli, 1995; Marshall et al., 1999). IL-12 production by 
DCs enhances Th1 cell phenotype which then produces more IL-12 and IFN-γ (Figure 1.5d). 
Together with IFN-γ, IL-12 enhances phagocytic and cytotoxic activity of T cells, NK and 
macrophages while impairing Th2 differentiation and production of related cytokines like IL-
4, IL-5 and IL-13 (Clerici et al., 1993; Marshall et al., 1999; Hamza, Barnett & Li, 2010). IL-
12 is thus the main cytokine that regulates Th1 differentiation and preferentially induces T cell 





Figure 1.5 Dendritic cell (DC) stimulation and initiation of T cell polarization and 
differentiation into various subsets guided by the appropriate cytokine environment. a) 
Following the recognition of pathogen-associated molecular patterns (PAMPs) by PRRs on immature 
DCs, they mature (Signal 0) by up-regulation of maturation markers like MHC II, CD80 and CD86. 
Pathogen is internalized into the endosomes/lysosomes and is processed into microbial peptides. b) 
Antigenic peptides are transferred and bound to MHC II molecules and transported to the cell surface 
where they are presented in complex with the MHC II to T cell receptor (TCR) of naïve T cells (Signal 
1). c) Mature and activated DCs express high levels of MHC, co-stimulatory (CD40, CD80 and CD86) 
and adhesion molecules (CD54 and CD58) (Signal 2) that helps to stabilize the immunological synapse, 
and secrete high amounts of cytokines IL-12 IL-10, IL-1 α, IL-1β, IL-6, IL-23, IL-4, IL-5, IL,13 and 
TNF-α and chemokines MIP1 α, MIP 1β, MCP-1, MIP3 α, IL-8 (Signal 3). d) The cytokines released 
by DCs play a very important role in inflammation and differentiation of CD4+ T cells into the right 
phenotypes or subset as Th1, Th2, Th17 and induced Tregs (iTregs). From (Ludewig et al., 2001; 
Aimanianda et al., 2009), Trends Pharmacol Sci 2009, 30:287-295.   
 
1.8.1.4. Pro-inflammatory cytokines 
IL-1, IL-6, IL-8 and TNFα together with IL-12 are pro-inflammatory cytokines predominantly 
produced by activated cells of the monocyte/macrophages lineage, including DCs, when 
exposed to inflammatory stimuli (Kedzierska & Crowe, 2001). They can also be produced by 
other cell types including B cells, T cells, fibroblasts and endothelial cells in response to viral 




HIV-1 infection deregulates pro-inflammatory and  anti-inflammatory cytokines (Breen et al., 
1990; Chehimi et al., 1994; Daftarian et al., 1995; Taoufik et al., 1997; Marshall et al., 1999; 
Narimatsu, Wolday & Patterson, 2005; Roberts et al., 2010; Shah et al., 2011; Borges et al., 
2014, 2015) by lowering the expression of Th1 cytokines such as IL-2, IL-12 and IFN-γ and 
increasing IL-10, IL-1, IL-6, IL-8 and TNF-α. It has been shown that TNF-α,  IL-1 and IL-6 
are suppressed by IL-10 under normal non-HIV conditions (Moore et al., 2001) whereas HIV 
infection seems to be associated with increased levels of inflammatory cytokines. Bebell et al. 
(2008) and Roberts et al., (2010, 2012) found elevated levels of IL-12, IL-1α, IL-1β, IL-6, 
TNF-α, and IL-8 in plasma and CVL of HIV infected women. A study by Stacey et al. (2009) 
which followed acutely infected HIV patients longitudinally also found up-regulation of these 
pro-inflammatory cytokines in plasma, with levels increasing over time (Stacey et al., 2009). 
These very cytokines have also been shown to enhance the risk of HIV acquisition in high risk 
women (Masson et al., 2015). IL-1β is one of the cytokines whose levels are indicative of 
infection and is highly correlated with HIV acquisition risk (Sturm-Ramirez et al., 2000; 
Masson et al., 2014, 2015; Liebenberg et al., 2016) However, these studies focussed on CVL 
and plasma of HIV-1 infected women and could thus not identify the source of increased 
inflammatory responses. 
It has been shown that HIV interaction with DCs enhances infection of co-cultured CD4+ cells 
(Cameron et al., 1992), suggesting that DCs could play a very important role in HIV 
transmission. Due to the paucity of DCs in vivo MDDCs are commonly used in in vitro 
experiments (Romani et al., 1994) to identify how HIV interacts with DCs and subverts their 
normal immune responses. MDDCs infected with HIV failed to mature while stimulating the 
release of IL-10, suggesting a role for immunosuppression in HIV-1 infection (Granelli-
Piperno et al., 2004; Shan et al., 2007).  There is thus, a disconnect between in vivo and in vitro 
studies where the one suggests that HIV-1 stimulates inflammation which results in IL-10 
levels increasing to prevent tissue damage (de Waal Malefyt, Abrams, et al., 1991) and the 
other suggesting that in DCs, HIV-1 binding to DC-SIGN induces IL-10 expression that, 
instead of down-regulating inflammatory cytokines, skews Th0 to Th2, facilitating HIV-1 
survival in the female genital tract (Gringhuis et al., 2007). Both approaches have limitations: 
MDDCs might not be ideal models to study DC immune responses and results must be carefully 
considered before extrapolation to in vivo HIV-1 infection (Wu & KewalRamani, 2006) and in 





1.9 Signal activation and transduction following interaction of PAMPs 
with DC receptors including DC-SIGN.  
The binding of extracellular ligand to specific transmembrane receptors leads to the conversion 
of extracellular stimuli to intracellular signaling pathways, which leads to inducible cellular 
processes such as transcription, translation, proliferation, differentiation and even apoptosis 
(Shaul & Seger, 2007).  
TLRs play a very important role in the initiation of the immune response to pathogens, usually 
by two major regulatory programs: 1) a universal one activated by nearly all TLRs triggered 
by a wide range of ligands and 2)  ligand-specific responses triggered by TLRs specific to 
individual microbial agents (Akira & Kiyoshi, 2004; Kawai T & Akira, 2005; Kawai & Akira, 
2007). Once TLRs are triggered by PAMPs, intracellular signaling pathways are activated that 
lead to the induction of pathogen-tailored immune responses  (Kawai & Akira, 2007). For NF-
кB to be activated, inhibitor of kappa kinase (IKK) is degraded leaving NF-кB to translocate 
to the nucleus where it binds to enhancers or promoters of gene targets (Silverman & Maniatis, 
2001; Janeway & Medzhitov, 2002).  
Although Raf-1 phosphorylation leads to enhanced IL-10 expression and is necessary for DC-
SIGN mediated modulation of TLR signaling, TLR activation is required before DC-SIGN 
activation can lead to NF-кB activation. A series of kinases downstream of Raf-1 are involved 
in NF-kB activation including phosphatidylinositol-3 kinase, Akt, and the most characterized 
and evolutionary conserved, the Ras-Raf-MEK/MAPK kinase pathway (Figure 1.6), 
responsible for the regulation of cell growth and differentiation in mammalian cells.  
1.10 Mitogen Activated Protein Kinases 
MAPKs are evolutionarily conserved protein kinases and central mediators that convey signal 
from cell surfaces to the nucleus. They are present in nearly all cell types and are called 
Serine/Threonine kinases after the amino acids that are phosphorylated during activation. 
Although they are the main components of signal transduction, they also phosphorylate other 
substrates including transcription factors such as c-Myc (Myelocytomatosis Viral Oncogene) 
and AP-1 (activator protein 1), which are both involved in cell growth, transformation and 
differentiation. In some cases, MAPKs amplify signals instead of just transmitting them and 




MAPKs play critical roles in key cellular activities like proliferation, differentiation, survival 
and are also implicated in a variety of human disorders including cancers, and 
neurodegenerative diseases (Johnson & Lapadat, 2002; Zhang, Wei , Tu Liu, 2002; Kim & 
Choi, 2010). Given that components of the MAPK signaling pathway act differentially in many 
human diseases, a proper understanding of this pathway in response to HIV could provide 
valuable information for the design of vaccines that elicit the most protective immune 
responses against viral infection. Three major groups of MAP kinases have been well 
characterized in mammalian cells and include the extracellular regulated kinases (ERK), the c-
Jun NH2 terminal kinases (JNK) and the p38 MAP kinases (Zhang, Wei , Tu Liu, 2002).  Each 
of these groups have a tripeptide motif, Thr-X Tyr, with each MAPK differing by X. X is 
Glutamine, Glycine and Proline for ERK, p38 and JNK respectively. The activation of these 
kinases is by dual phosphorylation of the Thr and Tyr units of the tripeptide motif that transmits 
signal via mitogen activated protein kinase kinase kinase (MKKK), mitogen activated protein 
kinase kinase (MKK) and MAPK cascade (or Ras-Raf-ERK) in response to different ligands, 
although there is considerable cross talk between them (Johnson & Lapadat, 2002; Wellbrock, 
Karasarides & Marais, 2004), Figure 1.6).  
P38 MAP kinases were first identified for their role in inflammation by regulating pro-
inflammatory cytokine biosynthesis. Both JNK and p38 are activated by the presence of 
mitogen but JNK is also activated by cellular stress and the presence of inflammatory 
cytokines. JNK together with ERK have been suggested to prevent maturation of DCs  (Tian, 
Zhang & Cohen, 2000). Activation of these MAP kinases leads to instructive signals that 
activate transcription factors present in the cytoplasm and the nucleus of DCs leading to the 
expression of target genes and then the appropriate biological response. Activation of the 
MAPKs occurs within minutes and their signals are transient (Shaul & Seger, 2007; Kim & 
Choi, 2010; Sancho & Reis e Sousa, 2012). Whereas ERK is mostly activated in response to 
pathogens, JNK and p38 are mostly activated in response to stress and inflammatory cytokines 






Figure 1.6 MAPK signalling pathways. Following activation of the PRR by either a mitogen 
(pathogen or pathogenic product) or growth factors, the receptors trigger a signal cascade in which 
Mitogen activated protein kinase kinase kinase (MAPKKK, e.g. Ras) is activated. This MAPKKK in 
turn activates a Mitogen activated protein kinase kinase (MAPKK, e.g. Raf-1 in the case of HIV-1 and 
MANLAM) which then activates Mitogen activated protein kinase (MAPK, e.g. ERK, JNK and p38). 
The MAPKs activate transcription factors such as NF-KB that then switches on genes involved in cell 
growth, inflammation, development, differentiation or apoptosis (Adapted from (Roberts & Der, 2007; 
Dzamko et al., 2014) 
 
Concluding remarks  
Current data shows that HIV-1 binds to DC-SIGN on DCs resulting in trans-infection of target 
cells, dissemination and systemic spread. DC-SIGN is a PRR, an antigen capture receptor that 
should, upon binding HIV, trigger DCs to process and present antigens to T cells to initiate an 
adaptive immune response via TCR, co-stimulation and secretion of cytokines and other 
soluble mediators. HIV and other pathogens instead use DC-SIGN to subvert DC function, 
preventing DC immune responses and enhancing their survival. How they do this has been a 
subject of debate.  
 It has been suggested that impaired maturation of DCs and deregulated secretion of cytokines 
and chemokines are the major mechanisms of sabotage. Triggering PRRs on the surface of DCs 




kinases and transcription factors. Activation of the NF-kB transcription factor can either result 
in the secretion of soluble mediators that clear infection or factors that promote pathogen 
survival. NF-kB activation has been found to activate the LTR of HIV and thus directly enhance 
viral replication. Mannose-carrying PAMPS and not fucosylated motifs activate Raf-1 which 
modulates TLR induced activation of DCs. As the type of carbohydrate influences activation 
of signaling kinases and kinases differentially modulate cytokine secretion by DCs, we 
hypothesised that Env N-glycosylation could play a role in modulating DC immune responses 
via ERK. Furthermore, PNGs of Env have been found to vary with disease state of HIV-1 and 
mannose type N-glycans that bind DC-SIGN are enriched at specific sites of TF Envs, 
suggesting that immune modulation during transmission might be advantageous for HIV 
survival.  
By providing insight into the molecular mechanism of how Env N-glycans impact DC immune 
responses, we might better understand the design of effective immunogens that do not suppress 




1.11 Aim and objectives  
Aim: The aim of this project is to determine the impact of HIV Envelope N-glycosylation on 
dendritic cell immune responses.  
Rationale 
Heterosexual transmission of HIV-1 across a healthy genital mucosa has a very low probability 
due to the protective mucosal barrier, leading to transmission of a single virus variant in 80% 
of cases. It has been suggested that Dendritic cells (DCs) are the first cell type to interact with 
HIV-1 following transmission. HIV-1 binds to DC’s DC-SIGN via its high mannose type N-
glycans and stimulates the release of IL-10 a regulatory cytokine linked to immune 
suppression. Transmitted founder Envs have differing N-glycan profiles than those from 
chronic infection, suggesting that Env N-glycans could be important for HIV transmission. We 
thus hypothesise that the N-glycans of transmitted founder Envs interact with DC-SIGN in 
such a way as to enhance DC IL-10 secretion, leading to deregulation of DC function and thus 
providing some variants with a survival advantage.   
1.11.1 Objectives: 
1. Characterise the N-glycosylation of subtype C Envelope and determine the role of 
specific N-glycans and types of N-glycans in Envelope function   
2. Determine the role of subtype C HIV-1 Envelope N-glycosylation in DC-SIGN-
mediated modulation of Dendritic Cell cytokine release and how this impacts 
pathogenesis. 
3. Understand the impact of Envelope N-glycosylation on activation of signaling 
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2.1 Biosafety statement 
This project was approved by the Faculty of Sciences Biological Safety Committee, University 
of Cape Town (approval number: FSREC 024-2014) for the use of hazardous biological agents 
and/or genetically modified organisms. Cell lines used here were maintained and used under 
Biosafety Level II conditions, while primary cell work which included generating monocyte 
derived dendritic cells (MDDCs) from donor PBMCs and experiments using HIV pseudovirus 
(PSV) were carried out under Biosafety Level II infrastructure with Biosafety Level III 
practices (BSL II+) in the departments of Molecular and Cell Biology, University of Cape 
Town. Some work was carried out in Dr. Fauci’s laboratory of Immunoregulation, NIAID, 
NIH,-Bethesda, USA. 
2.1.1 Consent statement  
PBMCs were collected from healthy donors through a NIH Department of Transfusion 
Medicine protocol that was approved by the Institutional Review Board of the National 
Institute of Allergy and Infectious Diseases, National Institutes of Health. A written informed 
consent was provided by study participants and/or their legal guardians before donating blood. 
2.2 Study Cohort 
This study will utilize reagents generated from the CAPRISA Acute Infection study, Durban, 
South Africa.  This cohort is a valuable tool for the study of HIV pathogenesis as acute infection 
was identified within three months of infection with longitudinal follow-up for up to 4 years. 
This project will focus on 4 study participants (CAP45, CAP206, CAP210 and CAP239) 
enrolled into the study between 2 and 4 weeks post-infection. 
2.3 Plasmids 
Eighteen functional full-length envelope (env) clones from five HIV positive women sampled 
longitudinally at two weeks post-infection (wpi) and 2-3 years post-infection (ypi) were used 
for this study. These envelopes were cloned into pcDNA/his-topo or pTarget mammalian 
expression vectors under the control of a CMV promoter (Gifts from Penny Moore, NICD, 
Carolyn Williamson, UCT and Liliwe Shuping, UCT). Four of the five women were infected 
with a single variant at 2 wpi as determined by single genome amplification (SGA) and five 
Env clones represented the transmitted founder (C1,  C3, C7, C12 and C15) whereas thirteen 




C11, C12, C14, C16, C17 C18). One individual was infected with more than one variant at 2 
wpi from whom clones C3, C4, C5, C6 were isolated.    
2.4 Cell culture  
Human embryonic kidney (HEK) 293T (ATCC) and TZM-bl cells (NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu and 
Tranzyme Inc) (Platt et al., 1998) are adherent cell lines that were maintained in complete 
growth medium made up of Dulbecco modified Eagle high glucose medium (DMEM) (Lonza, 
BE12-604E, Whitehead Scientific) supplemented with 10% fetal bovine serum (PAA, Biocom 
Biotech) and 1 U/ml penicillin and 1µg/ml streptomycin (Lonza, Whitehead Scientific). TZM-
bl cells are a HeLa cell line engineered to stably express CD4 and CCR5 and CXCR4 co-
receptors and the luciferase gene under the control of the HIV promoter (LTR). Raji cells and 
a DC-SIGN stably expressing variant (Raji-DC-SIGN) cells (Cat No. 9944 and Cat No. 9945;  
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Drs. Li Wu and Vineet N. 
KewalRamani) (Wu et al., 2004).  These are non-adherent cells that were maintained in RPMI 
supplemented with 10% fetal bovine serum. All cells were cultured in a humidified incubator 
at 37oC with 5% CO2 and were tested for mycoplasma infection using the Fluorescent Hoechst 
DNA stain (Mowles, 1990) every three months. 
2.4.1 Transfections  
HEK 293T cells were plated at 2 x 105 cells/ml (2mls per six well tissue culture plate) and 
grown O/N to 40-60% confluence.  Plasmid DNA at a ratio of 1:3 of DNA: Polyethylenimine 
(PEI) (1mg/ml) transfection reagent was mixed in serum free DMEM and incubated for 20 min 
at room temperature (RT). Fresh complete medium was added to the cells and the DNA-PEI 
mix was added drop-wise. The cells were returned to the CO2 incubator for 48 hrs.  
2.4.2 Env expression 
Env (6 µg) were transfected as outlined above. Once the 48 hr incubation is completed, the 
medium is removed and 300μl RIPA buffer (10mM Tris buffer pH 7.5, 2mM Na2EDTA pH 8, 
150mM NaCl2, 1% Triton X-100 detergent, with PMSF protease inhibitor added at 100µM) 
was added and incubated on ice for 10 min before transferring to an eppendorf and centrifuging 
at 14000 rpm for 5 min to remove cell debris. Supernatants are stored at -20oC and protein 
concentration was determined using a Bradford assay, with a standard curve constructed using 




2.5 N-glycosylation analysis of Env 
Growth mediums (1 ml) from HEK 293T cell transfections were diluted with 1 ml of binding 
buffer (20mM morpholineethanesulfonic acid, 130mM NaCl, 10mM CaCl2) at 4
oC. For each 
Env, 30µl of Galanthus nivalis agarose beads (Sigma-Aldrich®) was added and binding of the 
Env protein to the lectin agarose beads was carried out overnight at 4oC with gentle mixing on 
a rolling apparatus. The agarose beads were centrifuged at 14000 rpm for 2 min and the 
supernatant removed. The beads were washed twice with PBS (Whitehead Scientific) at 4°C, 
supplemented 0.9mM CaCl2 and 0.49mM MgCl2 and then treated with either endo-β-N-
acetylglucosaminidase H (Endo-H) (0.5 Units(U) in buffer containing 50mM sodium acetate 
(pH 5.5), 0.1% sodium dodecyl sulfate, and 0.1% bovine serum albumin at 37°C, peptide N-
glycosidase F (PNGase-F) (0.5 U) or Neuraminidase (0.5 U) according to the manufacturer’s 
recommendations (New England Biolabs®) and then analysed by SDS-PAGE and Western 
blotting to compare electrophoretic mobility shifts. 
HIV-1 IIIB gp120 recombinant protein (Cat # 11784) was used as positive control and 
endoglycosidase digestion controls in these experiments. The HIV-1 IIIB gp120 reagent was 
obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 
IIIB gp120 Recombinant Protein from ImmunoDX, LLC.” 
Once the Envs were visualized by autoradiography, the molecular weights (MW) of the bands 
were determined using their migration distances. Images of the autoradiography films were 
captured by a molecular imager, Chemi DocTM XRS (Biorad) and Image lab TM software was 
used to generate a standard curve of log MW vs relative migration distance (Rf) of the bands 
in the MW ladder. The Rf was measured from the top of the gel to the centre of the experimental 
bands. The MW of glycosidase treated and untreated Env bands were then calculated 
automatically by the software. Differences in N-glycosylation were determined by comparing 
the migration of the bands after Endo-H and PNGase-F treatment to those of the untreated 
samples (Lin et al, 2003). 
2.6 Pseudovirus production  
To produce pseudovirus, HEK 293T cells were transfected as in the Envelope expression above 
except that 2.5µg of env DNA and 5µg of the viral backbone pSG3ΔEnv were used. 
Pseudovirus was collected after 48 hours (hrs), filtered through a 0.22µm pore size filter, FBS 




2.6.1 Pseudovirus titration  
To determine the titre of pseudovirus, a TZM-bl infectivity assay was used. TZM-bl cells, a 
Hela cell line genetically engineered to express CD4 and co-receptors CCR5 and CXCR4 along 
with a luciferase gene under the control of the HIV LTR were used. The luciferase reporter 
under the control of the LTR is activated upon infection with HIV due to transactivation by Tat 
(Montefiori, in press; Wei et al., 2003). Cells were seeded at a density of 104 cell per well in 
200ul total volume of medium in a 96 well TC plate 18 hrs prior to infection. Two fold serially 
diluted pseudovirus (diluted in another 96 well plate before addition to TZM-bl cells) was 
added used to infect the TZM-bl cell. Triplicate wells of TZM-bl cells were infected with 
pSG3ΔEnv to control for the effect of other viral proteins and another triplicate of TZM-bl 
cells were left uninfected to serve as background luciferase of cells. Infectivity was allowed to 
carry on for 48 hrs following infection and the luciferase assay (BriteGlo® Luciferase Assay 
System; lysis buffer/substrate; Promega PRE263C-B, PRE264C-X) was used to determine the 
infectivity of the pseudovirus. The results were readout on a luminometer (Turner Biosystems® 
Modulus Microplate). Relative luciferase light units were plotted against the dilution factors 
and a linear regression analysis was used to relate the dilution factor to folds above background 
(cell infected with pSG3). The dilution factor that an infectivity relative ligh unit (RLU) gave 
50x above background titre was adopted for MDDC stimulation following optimisation.  
2.6.2 p24 ELISA 
In order to determine the concentration of pseudovirus (ng/ml), a chemiluminescent in-house 
modified p24 ELISA using Aalto Bio reagents (Capture antibody; D7230, Recombinant protein 
for standard; AG6054, conjugate antibody BC1071) and the TROPIX® detection system 
Sapphire II (T1025, CDP-Star®, Applied Biosystems or life technologies) was carried out. 
High bind assay plates (Porvair, Whitehead Scientific) were coated with 100µl of sheep anti 
HIV-1 p24 gag antibody (D7230, Aalto Bio reagents) diluted to 3µg/ml in coating buffer (100m 
M NaHCO3 pH 8.5) and incubated overnight at room temperature.  
Unbound antibody was removed and the wells were washed three times with 200µl 1x TBS 
(50mM Tris, 150mM NaCl, pH 7.5). Plates were blocked with 5% bovine serum albumin 
(PAA, Biocom Biotech) in TBS for 1 - 2 hrs at room temperature and thereafter stored at -20°C 
until needed. Pseudovirus was inactivated in 1% Empigen-TBS, and serial dilutions (100µl) 
were added to the antibody-coated plates that were washed four times to remove the bovine 
serum albumin. A p24 protein; (AG6054, Aalto Bio reagents) was serially diluted in 1% 




After addition of samples and p24 standards in triplicate to the appropriate wells, the plates 
were incubated for 2.5-3 hrs, before unbound p24 protein was removed and the wells washed 
four times with 200 µl TBS. An alkaline phosphatase conjugated mouse anti-HIV-1 p24 
antibody; (EH12AP, Aalto Bio reagents) was diluted  to 1 in 16 000 in TBS- 0.1% Tween-20 
(TBS-T) containing 20% sheep serum (PAA, Biocom Biotech) and 2% bovine serum albumin 
and 100µl was added to each well.  The plates were incubated for 1 hr at room temperature, 
protected from light. Unbound antibody was removed and the wells washed with TBS-T eight 
times and then twice more with 1x TROPIX® buffer (200mM Tris, 10mM MgCl2, pH 8.9). 
The detection reagent was diluted four times with TROPIX buffer and 50µl was added to each 
well. Luminescence was read using a plate reader (Turner Biosystems, ANATECH 
Instruments). Relative light units (RLU) of pseudovirion samples were converted to p24 
concentration (ng/ml) using the standard curve constructed from the standard protein used and 
a non-linear regression analysis plot. 
2.6.3 Entry efficiency assay 
To determine the entry efficiency of the pseudovirions stocks, TZM-bl cells were used. TZM-
bl cells were seeded at 104 per well in a 96 well plate 18 hrs before, were infected with 5-fold 
serial dilutions of the pseudovirus when the cell monolayers were 50 - 60% confluent. All 
pseudovirion stocks were normalised to 100ng/ml p24 (pre-determined by p24 ELISA Aalto, 
Bio-reagents), prior to serial dilution. Half of the growth medium was removed from each well 
and replaced with 100μl of titrated pseudovirus in triplicate (100ng/ml, 50ng/ml, 25ng/ml and 
12.5ng/mls). Triplicate wells of TZM-bl cells were infected with pSG3ΔEnv to control for the 
effect of other viral proteins and another triplicate of TZM-bl cells were left uninfected to serve 
as background luciferase of cells. Pseudovirus single round infection was carried out for 48 
hours at 37°C and infectivity was determined by the luciferase reporter assay (BriteGlo® 
Luciferase Assay System; lysis buffer/substrate; Promega PRE263C-B,PRE264C-X) where 
luciferase activity is measured using a luminometer (Turner Biosystems® Modulus 
Microplate). Background luciferase readings from cells not infected with virus or wells 
transfected with pSG3ΔEnv was subtracted from sample readings. For all comparisons 
between clones, RLU readings measured using a titer of 100 ng/ml of PSV was used as this 




2.7 DC-SIGN binding assay 
A DC-SIGN binding assay was adapted from Alexandre at al. (2012). Briefly, 100ng (in 100µl) 
of pseudovirus (predetermined by p24 ELISA) was added to Raji and Raji DC-SIGN cells 
seeded in a 96 well plate at a density of 1 x 105 cells per well in 100µl RPMI growth medium 
in triplicates (total volume 200µl per well). Pseudovirus was allowed to bind to the cells for 
2.5 hrs at 37°C in a humidified CO2 incubator and cells were then washed four times by 
centrifugation (2500 rpm) with RPMI to remove all unbound virus, then re-suspended in 130µl 
of lysis buffer (1% Empigen-TBS). A 100µl volume of cell lysate was used to assay by p24 
ELISA to determine the amount of pseudovirus (ng/ml) that bound to the DC-SIGN expressing 
cells. 
2.8 Trans-infection  
In this assay, 100ng/ml of virus (determined by p24 ELISA) was added to and incubated with 
105 Raji/DC-SIGN cells and allowed to bind for 2.5 hr in a 37oC incubator. Unbound virus was 
removed with four washes  as in the binding assay above before the Raji/ Raji-DC-SIGN cells 
bound to virus was added to TZM-bl cells seeded the day before at a density of 104 cells per 
well of a 96 well TC dish. Virus was allowed to infect TZM-bl cells for 48 hr and the PSV 
entry was measured by luciferase reporter assay in a luminometer (Turner Biosystems® 
Modulus Microplate reader) as outlined in the infectivity assay. Direct infection was also 
carried out whereby 100ng/ml of PSV was used to infect TZM-bl cells without prior binding 
to Raji/Raji-DC-SIGN cells. Trans-infection RLU was normalised to RLU of direct infection 
to control for the effect of varying entry efficiency across the Env clones. 
2.9 Generation of mutants 
A modified Quikchange® Site-Directed mutagenesis (SDM) protocol (Stratagene, La Jolla,) 
was used to generate Env mutants lacking specific PNGs and soluble gp140. Complimentary 
primers carrying the desired mutations were designed using Dnaman software and restriction 
enzymes sites were introduced through silent mutation analyses using WATCUT 
(http://watcut.uwaterloo.ca). All primers were at least 45 nucleotides long with a minimum of 
15 bases on either side of the mutated nucleotides. PCR annealing was carried out between 
55°C - 58°C and the cycling conditions were as follows: 94°C for 3 min followed by 20 cycles 
of 94°C for 30 sec, annealing for 30 sec, and elongation 72°C for 12 min, followed by a final 




SDM PCR products were verified on 1% agarose electrophoretic gels prior to digestion with 
20 U of DpnI (Thermo Scientific). This enzyme recognises methylated DNA and will digest 
template DNA but leave the SDM PCR product intact. DpnI digested DNA was checked using 
a 1% agarose gel alongside an aliquot of the undigested sample before competent E.coli 
(JM109, Promega) were transformed, spread on Luria agar (LB, 1.5% w/v agar) plates and left 
to incubate at 37oC overnight (O/N). Colonies were picked, grown in 5ml Luria broth (1% 
NaCl, 1% tryptone, 0.5% yeast extract) overnight with carbenocillin disodium (100 µg/ml)  and 
plasmid extracted using the PureYield™ Plasmid Miniprep System (Cat # A1222 Promega) 
according to the manufacturer’s instructions. Colonies were screened by digestion using the 
restriction site added during SDM and positive clones were cultured in 50ml Luria broth 
overnight before plasmid DNA was extracted using the PureYield™ Plasmid Midiprep kit (Cat 
# A2495, Promega). Introduction of the mutation was confirmed by sequencing (DNA 
Sequencing Unit, Stellenbosch University, South Africa). 
2.10 Recombinant envelope protein preparation  
2.10.1. Codon optimization, expression and purification 
Env coding sequences of CAP88, C12, C13 and C14 were commercially synthesized 
(Mutagenex, Piscataway, NJ), codon-optimized for expression in mammalian cells (DNA2.0, 
Menlo Park, CA) and the endogenous Env signal peptide was replaced with that of the tissue 
plasminogen activating protein (TPA) to improve the yield . The sequences of each envelope 
protein following synthesis from +1 to the gp120-gp41 junction were cloned into a mammalian 
expression vector downstream of a synthetic TPA leader sequence. Non-adherent Chinese 
hamster ovary cells (CHO-S cells) (Invitrogen, Grand Island, NY) were transfected using the 
FreeStyleTM MAX expression medium (Gibco, 12651-014) according to the manufacturer’s 
instructions in a 37oC incubator on a rotator. CHO cells were used to maximize expression 
since Go et al. (2011) proposed that Env N- glycosylation was similar when  expressed in CHO 
and HEK 293 cells (Go, Hewawasam, et al., 2011). Cell culture medium was harvested 72 hrs 
post transfection by centrifugation at 2000 rpm for 10 mins to remove any cells then filtered 
through a 0.22um filter (Millipore). The supernatants were then stored at -20oC if not used 
immediately. They were thawed in a 37oC water bath and passed over a column of Galanthus 
nivalis lectin sepharose (Vector Labs, Burlingame, CA) for lectin affinity chromatography. 
Galanthus nivalis sepharose was diluted 5 fold with unliganded sepharose 4B (GE Healthcare; 




with 20mM Glycine-HCl, pH 2.0, 150mM NaCl, 500mM α-methyl-mannopyranoside (Sigma, 
St. Louis, MO) and collected in 5ml fractions directly into 1M Tris-HCl, pH 8.0. SDS PAGE 
and Western blotting was used to identify peak fractions which were pooled and then 
concentrated with a stirred cell concentrator (Millipore, Billerica, MA). The protein was then 
dialysed exhaustively against HEPES, pH 7.4, 150mM NaCl and the proteins were quantitated 
by absorbance  at O.D. λ280 (extinction coefficient 1.1). The values were then confirmed by 
measurement with a bicinchoninic acid protein assay (Thermo Scientific, Rockford, IL). This 
was done at the laboratory of Immunoregulation, NAID, NIH-Bethesda under the supervision 
of Dr. Arthos James.  
2.10.2 Endotoxin removal (Triton extraction) from gp140 protein and DC-
SIGN protein  
To remove endotoxins from the purified protein, gp140 aliquots were slowly thawed on ice. 
Triton (10%) was added to the protein (final 1% triton concentration), gently mixed by 
inverting the tube and incubated for 5 min at 37oC. The mixture was centrifuged at 14000 rpm 
for 1 minute. The protein precipitate (upper layer) was removed, transferred into a new tube 
and the extraction repeated 3-4 times. Protein was then dialysed extensively in 1x PBS or 1x 
Hang’s buffered saline (HBS) for 48 hrs, changing buffer after the first 6 hrs, and then after 24 
hrs. 
2.11 Generation of monocyte derived dendritic cells (MDDCs) 
Peripheral blood monocytes (PBMCs) were obtained from healthy blood donor buffy coats 
from the Department of Transfusion Medicine, NIH, Bethesda or the Western Cape Province 
blood bank, Cape Town. PBMCs were isolated by density gradient centrifugation using Ficoll-
Hypaque (1077, Sigma-Aldrich). Monocytes were isolated from the PBMCs by positive 
selection using CD14+ coated beads (130-050-201 Miltenyi Biotec, USA or Biochom Biotech, 
S.A) according to the manufacturer’s instructions with the following exception: Beads were 
pre-washed to remove azide (Appendix II) and 5µl of washed beads were used (instead of 20µl 
as recommended by the manufacturer) per 107 PBMCs. In some experiments, monocytes were 
isolated by plastic adherence in 100cm dishes. Elutriated monocytes were also sometimes 
obtained from the department of Transfusion medicine, NIH, Bethesda. Elutriated monocytes 
(and PBMCs when isolated by plastic adherence) were adhered to TC plates (100cm dishes for 
PBMCs and six-well TC plates for elutriated monocytes) in serum free medium for two hours 




Gibco; without Ca2 or Mg2) then rinsed with RPMI and differentiation medium (RPMI with 
2% human serum AB, 100µg/ml penicillin /streptomycin, 2mM L-glutamine, 10mM HEPES), 
was added. Differentiation was done in the presence of 1000 U/ml of recombinant human GM-
CSF (PHC2005, Life Technologies) and 500 U/ml of recombinant human IL-4 (PHC0045, Life 
Technologies) for six days with recombinant cytokines supplemented every other day.  
2.11.1 Flow cytometry analysis of MDDCs 
Before MDDC stimulation with pseudovirus or with Env protein, an aliquot of MDDCs were 
stained for surface expression of surface markers to confirm differentiation and maturation 
status. Antibodies including CD83-APC (BD Cat # 551073), CD86-BV450 (BD Cat # 560359) 
and CD209-FITC (BD Cat # 561764) were used for MDDCs while monocyte purity was 
checked with CD14-PE, CD3-FITC CD4-PE and, IgG-PE for the isotype control. 
For the surface phenotype check, 2 x105 cells were used per donor and staining was done in V-
bottom 96 well plates. Cells were washed by centrifugation, re-suspended in 100µl staining 
buffer (1x PBS containing 0.1% FBS) and 2µl of the required fluorophore conjugated antibody 
(as recommended by the manufacturer, < 0.25µg per million cells) was added and incubated at 
4oC for 30 min. Samples were then washed 3x with 200µl of wash buffer by centrifugation 
before re-suspension in 1x PBS and fixed with 2% paraformaldehyde. Flow cytometry 
acquisition of MDDCs or monocytes was done using a FACS Canto II, (BD USA) and analysed 
by Flowjo software (TreeStar Inc, USA) 
2.11.2 Stimulation of MDDCs 
After six days of differentiation, MDDCs were lifted by pipetting and transferred into 50 mL 
polypropylene tubes. The plate was washed with pre-warmed 1x PBS without calcium or 
magnesium (10010049, Gibco) and added to the tube. Cells were centrifuged at 1200 rpm for 
10 min to pellet cells and washed twice with warm 1x PBS.MDDCs were washed to remove 
all differentiation medium with warm 1x PBS, re-suspended at 4 x 106 cells/ml and stimulated 
in a 48 or 96 well tissue culture dish (Coster) at a final concentration of 2 x 106/ml with either 
pre-titered PSV (50 fold background) or purified gp140 at a concentration of 2µg/ml. 
Stimulation was done in culture medium consisting of RPMI containing 2% human AB, serum 
1% Penicillin/Streptomycin, 1% non-essential amino acids, 1% sodium pyruvate and 2mM L-
glutamine for 24 hrs. Following stimulation for 24 hrs, the plates were centrifuged at 2000 rpm 




supernatants were stored in single-use aliquots at -80oC until cytokine analysis by Luminex 
assay, which read on a Bio-plex 200 array system platform (Bio-rad).  
2.11.3 Quantification of Cytokines in culture supernatants  
2.11.3.1 Luminex Multiplex assay 
The amount of each cytokine secreted into culture supernatants was determined using a 
multiplex cytokine assay, Luminex, according to the manufacturer’s instructions with some 
changes. This assay quantifies the cytokines released by MDDCs into the culture supernatant 
based on Luminex suspension array technology. The principle is similar to sandwich ELISA 
but uses cytokine-specific antibody-immobilized magnetic beads to capture cytokines in 
culture supernatants. In summary, antibody-coated microsphere beads were sonicated for about 
30 secs before pipetting to avoid clumping. Samples were assayed without dilution due to very 
low levels of some cytokines. A total of 25μl of each sample was added to the well containing 
antibody coated beads and incubated for 2 hr at ambient temperature (RT) away from light in 
a Millipore multiscreen plate (Millipore, Billerica, MA). The liquid was then aspirated using a 
BioPlex Pro II plate washer (Bio-rad, Hercules, CA), and the plates were washed twice with 
200μl of assay buffer (provided with kit). The beads were then re-suspended in 25μl of assay 
buffer and 25μl of biotinylated secondary antibody was added, incubated for 30 min at RT 
away from light. The plates were again washed twice with PBS, the beads re-suspended in 25μl 
of assay buffer, and 25μl of streptavidin-phycoerythrin conjugates (SA-PE, Millipore, MA) 
was added. The median fluorescence intensity (MFI) of these beads was recorded (a minimum 
of 62 beads were required for each read) with a Luminex 200 platform (Bio-rad) and analysed 
with Bioplex Manager Software (Version 6.0, Bio-Rad) using a 5P regression algorithm. In 
order to quantify the level of cytokines, standards were used and MFI was plotted against 
protein concentration for the standard protein. Linear regression was used to determine the 
concentration of cytokines in each experimental sample using the standard concentration. 
Cytokines analysed included IL-10, IL-12, IL-6, IL-8, IL-1β, TNF-α, MIP1-α and MIP-1β and 
MIP-3α.  
2.11.4. MDDC Stimulation and of MAP kinases detection 
For intracellular detection of MAPK, MDDCs were re-suspended in incomplete medium 
(serum-free RPMI medium with 100μg/ml Penicillin/Streptomycin and 2mM L-glutamine) at 
a concentration of 106 per ml in round bottom polypropylene tubes, with 1ml per tube and 




at 2000 rpm to remove medium and re-suspended in stimulation medium (2% human AB 
serum) at a density of 5 x 106/ml, taking into consideration the volume of PSV required  to 
obtain a final concentration of 1% serum medium for stimulation This was  maintained at 37oC 
for the required time. Lipopolysaccharide (LPS) at a concentration of 1 µg/million cells was 
included as a positive control. To enhance signal, IL-1β at 10ng/ml and TNF-α at 25ng/ml were 
added to the LPS in some experiments. Mock-treated cells not exposed to PSV or gp140 was 
also included. Mock-treated cells included 1) MDDCs stimulated with viral-like particles 
generated by transfection of HEK 293T cells with only the pSG∆Env backbone to determine 
the effects of viral proteins other than Env, 2) culture medium of HEK 293T cells seeded during 
PSV preparation but not transfected to control for effects of the culture medium. In the case of 
when recombinant protein was used for stimulation, 1% complete medium was used as a 
negative control.  
2.11.4.1 Intracellular staining and flow cytometric detection of MAPKs 
Initially sufficient MDDCs were prepared for stimulation for three time periods (5, 15 and 30 
min), but 15 mins had the least background and subsequent stimulations were done for 15 mins. 
PSV or gp140 were added and stimulation carried out in a 37oC incubator for the required time 
and subsequently an equal volume of 4% paraformaldehyde (PFA) was added to the sample to 
fix the cells and stop further stimulation. Fixation was done for 10 - 12 min at RT. Cells were 
then centrifuged to remove medium and PFA and permeabilised by adding cold BD perm 
buffer III (BD Cat# 558050) or 90% methanol (kept at -20oC before use). Permeabilisation 
was done on ice for 30 min after which cells were centrifuged to remove perm solution and 
stained in 50µl of half strength perm buffer. Fluorescent-conjugated antibodies were added for 
detection of phosphorylated MAPK using BV421-pERK1/2 (pT202/pY204, BD Cat # 562981, 
clone 20A, monoclonal), PE-pJNK (pT183/pY185, BD Cat # 562480, Clone N9-66, 
monoclonal), PerCp-Cy-p38 (pT180/pY182 BD Cat # 560406, Clone 36/p38) at RT away from 
light. Following staining, samples were washed 3x using half strength perm buffer III and re-
suspended in half strength perm buffer III with 2% PFA for analysis on a flow cytometer 
(FACScanto II, B D, USA). Flow data was analysed using Flowjo software (Treestar Inc, 
USA). Fixed and stained cells were either analysed immediately or after overnight storage at 
4oC. Results from single colour -stained and unstained mouse kappa beads and stimulated 
MDDCs stained with single colours were used to calculate compensations. Cell doublets were 




For inhibition experiments, using DC-SIGN protein or anti-DC-SIGN monoclonal Ab, PSVs  
were pre-incubated with 2µg/ml DC-SIGN protein in the presence of 2mM Ca2+and allowed 
to rock at RT for 1 hr, then incubated for one additional hour at 37oC before being used to 
stimulate MDDCs. For inhibition of PSV-CD4 interaction, sCD4 (Cat # 7356, ARP) or VRC01 
(Cat # 12033, ARP) was added to PSV and incubated on ice for 1 hr before being used to 
stimulate MDDCs. When Leu3A antibody was used to block CD4 binding [Leu 3A(SK3), BD 
Biosciences, San Jose, CA], Leu3A was added to the MDDCs, incubated for 2 hr at 4oC, and 
excess antibody removed by washing before stimulation with PSV. 
2.11.4.2 Western blot detection of phosphorylated MAPKs 
For the western blot experiments, 1 x 106 cells were used for each experimental condition. Cells 
were centrifuged immediately following stimulation at 2000 rpm to remove stimulation 
medium, then 2x Ripa  lysis buffer for primary cells was added [40mM HEPES (pH 7.6), 
300mM NaCl, 2mM EGTA, 1% NP-40, 100M phenylarsine oxide, 100mM NaF, 2mM 
Na3VO4, 2 mM Pefabloc, 20mM iodoacetamide, and  2mM phenylmethylsulfonyl fluoride]. 
Lysis was done on ice for 10 min followed by sonication for 10 sec, and then cell lysates were 
transferred into eppendorfs and centrifuged at 14000 rpm  for 10 min. Supernatants were 
collected and stored at -20oC.  
Concentrations of cell lysates were determined by Bradford assay according to the 
manufacturer’s instructions and equal amounts of lysates from each  experimental  condition 
were added to 5x protein sample buffer (100mM TRIS-HCl pH 6.8, 5% (w/v) SDS, 20% (v/v) 
glycerol, 2% β-mercaptoethanol and 0.1% (w/v) bromophenol blue) and heated at 100oC for 5 
min. Samples were then centrifuged for 1 min and then separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions at 25mA/gel. The 
separated proteins were transferred to an Immobilon polyvinylidene difluoride membrane 
(PVDF; Millipore, Bedford-MA) for 1 hr at 100 V. After blocking non-specific protein binding 
sites with 4% skimmed milk in 1x TBS-T pH 7.6 (50 mM Tris-Cl, 150 mM NaCl, 0.1% Tween-
20 ) at RT for 1 hr, protein on the membranes were probed with primary antibodies (rabbit anti-
human MAPKs) to phosphorylated ERK and JNK [Phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204)(Cat #9101) and Phospho-SAP/JNK (Thr183/Tyr185) (Cat # 9251)] diluted 
1: 1000 in blocking buffer at 4oC overnight. Membranes were washed 3 times with TBS-T 
before incubation with horseradish peroxidase-conjugated anti-rabbit secondary antibodies 




T and detection was performed using the Super signal West Pico Chemiluminescent system 
(Pierce, Rockford, IL). Membranes were stripped of the primary antibody in stripping buffer 
(62.5mM Tris-HCl pH 6.7, 100mM β-Mercaptoethanol, 2% SDS). Stripping was done for 30 
min at 50°C with occasional agitation, membranes were washed with 1x TBS-T and re-probed 
with antibodies against phosphorylated and unphosphorylated MAPKs: p44/42 MAPK 
(ERK1/2) for total ERK (Cat # 9102) and SAPK/JNK for total JNK (Cat # 9252) to normalise 
the level of MAPK phosphorylation between different samples and these were normalized to 
the negative controls included; mock treated MDDCs for that donor as outlined in section 
2.11.4 above. 
2.12 Statistical analysis  
Analysis of data obtained was done using GraphPad PRISM (version 5). Mann-Whitney test 
was used to compare unpaired events and Wilcoxon matched test for pairwise comparison. 
Comparison of mutants with WT was done using ANOVA with Bonferoni post-test. Each 
experiment done in triplicate was repeated independently 2–3 times for comparison of mutants 
to WT, and 2-5 times for phenotypic characterisation of Env clones. Figure legends indicate 
the number of biological repeats carried out. When we identified PNGs associated with entry 
efficiency, DC-SIGN binding, trans-infection and IL-10 secretion the median or mean 
(depending on extent of variation) of the biological repeats were compared between the two 
groups using a Mann-Whitney test. Due to high inter-donor variation between experiments, 
and to identify Env PNGs most likely to stimulate IL-10 release irrespective of donor, we 
compared IL-10 levels from different MDDC donors using a Mann Whitney test. Statistical 
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Heterosexual contact remains the predominant route of HIV-1 acquisition despite the apparent 
low efficiency of  transmission (Wawer et al., 2005; Boily et al., 2009; Patel et al., 2014). As 
Env orchestrates the first interaction with host cells during infection and is the main target for 
neutralizing antibodies (nAb) (Earl et al., 1994; Pantophlet & Burton, 2006), it is one of the 
chief targets for vaccine design.  
Almost half of the molecular weight of gp120 is made up of N-glycans forming a dense array 
of carbohydrates that covers the protein backbone (Leonard et al., 1990; Fenouillet & Jones, 
1995). Gp120 has an average of 25  potential N-glycan sites (PNGs) (Leonard et al., 1990) and 
these N-glycans help in the proper folding (Li et al., 1993; Fenouillet, Gluckman & Jones, 
1994) and processing of Env (Doores et al., 2010; Pritchard, Spencer, et al., 2015). Inhibition 
of N-glycosylation was shown to impair function and/or lead to reduced infectivity (Montefiori, 
Robinson Jr. & Mitchell, 1988; Ratner, Heyden & Dedera, 1991; Land & Braakman, 2001) 
while other studies reported that PNGS at N156, N160, N181, N197, N289 and N448 in 
subtypes BC and  N262 in both BC and C clades were required for structure and function, 
although this was not true for all subtypes (Wang et al., 2013; Mathys et al., 2014). Loss, gain 
and shifting of PNG positions occur during HIV disease progression and can influence viral 
pathogenicity (Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006). This is not only 
by directly altering Env structure, but also by altering the processing of Env (Pritchard, 
Spencer, et al., 2015). 
Despite reliance on N-glycans for structure and function, Env can remain unaffected by a 
number of PNG changes that contribute to immune evasion. N-glycans shield epitopes from 
immune recognition (Binley et al., 1998; Wei et al., 2003; McCaffrey et al., 2004; Scanlan, 
Offer, et al., 2007) and the shifting nature of Env N-glycans is a major challenge to vaccine 
design. Moore et al. (2012) showed that the shift of an Env PNG from positions 332 to 334 at 
six months post-infection was linked to escape from broadly neutralizing antibodies (bnAb) 
(Moore et al., 2012). This was supported by studies that showed that deletion of variable loop 
N-glycosylation sites or enzymatic removal of N-glycans improved antibody recognition of 
Env (Binley et al., 1998; Koch et al., 2003; Banerjee et al., 2009; Ma et al., 2011). However, 
paradoxically the type and extent of N-glycosylation can also enhance the immunogenicity of 
Env. Li et al. (2008) suggested that N197 enhanced sensitivity to neutralization (Li, Cleveland, 




properly processed trimers which allowed antibodies to bind better to CD4 binding sites (BS) 
and to CD4 inducible BS (Kong et al., 2010; Raska et al., 2010). Furthermore, some N-glycans 
at N295, N332 and N392 were found to constitute or support the proper conformation of 
epitopes for bnAb like 2G12, PG9 and PG16 (Sanders et al., 2002; Scanlan et al., 2002; 
Calarese et al., 2003; McLellan et al., 2011). Also, more recently, it was suggested that the 
“mannose patch” which includes N332 and other PNGs, form part of the epitopes of some of 
the most potent bnAbs like the PGT121 and PGT138. These epitopes are stable in the face of 
sequence variation and this mannose patch has thus been termed the “supersite of immune 
vulnerability” (Doores et al., 2010; Pejchal et al., 2011; Walker et al., 2011; Garces et al., 2014; 
Pritchard, Spencer, et al., 2015).   
Apart from influencing Env entry efficiency, tropism and Ab neutralization (Pollakis et al., 
2001; Clevestig et al., 2006; François & Balzarini, 2011; Wang et al., 2013; Raska et al., 2014), 
N-glycosylation has also been suggested to play a role in HIV transmission (Go, Hewawasam, 
et al., 2011; Shen, Raska, et al., 2014). Identification of genotypic and phenotypic traits 
common to transmitted founder variants (TFs) is essential to inform the design of novel HIV-
1 preventive therapy. Micro-abrasions or ulcerations resulting from sexual intercourse-related 
trauma or sexually transmitted infections, thinning of the genital mucosa by hormonal 
contraceptives or inflammatory responses to altered vaginal microbiota could facilitate virus 
access to CD4+ T cells, dendritic cells (DCs), macrophages and Langerhans cells (LCs) 
resulting in productive infection by multiple variants (Selhorst et al., 2016; Abrahams et al., 
2009; Haaland et al., 2009).  However, as a single TF variant is responsible for initiating 
productive infection in 80% of infections, in the absence of predisposing conditions, it is 
possible that the virus is able to overcome the mucosal barrier due to advantageous phenotypic 
traits that could include binding to DCs via Env N-glycans, high infectivity or replication 
efficiency, and binding to the integrin 47 (Selhorst et al., 2016; Geijtenbeek, Kwon, et al., 
2000; Arthos et al., 2008; Cicala, Arthos & Fauci, 2011; Nawaz et al., 2011; Wilen et al., 2011; 
Parrish et al., 2013; Shen, Kappes, et al., 2014). Genotypic features of TFs have included 
shortening of variable loops and reduction in the number of potential N-glycans (PNGs) for 
subtypes A and C (Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006) compared to 
variants from chronic stages of infection. Previous research has suggested that subtle 
differences exist in how gp120 interacts with DC-SIGN due to  the length of the V1/V2 loop 
and the charge of the V3 loop (Nabatov et al., 2006). As shortening of the variable loop and 




HIV-1 transmission requires either specific Env PNGs or a precise combination of N-glycans 
for optimum interaction with receptors on target cells.  
DCs and LCs are said to extend their dendrites through an intact mucosa into the lumen to trap 
HIV-1 prior to translocation to lymphoid tissues and may result in degradation or trans-
infection of CD4+ cells (Hu et al., 2000; Spira et al., 1996). Env binds to DCs via the DC-
SIGN receptor and other C-type lectin receptors (CLR) (Geijtenbeek, Kwon, et al., 2000; 
Turville et al., 2001, 2004). Gp120 expressed in cell lines that enhanced the level of high 
mannose (HM) N-glycans bound better to DC-SIGN (Lin et al., 2003; Montfort et al., 2011), 
suggesting that DC-SIGN interacts more favourably with HM type N-glycans. However, other 
studies found that a flexible combination of both HM and complex type N-glycans were 
required for Env interaction with DC-SIGN.  Studies  by Hong et al. (2007) and Liao et al. 
(2011) suggested that Env PNGs at N275, N295 N351, N386, and N392 in subtype B (JR-CSF) 
and recombinant CRF-07 BC were involved in interaction with DC-SIGN and termed them 
“DC-SIGN interactive sites” (Hong et al., 2007; Liao et al., 2011). Go et al. (2011) found that 
N-glycans at positions N241, N262, N386, N392 and N448 were predominantly HM/hybrid 
(HM/H) in subtype C TF Envs (Go, Hewawasam, et al., 2011), suggesting that not only were 
the positions of some PNGs conserved but also the type of N-glycan at each site. As Env HM 
residues are important for binding to DC-SIGN (Lin et al., 2003; van Montfort et al., 2011), 
we hypothesised that sites with HM residues could be involved in interacting with DC-SIGN. 
Therefore, the aim of this project was to understand the importance of N-glycosylation on Env-
mediated PSV entry into TZM-bl cells, binding to DC-SIGN and trans-infection of CD4+ cells. 
Although N275, N295 and N351 were suggested to play a role in binding to DC-SIGN in 
subtype B and recombinant CRF-07BC (Hong et al., 2007; Liao et al., 2011), these sites were 
not present in our subtype C clonal sequences and were thus excluded from the analysis. As 
DC-SIGN was found to interact more favourably with HM type N-glycans (Lin et al., 2003; 
Eggink et al., 2010; Montfort et al., 2011) and TF subtype C Env PNGs at N241, N262, N386, 
N392 and N448 preferentially carried HM/H type N-glycans (Go, Hewawasam, et al., 2011), 
we deleted these PNGs by site directed mutagenesis (SDM) and studied the impact of each on 
Env function. Moreover, to identify other PNGs that could also be involved in Env function, 
we used sequence analysis to determine whether the presence or absence of PNGs within the 





3.2 Aim and Objectives 
 Aim: Characterise the N-glycosylation of subtype C Envelope and determine the role in 
Envelope function.  
Rationale: 
Env N-glycosylation is essential for correct folding and processing and deletion of specific 
PNGs have resulted in loss of function and viral infectivity (Li et al., 1993; Fenouillet, 
Gluckman & Jones, 1994; Wang et al., 2013; Pritchard, Spencer, et al., 2015). However, the 
number and position of PNGs shift over the course of infection to enable the virus to evade 
nAb responses (Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006). Therefore, viral 
survival depends on a delicate balance between immune escape and maintaining Env function. 
Subtype C TF Envs tend to be more compact with fewer PNGs, suggesting that they could 
differ phenotypically from variants that emerge during chronic infection (Derdeyn et al., 2004; 
Chohan et al., 2005; Sagar et al., 2006). This difference could provide TFs with a functional 
advantage during transmission and targeting these features in vaccine design could prevent 
HIV-1 infection. However, loss and gain of PNGs in response to a vaccine-elicited immune 
response could also enhance viral infectivity and it is thus important to understand how changes 
in N-glycosylation influence Env function. 
3.2.1 Specific Objectives: 
1.  Determine whether differentially N-glycosylated Env pseudovirus (PSV) differ in 
entry efficiency, binding to DC-SIGN and trans-infection of CD4+ cells  using both 
Raji-DC-SIGN cells and monocyte-derived dendritic cells (MDDCs).  






3.3.1 PNG frequency analysis 
Env generally has about 24 PNGs in gp120 and five in gp41 (Leonard et al., 1990). Despite 
earlier studies focussing on the role of Env N-glycosylation in HIV-1 pathogenesis, the impact 
of specific PNGs and how they might act in concert to influence Env function are not fully 
understood. This study thus aimed to determine how specific PNGs and overall HM/H N-
glycosylation influenced subtype C Env entry efficiency, binding to DC-SIGN and trans-
infection of CD4+ cells. Eighteen Env SGA-derived amplicons were cloned and used for 
genotypic and phenotypic analysis. The number of PNGs (range: 25 – 33) and frequency of 
PNGs at specific N-glycan sites varied between our clones (Figure 3.3.1; Table 3.3.1). 
Consistent with previous studies (Derdeyn et al., 2004; Chohan et al., 2005) , the number of 
PNGs increased significantly over the first 2-3 years post-infection (p < 0.009). The caveat of 
this analysis was that multiple clones were compared from only 5 participants and further 
sampling is needed to confirm the observed correlation (Figure 3.3.1). However, comparing 
multiple chronic infection clones to a single TF indicates that an increase in PNGs is not 
restricted to only a single variant. 
 To confirm that our clone sequences were representative of the larger cohort we compared the 
frequency of the PNGs of our 18 clones to 36 phylogenetically distinct, consensus sequences 
from the same cohort. We found an overall significant association (p < 0.0088, r = 0.70) 
between our clones and that of the other cohort sequences but the variation between the two 
groups indicates some sampling bias. Only PNGs at position 241 and 262 were 100 % 
conserved in our cohort sequences and this was supported by frequency analysis of 589 random 
subtype C sequences from the Los Alamos database and published data (Moore et al., 2012; 
Pritchard, Spencer, et al., 2015). PNG frequency in the cohort sequences correlated with those 
from the subtype C database (p = 0.0002, r = 0.94) whereas PNG frequency in our clonal 
sequences did not always correlate with those in the population (r = 0.5), likely due to the small 
sample size of our clonal sequences. However, those that were conserved and those that were 
infrequent were consistent between the two alignments. N674 seemed to be under negative 




Table 3.3.1 Characterisation of Envelop clones and frequency of potential N-glycan sites (PNGs) deleted by site-directed mutagenesis.   
Participant ID ID Time post infection (wks) No. of PNGs Position of N-Glycan sites 
    N241 N262 N448 N386 N392 N130 N289 332 N356 N674 
CAP45 C1 2 29 + + - - - - + - + + 
 C2 108 28 + + - - - - + + + + 
CAP177 C3 2 24 + + + - + - - - - - 
 C4 173 33 + + + - + + + - - + 
 C5 173 31 + + + - + + + - - - 
 C6 173 35 + + + - + + + - - + 
CAP206 C7 4 25 + + - - - + - + - - 
 C8 173 28 + + - - - + + + - - 
 C9 173 27 + + - + - + + + - - 
 C10 173 27 + + - + - + + + - - 
 C11 173 26 + + - - - + + + - - 
CAP210 C12 2 33 + + + + + + + + + - 
 C13 80 32 + + - + - + + + + + 
 C14 80 33 + + - + - + + + + + 
CAP 239 C15 5 29 + + + + + + - + + - 
 C16 173 31 + + + + + - - - + - 
 C17 173 32 + + + + + + - - + - 
 C18 173 30 + + + + + - - - + - 
Clonal frequencya    100 100 50 89 50 72 67 55 50 33 
Study cohort frequency b    100 100 58.33 91.67 69.44 55.56 80.56 72.22 72.22 16.66 
Population frequencyc    99.5 100 71.5 85.56 71.5 54.5 83.5 80.5 87.9 24.5 
Published frequencyd    97 99 72 89 70 54 81 77/75 74 ND 
aFrequency of PNGs in the 18 functional clonal sequences used in this study 
bFrequency of PNGs in 36 sequences from the same cohort  
cFrequency of PNGs in 589 Subtype C sequences from the Los Alamos database (www.Los Alamos.com) 




3.3.2 N-glycosylation analysis 
Mannose type N-glycans have been found to help in the folding of Env into conformations 
required for recognition by some bnAb epitopes (Sanders et al., 2002; Scanlan et al., 2002; 
McLellan et al., 2011), binding to DC-SIGN on MDDCs and DC-SIGN-expressing cell lines 
(Lin et al., 2003; Shan et al., 2007; van Montfort et al., 2011) and infectivity (Montefiori, 
Robinson Jr. & Mitchell, 1988). As N-glycosite analyses of our 18 Env clones using the Los 
Alamos tool (www.lanl.gov) indicated high variation in number (24-33) and frequency of 
PNGs (50 - 100%) (Figure 3.3.1), we determined if this translated into varying ratios of HM/H 
to complex type N-glycans. We truncated the gp160 of 9/18 Env clones by introducing a stop 
codon before the transmembrane (TM) domain of gp41. Based on previous publications, the 
soluble gp140 (gp140) construct would be N-glycosylated, cleaved into gp120 and truncated 
gp41 and form soluble trimers that would be directly secreted into the culture medium of 
HEK293T cells. However, it has also been suggested that cleaved gp140 forms unstable trimers 
that are stabilised by deletion of the cleavage site and introduction of a disulphide bond, 
covalently tethering gp41 to gp120 (Binley et al., 2000; Herrera et al., 2005; Pancera et al., 
2005; Moore et al., 2006; Chung et al., 2014). Deletion of the cleavage site has been shown to 
prevent folding of gp120 into its native conformation and introduction of a disulphide bond 
affected Env function (Binley et al., 2002; Abrahamyan et al., 2003) and we elected not to 
include these modifications in our gp140 constructs. 
Figure 3.3.1 Characterisation of potential N-glycan sites in eighteen functional Env 
clones. BioEdit was used to align Env sequences and the alignment was analysed by N-glycosite 
(www.los Alamos.com). A) Env clones were grouped according to time of sampling (Acute infection: 
2-5 weeks post-infection; Chronic infection: 80-173 weeks post-infection) and the number of potential 
N-glycan sites (PNGs) was compared between the two groups using a paired t test (Prism 5.0). B) N-







frequency of the PNGs in the 18 Env sequences. Each blue bar indicates a unique PNG found in one 
or more sequences. 
Endoglycosidase digestion with enzymes that either cleave only HM/H type N-glycans 
(EndoH) or all types of N-glycans (PNGaseF) is a useful technique to determine the relative 
composition of HM/H to complex type N-glycans associated with Env (Raska et al., 2010). 
After transient transfection of HEK293T cells, gp140 was harvested using lectin affinity 
chromatography and digested with EndoH and PNGaseF and the change in electrophoretic 
mobility of the bands were compared to undigested controls.  The expression levels of C1 and 
C2 were too low to purify gp140 from the culture medium (Data by Ms Liliwe Shuping; 
Appendix 1, Figure A1) and these clones were thus excluded from the analysis.  
Only undigested (U) C13, C14, C15 and C16 gp140 indicated two bands representing 
uncleaved (UNC) gp140 and gp120 assumed to derive from fully N-glycosylated and cleaved 
gp140 trimers (Figure 3.3.2). The average apparent molecular weight of                                       
undigested gp120 was 131 kDa, similar to the purified gp120 positive control (132 kDa) (Table 
3.3.2) with a standard deviation (SD) of 10.43, indicating high heterogeneity in N-
glycosylation across the 4 clones. However, bands corresponding to gp120 were not apparent 
in the untreated samples of most of the clones and thus bands representing gp140 were used to 
compare the ratio of HM/H: complex type N-glycans between the clones. Cleavage of gp160 
occurs after N-glycosylation and trimerisation en route to the plasma membrane and thus 
uncleaved gp140 could represent the fully N-glycosylated native form of gp120 (Checkley, 
Luttge & Freed, 2011). The variation in the average apparent molecular weight of undigested 
UNC gp140, 144 kDa (SD: 10.33), was very similar to that of fully glycosylated gp120 
suggesting similarly high heterogeneity in N-glycosylation of gp140 and gp120 across the 9 
clones. 
 The absence of two clear bands for gp140 and gp120 was likely due to overloading, weak 
cleavage of gp140 resulting in low levels of gp120 and/or poor resolution of gp140 and gp120 
with similar molecular weights. After PNGaseF treatment, deglycosylated gp140 and gp120 
bands became apparent for all of the clones, confirming that a fraction of all gp140 clones was 
cleaved into gp120. The secretion of UNC gp140 into the culture medium supports the finding 
by Moore et al. (2006) that gp160 reaches the cell surface and is incorporated into virus 




The difference in MW between untreated and PNGaseF-digested UNC gp140 is the weight due 
to N-glycosylation. Similarly, the difference in MW between untreated and EndoH-digested 
UNC gp140 indicates the weight contributed by HM/H N-glycans. The ratio of HM/H: total 
N-glycans provides a measure of mannosylation (%) of UNC gp140 (Table 3.3.2; Figure 3.3.3). 
The control, deglycosylated purified gp120, had the apparent MW of 57.9 kDa, higher than the 
predicted MW of 53.32 kDa calculated using the Compute pI/Mw tool available at SIB Expasy 
Bioinformatics Resources Portal (https://www.expasy.org/) (Table 3.3.2). EndoH digestion of 
the purified gp120 positive control resulted in an electrophoretic mobility shift which 
corresponded to a change in molecular weight of 132.2kDa to 105.1 kDa, suggesting that 
36.57% of the overall molecular weight of gp120 is due to HM/H. Similar to the purified gp120 
control, the average apparent MW of PNGaseF-treated UNC gp140 differed by nearly 4 kDa 
to the predicted mass of unglycosylated gp140 (Table 3.3.2).  
The level of gp140 mannosylation varied between clones with HM/H N-glycans contributing 
23.43 – 42.9% to the total molecular weight of all clones except C3 with only 6.8% 
mannosylation (Figure 3.3.3).  Comparison between the number of Env PNGs and UNC gp140 
mannosylation showed a significant association (p = 0.017, r = 0.78), suggesting that as the 
number of PNGs increase, so does the level of mannosylation. This supports the suggestion 
that increased number of PNGs could lead to denser N-glycosylation which would sterically 
hinder Man9GlcNac trimming, increasing the level of HM/H associated with Env (Bonomelli 
et al., 2011; Pritchard, Spencer, et al., 2015). Mannosylation of UNC gp140 was less than what 
was previously reported for virion-associated gp120 (56 – 79% oligomannose)  (Bonomelli et 
al., 2011; Doores et al., 2010; Go et al., 2015; Pritchard, Harvey, et al., 2015; Pritchard, 
Vasiljevic, et al., 2015) but similar to what Go et al. found when they analysed subtype C 
gp140 (20 – 30%) (Go, Hewawasam, et al., 2011). To determine whether gp120 derived from 
gp140 cleavage was more similar to virion-associated gp120, we determined the level of 
















Figure 3.3.2 N-glycosylation of soluble gp140 constructs. N-glycan processing of nine gp140 
clones (C3, C4, C7, C8 and C12-C16), were determined by endoglycosidase treatment following 
transient expression in 293T and partial purification using Gallanthus nivalis lectin agarose. Western 
blotting for each clone was done to compare the electrophoretic mobility shift of fully N-glycosylated, 
partially N-glycosylated and fully deglycosylated gp140 and gp120. Representative Western blots of at 
least three independent repeats of undigested (U), Endo H- (E) and PNGaseF-digested (P) gp140 were 
compared to digested purified gp120 (PP)(AIDS Reagent Programme; Catalogue # 11784). The 
Western blots were aligned according to the molecular weight marker included on all gels (not shown) 
so that N-glycosylated, demannosylated and deglycosylated gp120 and gp140 were juxtaposed across 
all clones. The MW of each band was calculated according to the MW standard and the relative 
migration of digested bands was determined relative to undigested controls using Image labTM software 
on a Chemi DocTm Bio-rad imaging (visualizing) system. The relative positions of deglycosylated gp140 
and deglycosylated gp120 are shown by red and green arrows, respectively.  + indicates purified gp120 
(PP) (AIDS Reagent Programme; cat # 11784) as a loading control for Env.  
The MW of deglycosylated gp120, 56 kDa (+/- 2) was similar to the expected average gp120 
MW, 57 kDa (+/-0.8) with low heterogeneity between clones (Table 3.2.2). Mannosylation of 
gp120 ranged from 37 to 50 %, higher than that of gp140 but still lower than previously 
reported for virion-associated gp120 (Bonomelli et al., 2011). Mannosylation of UNC gp140 
correlated with that of gp120, suggesting that if gp140 carried higher levels of HM/H then so 
did gp120, although this correlation did not reach significance (p = 0.0833; r = 1.0), most likely 





















Figure 3.3.3 Mannosylation of soluble gp140 and correlation with number of Env PNGs. 
Molecular weight comparison of EndoH- and PNGaseF-digested gp140 relative to undigested gp140 
was used to determine the relative level of high mannose/hybrid N-glycans. A) Level of mannosylation 
(%) was calculated using the equation: (MW of untreated gp140 - EndoH-treated gp140) / (MW of 
untreated gp140 - PNGaseF-treated gp140) X 100. The data above is an average of two biological 
repeats with error bars representing standard error of the mean (SEM). B) The correlation between 
number of potential N-glycan sites (PNGs) and gp140 mannosylation was determined using the 
Spearman Test (GrapPad Prism 5.0).    
 
 























Table 3.3.2 Endoglycosidase analysis of undigested, Endo H and PNGase F digested gp140 to determine relative levels of high 














The data in this table represents one of two independent experiments shown in Figure 3.3.3 to indicate how values were derived using molecular weight of N-glycosylated, 
demannosylated and deglycosylated gp140. 
# Predicted Molecular Weight: ProtParam calculator on Expasy programme 
^ Apparent Molecular Weight: Derived from standard MW marker using Chemi DocTm Bio-rad imaging system and Image lab software  
* Calculations: 
HM/H MW = Apparent MW of undigested – Apparent MW of Endo H-digested 
Total N-glycan MW = Apparent MW of undigested – Apparent MW of PNGase F-digested 
Level of HM/H= [(HM/H MW)/ (Total N-glycan MW) x 100] 
aOnly 4/9 clones had bands corresponding to N-glycosylated gp120. 
bAverage of clones excluding purified gp120   
Purified gp120 (Aids Reagent Programme cat # 11784) Accession number: AF189159 was used as a positive control. 
Clone ID No. of 
PNGs 
Apparent MW 
(kDa) of undigested  
 



































 N/A 132.2 N/A 105.1 N/A N/A 53.32 57.9 27.1 74.1 36,57 
C3 24 149 N/A 143.3 N/A 75 73.1 55.05 57.6 5.6 75.8 7.4 
C4 33 146 N/A 119.6 N/A 77 72.4 57.11 56.0 26 73.2 35.52 
C7 25 130 N/A 112.2 96.8 75.93 72 56.16 53.3 17.92 58.12 30.83 
C8 28 131 N/A 116.2 95.8 76.56 76.2 56.78 55.8 14.5 54.5 26.61 
C12 33 159 N/A 128 108 77.34 76.8 57.58 60.8 30.5 81.7 37.33 
aC13 32 157 139.3 131.8 101.3 76.62 71.5 57.0 57.8 25.6 85.9 29.8 
aC14 33 157 140.1 126.2 99.2 76.81 71.1 56.9 57.6 30.4 85.5 35.55 
aC15 29 135 119.2 109.0 87.4 76.0 72.0 56.56 56.1 30.0 63.3 42.11 
aC16 31 146 125 122.6 98.8 78.0 76 57.85 53.3 23.2 698 33.24 




3.3.3 Entry efficiency of Env clones 
N-glycosylation was previously shown to influence infectivity but not replication (Montefiori 
et al, 1988). As mannosylation levels as well as the number and position of PNGs varied across 
the 18 Envs, we determined whether this variation influenced the efficiency with which PSVs 
could enter CD4+ CCR5+ CXCR4+ cells.  
There was high variation in entry efficiency, ranging from 3.5 - 100% (Figure 3.3.4). C3, with 
the lowest level of oligomannose moieties was also the weakest enterer, followed by C2 which 
was very poorly expressed as determined by Western blotting (Data by Ms Liliwe Shuping; 
Appendix I, Figure A1). There was no statistically significant correlation between 
mannosylation and entry efficiency (p = 0.25, r = 0.37).  This could suggest that entry efficiency 
is not dependent on the type of N-glycans associated with Env.  
  




















Figure 3.3.4 Pseudovirion entry efficiency. Pseudotyped Envs (PSV) equivalent to 100 ng p24 
were compared for their ability to enter TZM-bl cells. Entry was monitored through the activation of a 
luciferase reporter gene under the control of the LTR. Four biological repeats were carried out in 
triplicate and each repeat was normalised to C1 to control for inter-experimental variation. The bar 
graphs are means of the four biological repeats with error bars showing standard error of the mean. 
3.3.4 Binding to DC-SIGN 
DC-SIGN binding was also variable with 2.3 - 11.5% PSV captured by Raji-DC-SIGN cells 
relative to input virus or 1 - 3% when normalised to C1 (Figure 3.3.5). To make sure the PSVs 
were captured due to DC-SIGN-Env interactions and not through non-specific binding, PSVs 
were also added to Raji cells not expressing DC-SIGN and PSVs lacking Env (PSG3∆Env 
only) was used as a control. No binding was observed (Data not shown), confirming that Env-
DC-SIGN interactions are required for PSV binding to Raji cell. There was no correlation 
between binding to DC-SIGN and entry efficiency. This was expected since Raji cells do not 




association between binding to DC-SIGN and the level of mannosylation (p = 0.0369, r = 0.71) 
(Figure 3.3.6) which supported previous findings by Lin et al. (2003) that DC-SIGN-Env 
interactions depend on Env HM/H N-glycans (Lin et al., 2003; Montfort et al., 2011). There 
were, however, instances where this relationship was not supported such as C14 which had 
high levels of HM/H but did not bind to DC-SIGN better than C4 that was less mannosylated.  
Liao et al. (2011) suggested that a flexible combination of HM/H and complex-type N-glycans 
form the optimum binding sites for DC-SIGN (Liao et al., 2011). It is thus possible that DC-
SIGN binding is via HM/H but that the clone-specific arrangement of complex N-glycans 
within the 3-dimensional structure could influence the binding efficiency. 



















Figure 3.3.5 Pseudovirion binding to DC-SIGN on Raji-DC-SIGN cells. Pseudovirus (PSVs) 
(10ng total p24) binding to DC-SIGN was compared by capturing PSVs using Raji-DC-SIGN cells and 
measuring the amount of PSV bound to DC-SIGN by p24 ELISA and normalised to input PSV. To 
compare data between biological repeats, percentage PSV captured was normalized to a single clone 











Figure 3.3.6 Correlation of DC-SIGN binding with level of Env mannosylation. Percentage 
PSV captured by DC-SIGN relative to input virus from two biological repeats was normalized to C1 
and Spearman correlation analysis (GraphPad Prism 5.0) was used to determine whether there was a 
relationship between percentage Env mannosylation and DC-SIGN binding of nine PSV clones.  
 
3.3.5 Trans-infection 
Env binds to DC-SIGN on MDDCs facilitating trans-infection of CD4+ T cells, but the role 
this interaction plays in HIV transmission and pathogenesis in vivo is debated (Geijtenbeek, 
Kwon, et al., 2000; Turville et al., 2001; McDonald, 2003, 2010; de Witte, Nabatov & 
Geijtenbeek, 2008). Both in vitro and ex-vivo, studies have shown that MDDCs and DCs can 
bind and transfer virus to target cells via DC-SIGN and other C-type lectins (Geijtenbeek, 
Kwon, et al., 2000; Kwon et al., 2002; Shan et al., 2007; Shen, Kappes, et al., 2014). Non-
CLR-mediated (heparin sulphate proteoglycans, CD169, GarCer) mechanisms of HIV trans-
infection have also been reported for MDDCs (Saphire et al., 2001; Magerus-Chatinet et al., 
2007; Izquierdo-Useros, Lorizate, Puertas, et al., 2012; Puryear et al., 2013). To determine 
whether trans-infection of PSVs was influenced by cell type and/or receptor identity, we 
investigated the trans-infection of our differentially N-glycosylated Envs using both Raji-DC-
SIGN cells (Figures 3.3.7 and 3.3.8) and MDDCs (Figure 3.3.9). PSVs were also added to 
TZM-bl cells to determine the ability of the input virus to directly enter the reporter cell line 
without DC-SIGN-mediated trans-infection. This provided a measure of the entry efficiency 
of each PSV stock. An equal quantity of PSV was added to DC-SIGN+ cells (Raji-DC-SIGN 
and MDDCs) before cells were washed and mixed with TZM-bl cells to measure the amount 





3.3.5.1 Raji-DC-SIGN-meditated trans-infection 
Trans-infection of TZM-bl cells using Raji-DC-SIGN cells for capture varied widely across 
PSVs: 3.3 to 160% relative to C1 (48-fold) (Figure 3.3.7 A). Since trans-infection consists of 
two steps, first binding to DC-SIGN and then entry of target cells, PSVs with high entry 
efficiency should have high trans-infection efficiency. There was a significant correlation 
between trans-infection and entry efficiency (p = 0.0001, r = 0.95), confirming this relationship 
(Figure 3.3.8 A). To determine whether the apparent variation in trans-infection of TZM-bl 
cells was entirely due to differences in PSV entry efficiency, trans-infection values were 
normalized by the entry efficiency of the input PSVs. Dividing the trans-infection values by 
the entry efficiency of each PSV did not have a consistent effect across all clones as variation 
was reduced (e.g. C1 vs C3), not affected (e.g. C10 vs C11) and increased (e.g. C15 vs C18) 
(Figure 3.3.7 B).  However, normalising with entry efficiency lowered the overall variation in 
trans-infection 12-fold (i.e. from 48-fold to 4-fold variation across clones) and weakened the 
relationship between trans-infection and entry efficiency (p = 0.0138, r = 0.6), suggesting that 
entry efficiency was an important determining factor (Figure 3.3.7 B and Figure 3.3.8 B). DC-
SIGN binding was also an important determining factor as there was a significant association 
between DC-SIGN binding and Raji-DC-SIGN-mediated trans-infection (p = 0.0088, r = 0.6) 
and this relationship was strengthened when trans-infection was normalised by entry efficiency 
(p = 0.0022, r = 0.7) (Figure 3.3.8 C and D). These findings confirm that both Env entry 
























Figure 3.3.7 Raji-DC-SIGN-mediated trans-infection of CD4+ cells. Pseudovirus equivalent 
to 100 ng p24 was added directly to TZM-bl cells to measure entry efficiency or first captured by Raji-
DC-SIGN cells before adding to TZM-bl cells to measure trans-infection. Entry of TZM-bl cells was 
measured by luciferase reporter assay. A) The raw RLU values of each PSV DC-SIGN meditated trans-
infection were expressed as a relative percentage of a single clone C1 or B) were first normalized to 
entry efficiency and then expressed as a percentage relative to C1. Experiments were done in triplicates 
























Figure 3.3.8: The relative role of Env entry efficiency and DC-SIGN binding in Raji-DC-
SIGN-mediated trans-infection. Following Raji-DC-SIGN-mediated trans-infection, the results 
were normalized to C1 and an association with entry efficiency (A, B) and DC-SIGN binding (C, D) 
was determined using Spearman correlation analysis. To determine if entry efficiency is an important 
determining factor of trans-infection, trans-infection values were first divided by PSV entry efficiency 
before normalisation to C1 (B, D).  
3.3.5.2 MDDC-mediated trans-infection  
DC-SIGN, mannose C-type lectin receptors (MCLRs), CD4, CCR5 and CXCR4 have been 
documented to play a role in DC enhancement of HIV infection (Turville et al., 2002, 2008; 
Lambert et al., 2008). Other non-CLR receptor mechanisms have also been found to contribute 
to HIV trans-infection (Saphire et al., 2001; Magerus-Chatinet et al., 2007; Izquierdo-Useros, 
Lorizate, Puertas, et al., 2012; Puryear et al., 2012). MDDCs are physiologically close to 
myeloid dendritic cells and express CLRs and other virus capture receptors which have been 
suggested to aid in trans-infection. We thus determined whether MDDC-mediated TZM-bl 
trans-infection was similar to when using Raji-DC-SIGN for PSV capture. Trans-infection 
using MDDCs varied between 6 – 100% (16-fold) between clones and was therefore, not as 





to low trans-infection efficiency was also altered (Figure 3.3.9 A). Despite these differences, 
there was a significant correlation between trans-infection by both cell types (p = 0.0001) 
(Figure 3.3.10 C),   
When trans-infection efficiency was normalized to entry efficiency, the variation between 
clones was reduced from 16-fold to 2.5-fold similar to Raji-DC-SIGN-mediated trans-infection 
although the effect on specific clones differed (e.g. C15 vs C18) (Figure 3.3.9 B).  There was 
a significant correlation between MDDC-mediated trans-infection and entry efficiency (p = 
0.0001, r = 0.8535) but once normalized to entry efficiency this relationship lost significance 
(p < 0.56) (Figure 3.3.10 A & B). This suggests that the variation in MDDC-mediated trans-
infection was largely due to differences in TZM-bl entry. Furthermore, contrary to capture 
using MDDCs, in some experiments direct infection of TZM-bl cells was less efficient than 
Raji-DC-SIGN mediated trans-infection, suggesting that pre-exposure to Raji-DC-SIGN 
enhanced TZM-bl entry (Appendix I, Figure A2). There was a significant correlation between 





Figure 3.3.9 MDDC-mediated trans-infection of CD4+ cells. PSV equivalent to 100 ng p24 
were captured for 2.5 hrs by MDDCs and used to infect TZM-bl cells. The relative luciferase units from 
MDDC PSV trans-infection relative light units (RLUs) were normalized to a single clone (% of C1) for 
each repeat (A) or normalized to entry efficiency and then as a percentage of C1 (B). Bar graphs are 
means and error bars represent standard error of the mean (+/- SEM) for three biological repeats done 






Figure 3.3.10: The role of Env entry efficiency in MDDC-mediated trans-infection and its 
similarity to Raji-DC-SIGN-mediated trans-infection. The association of MDDC-mediated 
trans-infection with entry efficiency (A,B) and Raji-DC-SIGN-mediated trans-infection (C) was 
determined using Spearman correlation analysis (GraphPad Prism 5.0). Following MDDC-mediated 
trans-infection, the RLU were normalized to C1 (A,C) or divided by Env entry efficiency first before 
normalization to C1 (B) to determine whether entry efficiency is an important determining factor of 





Trans-infection did not correlate significantly with Env mannosylation when using Raji-DC-
SIGN cells and MDDCs for PSV capture despite the significant positive correlation between 
DC-SIGN binding and Env mannosylation and DC-SIGN binding and Raji-DC-SIGN-
mediated trans-infection. This is possibly because of the strong dependence of successful 
trans-infection on entry efficiency which over-shadows the importance of DC-SIGN binding 
capacity. There is also the avidity effect: the ability of DC-SIGN-bound virus to dissociate 
from the receptor when added to the TZM-bl cells. They could be so that tightly bound PSVs 
and might not easily be transferred to TZM-bl cells. However, high DC-SIGN binding was 
associated with high trans-infection efficiency and it is thus unlikely that the mannosylation is 
influencing trans-infection by the avidity effect. An alternative explanation could be that 
successful trans-infection is more dependent on Env entry efficiency than DC-SIGN binding 
and Env entry is not influenced by mannosylation.  
 
3.3.6 Role of specific PNGs in Env function 
3.3.6.1 Impact of PNG deletions on Env function 
3.3.6.1.1 Impact of PNG deletions on entry efficiency 
HIV-1 Env PNGs have been found to impact interaction with target cell surface receptors 
(Pollakis et al., 2001; Clevestig et al., 2006; Li, Cleveland, et al., 2008; François & Balzarini, 
2011; Wang et al., 2013; Mathys & Balzarini, 2014). To gain further insights into which 
specific PNGs are involved in entry efficiency, binding to DC-SIGN and trans-infection, PNGs 
previously suggested to be involved in DC-SIGN binding were deleted by SDM (Hong et al., 
2007; Liao et al., 2011). Furthermore, Go et al. (2011) showed that PNGs at N241, N262, 
N386, N392 and N448 of subtype B and C TFs were enriched for HM/H N-glycans.  As DC-
SIGN binding has been suggested to favour mostly mannose type N-glycans (Lin et al., 2003; 
Shan et al., 2007; van Montfort et al., 2011), these sites were mutated and their impact on the 
function of C15 and C16 measured. These PNGs were conserved in C15 and C16 and the PSVs 
of these clones bound DC-SIGN with similar efficiency (1.5%) (Figure 3.3.5). However, C15 
and C16 differed in entry efficiency (100 vs 40%, respectively) (Figure 3.3.4), percentage 
mannosylation (47 vs 33%, respectively) (Table 3.3.2), Raji-DC-SIGN mediated trans-
infection (196 vs 44%, respectively) (Figure 3.3.7) and MDDC-mediated trans-infection (56 
vs 13%, respectively) (Figure 3.3.9).  The Asparagine of the NXS/T sequon was replaced by 




constituting single, double and triple mutants in various combinations of PNGs. The entry 
efficiency, binding to DC-SIGN and trans-infection of the deletion mutants were compared to 
WT.  
C15 N262Q and C16 N392Q were unable to infect TZM-bl cells (Figure 3.3.11). Other studies 
have shown that  deletion of the PNG at N262 lead to complete loss of infectivity (François & 
Balzarini, 2011; Wang et al., 2013; Mathys et al., 2014) and it was suggested that deletion 
resulted in misfolding of Env (Doores, 2015). C16 N262Q and C15 N386Q had only 10% 
residual function while deletion of PNGs at N241 and N448 were the only mutations that did 
not significantly alter the entry efficiency of C16 even when both were absent, contrary to what 
was observed for C15 (Figure 3.3.11). The differential effect of PNG deletion on the entry 
efficiency of the two clones suggests that loss and gain of some N-glycans affect Env function 
in a clone-dependent manner. 











































































































Figure 3.3.11: Impact of Env PNG deletion on PSV entry efficiency. N-Q mutants of C15 (A) 
and C16 (B) were pseudotyped and compared to WT for their ability to infect TZM-bl cells. Entry was 
measured by the luciferase reporter assay and the RLU values are indicated relative to WT.  Bars 
indicate the mean of two independent experiments and the error bars indicate standard error of the mean. 
Statistical analysis was done using ANOVA. *, **and *** indicate p < 0.05, p < 0.01 and p < 0.001, 
respectively relative to WT, ns was not significant 
PNGs at N241 and N262 in the C2 region of gp120 are 100% conserved in most subtypes 
including subtype C. The high conservation of these PNGs suggests that they are probably 
important for protein structure or function. Indeed, that deletion  of PNGs at N241 and N262 




(Pritchard, Spencer, et al., 2015).  However, like in the case of C16 N262Q the same deletion 
in BaL (N262A) did not render PSVs non-infectious (Pritchard, Spencer, et al., 2015).  
N386 and N392 are in the C3 region and together with N241 and N262 were profiled to 
preferentially carry oligomannose N-glycans in subtype B and C TFs (Go, Hewawasam, et al., 
2011). Pritchard et al. (2015) reported that loss of certain PNGs in this region resulted in 
disruption of Env structure and function. Structural modelling of the N-glycan shield in this 
region showed that the Asparagine Cα-atoms of N386 and N392 were positioned about 12 Å 
(Angstroms) apart, leading to glycan-glycan interactions that could prevent mannosidase II 
from gaining access for oligomannose trimming. They suggested that due to bystander 
processing effects, deletion of one PNG could provide 1,2 α-mannosidase with access to a high 
mannose N-glycan, leading to trimming and the addition of complex carbohydrates which 
could then alter Env structure (Pritchard, Spencer, et al., 2015). Although we showed that total 
Env mannosylation was not associated with PSV entry efficiency, the presence or absence of 
either a HM/H or complex-type N-glycan at specific PNGs could be important for Env structure 
and/or function.  
3.3.6.1.2 Impact of PNG deletions on binding to DC-SIGN 
Deletion of N-glycans at positions N241, N262, N448, N386 and N392 led to significant 
reduction in binding to DC-SIGN for the C15 mutant, concomitant with loss of entry efficiency. 
C16 N241, N262 and N392 also had significantly reduced binding to DC-SIGN although 
deletion of N448 and N386 had no effect. PNG deletions impacted DC-SIGN binding of C15 
and C16 differently: the DC-SIGN binding efficiency of C15 mutants ranged from 20 to 90% 
and approximately 20 to 60% for C16, suggesting that C15 was more sensitive to N-Q mutation 
than the C16 (Figure 3.3.12). However, the impact of each PNG on DC-SIGN binding was 
difficult to deduce because entry efficiency was compromised in nearly all mutants. We could 
therefore not distinguish whether a PNG was important for interacting with DC-SIGN or 














































































































Figure 3.3.12: Impact of PNG deletion on Env-DC-SIGN interactions. The equivalent of 100 
ng p24 PSV was added to Raji-DC-SIGN cells and allowed to bind for two and half hours before bound 
PSV was measured by p24 ELISA. Raji cells not expressing DC-SIGN were used as a control (Not 
shown). Percentage DC-SIGN binding relative to WT are indicated for C15 mutants (A) and C16 
mutants (B). Bars indicate mean and SEM for two independent experiments. Results were compared to 
WT using one way ANOVA. *, **and *** indicate p < 0.05, p < 0.01 and p <0.001, respectively relative 
to WT. 
 
3.3.6.1.3 Impact of PNG deletion on trans-infection 
As the trans-infection assay is dependent on TZM-bl entry, it was expected that the loss or 
reduction of entry efficiency of most PNG deletion mutants would result in poor trans-infection 
efficiency. The relationship between entry efficiency and trans-infection was apparent when 
deletion of C15 PNGs at N241, N392 and N448 reduced trans-infection to 7%, 23% and 39% 
respectively (Figure 3.3.13), with a concomitant decrease in entry efficiency to 29%, 50% and 
60%, respectively (Figure 3.3.11). C16 N448 deletion mutant retained 100% entry efficiency, 
DC-SIGN binding and trans-infection capacity. However, although the entry efficiency of C16 
N241 deletion mutant was not significantly reduced, its trans-infection was lowered. This is 
likely due to lowered DC-SIGN binding, suggesting that for C16, a PNG at position 241 could 
be important for DC-SIGN binding. This finding supports our data that trans-infection is 
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Figure 3.3.13 Impact of PNG deletions on trans-infection. PSV (100 ng p24) of PNG deletion 
mutants and WT were captured by Raji-DC-SIGN and added to TZM-bl cells and entry was measured 
after 48 hours using the luciferase reporter assay. The RLU values of the PNG mutants were normalised 
to WT. Bars represent means with SEM from two independent biological repeats. Statistical analysis 
was done using one way ANOVA and post-test. *, **and *** show degree of significance for p < 0.05, 
p < 0.01, p < 0.001, respectively relative to WT. 
 
3.3.6.2 Impact of presence or absence of specific PNGs on Envelope function 
The impact of specific PNGs on Env function has been studied mostly in the context of PNG 
deletion (Wang et al., 2013; Mathys & Balzarini, 2014; Mathys et al., 2014). As deletion of 
PNGs impacted Env function, it remains unknown how the presence or absence of PNGs can 
influence DC-SIGN binding and trans-infection and thus HIV pathogenicity. We thus 
compared the phenotype of PSVs between groups that either carried or did not carry specific 
PNGs. In order to carry out accurate statistical sequence analysis on the Env clones, the 
following criteria had to be met: the frequency of the PNGs had to be between 33 – 67% and 
had to fall within the constant regions to unambiguously assign the correct position to each 
PNG. Envs were grouped based on the presence or absence of specific PNGs and compared 
phenotypically: entry efficiency, binding to DC-SIGN and trans-infection.  
3.3.6.2.1 Impact of specific Env PNGs on entry efficiency 
Statistical comparison of the entry efficiency of Env clones grouped based on the absence and 
presence of PNGs identified that the presence of N356 and N392 were significantly associated 
with enhanced entry (Figure 3.3.14). Of the five PNGs deleted, only the PNG at N392 was 
identified by both sequence analysis and PNG mutagenesis as essential for entry efficiency. 
N448 was not identified through statistical comparison, confirming deletion analysis that this 




entry efficiency by both statistical analysis and mutagenesis, in part, validates the two 
approaches. The remaining three PNGs deleted at N241, N262 and N386 could not be included 
in the analysis as they were > 67 % conserved across all sequences.  
Wang et al. (2013) found an increase in infectivity when N448 was deleted in subtypes A, B 
and BC despite deletion resulting in reduced gp120 incorporation. N448 was 100% present in 
the Wang et al. study whereas the PNG was present in only 50% of our sequences and 72% in 
the subtype C database. This could suggest that either N448 could be important for entry 
efficiency in a clone dependent manner, influenced by HIV-1 subtype or play a role in an 


















































Figure 3.3.14 Identification of Env PNGs involved in PSV entry efficiency. Entry efficiency 
(RLU) was compared between Env clones grouped based on the presence or absence of PNGs in the 
constant regions with a frequency between 33 – 67 %. Results indicate mean RLU values from at least 
four biological repeats compared using a Mann-Whitney test, two tailed comparison.  
 
PSVs lacking a PNG at N674 had higher DC-SIGN binding than those which carried a PNG at 
this position and this association almost reached statistical significance (p < 0.067) (Figure 
3.3.15). This supported previous findings that deletion of the PNG at N674 resulted in enhanced 
virus capture (DC-SIGN binding) by 30% (Mathys & Balzarini, 2014), suggesting that a PNG 
at this site might hinder Env binding to DC-SIGN. Furthermore, as only 33% of the sequences 




























Figure 3.3.15 Identification of Env PNGs involved in binding to DC-SIGN. Envs were 
grouped based on the presence or absence of PNGs in the constant regions that varied between 33 – 
67% and compared for binding to DC-SIGN using Raji-DC-SIGN cells. Means from two biological 
repeats were compared using the Mann-Whitney test. 
3.3.6.2. Impact of specific Env PNGs on PSV trans-infection 
Possession of a PNG at N392 and absence of one at N674 were significantly associated with 
enhanced trans-infection (Figure 3.3.15) when Raji-DC-SIGN cells were used for PSV capture. 
When MDDCs from healthy human donors were used for PSV capture, a PNG at N356 and 
absence of PNGs at N289 and N674 were associated with enhanced trans-infection although 
did not reach statistical significance probably due to variability in donor responses from 
different human donors (data not shown). More donors tested could confirm the importance of 
PNGs at N289, N356 and N674 in MDDC-mediated trans-infection. The fact that different 
PNGs were identified to influence MDDC-mediated trans- infection and Raji-DC-SIGN-
mediated trans- infection could also be due to differences between Raji-DC-SIGN cells and 
MDDCs  such as the expression of other receptors on MDDCs that could play a role in HIV 
trans-infection as well as the concentration of DC-SIGN on the surface of the cells (Pohlmann 






















































Figure 3.3.15 Identification of Env PNGs that influences PSV trans-infection using Raji-
DC-SIGN cells for capture. PSVs were captured by Raji-DC-SIGN cells before adding to TZM-bl 
cells as described in materials and methods and trans-infection (RLU) values from all Env clones were 
compared between groups that carried or lacked PNGs in the constant regions varying in frequency 
from 33 – 67%. Results show medians from two biological repeats compared using the Mann-Whitney 
test.  
 
Table 3.3.3 N-glycan sites associated with changes in Env entry efficiency, and trans-
infection 
Phenotype Position of PNGs 
 356 392 674 




 +(0.020) -(0.027) 
-/+ indicates negative and positive associations, respectively 











As Envelope mediates the first step in HIV infection and is highly immunogenic, it is the 
favoured target for vaccine design. However, one of the stumbling blocks to identifying an 
effective vaccine candidate is the high genetic diversity of Env because an immune response 
against one variant might not result in an immune response to all. Env N-glycosylation is an 
important factor in immune evasion as it not only hides epitopes, it is highly immunogenic 
resulting in the production of decoy non-neutralising antibodies and bnAbs (Sanders et al., 
2002; Calarese, 2003; Pejchal et al., 2011). N-glycans have also been found to play an 
important role in processing and folding of Env into its native conformation essential for 
interaction with receptors and co-receptors on target cells (Li et al., 1993; Pollakis et al., 2001; 
Clevestig et al., 2006). It has also been suggested that the type of glycan present on Env 
influences biological properties especially the immunogenicity of this protein (Go et al., 2015) 
and that Env N-glycosylation could be important for HIV transmission (Go, Hewawasam, et 
al., 2011; Shen, Raska, et al., 2014). With the recent findings that N-glycans form epitopes for 
potent bnAbs (McLellan et al., 2011; Moore et al., 2012; Kong et al., 2013; Pritchard, Spencer, 
et al., 2015), one of the key aims in HIV vaccine research is the design of immunogens with an 
N-glycosylation profile that represents that of transmitted founder-associated, native functional 
trimers (Sattentau, 2013). In this study, we investigated the impact of N-glycosylation on Env 
entry efficiency, binding to DC-SIGN and trans-infection to provide information on the PNGs 
involved in Env function.  
To study the impact of the type of N-glycans on Env function, mannosylation of 9/18 functional 
clones were determined by comparing the molecular weights of fully N-glycosylated, 
demannosylated and deglycosylated gp140. Contrary to oligomannose-enriched cell-associated 
gp140 (Ms Liliwe Shuping; Data not shown), all clones carried both HM/H and complex type 
N-glycans and cleavage (e.g. furin) was observed for all PNGaseF-treated clones. Interestingly, 
uncleaved gp140 was present in the culture medium of all clones and EndoH treatment 
deglycosylated C3, C8 and C12, suggesting that not only was cleavage inefficient but also that 
a fraction of gp140 carried only HM/H. Furthermore, based on PNGaseF treatment which 
resolved both gp140 and gp120, the apparent amount of gp140 released into the culture medium 
exceeded that of gp120 for nearly all clones except C12, C13 and C14. Therefore, a band 
representing gp120 was not apparent in most undigested controls most likely due to inefficient 
cleavage of gp140 leading to low levels of fully processed gp120 as seen in a previous study 




clones, bands corresponding to gp140 were used to compare mannosylation between clones. 
We hypothesised that gp140 N-glycosylation could represent that of native Env as uncleaved 
gp140 form trimers with compact, native-like structures (Kovacs et al., 2014).  
Mannosylation of gp140 varied from 23 – 43%, except for C3 with only 7% HM/H. There was 
no statistical correlation between mannosylation and Env entry efficiency, suggesting that the 
level of HM/H did not influence PSV entry. It has been suggested that Env entry efficiency 
depends on the structure and/or presence and location of specific N-glycans and not the type 
of carbohydrate (Wang et al., 2013; Mathys et al., 2014). Furthermore, the use of mutant cell 
lines to produce virus that resulted in the addition of mainly Man5GlcNac residues did not 
influence infectivity (Montefiori, Robinson Jr. & Mitchell, 1988; Eggink et al., 2010), while 
inhibition of all N-glycosylation lowered infectivity most likely due to misfolding of Env 
(Montefiori, Robinson Jr. & Mitchell, 1988). However, due to the level of gp140 
mannosylation it is also possible that the N-glycan profile is not representative of PSV-
associated Env trimers (Beddows et al., 2006).  
It was shown that PSV- and virus-associated gp120 carried mainly oligomannose (Table 3.4.1) 
and the authors suggest that this is an intrinsic feature of HIV-1 Env (Bonomelli et al, 2011; 
Doores et al., 2010). Conversely, monomeric gp120 carried more complex-type N-glycans and 
it was suggested that trimer formation precludes HM trimming and the addition of complex-
type carbohydrates (Bonomelli et al., 2011). However, Crooks et al. (2011) proposed that 
oligomannose-rich Env represented “junk” gp120/gp160 due to aberrant processing pathways 
and did not represent native functional trimers (Crooks et al., 2011). Irrespective of whether 
Env trimer oligomannose levels are due to native or aberrant processing pathways, it was 
recently confirmed that membrane-associated Env had much higher levels of oligomannose N-
glycans than soluble gp140 (Go et al, 2015). Our results were consistent with these studies that 
showed monomeric gp140 carried 23 – 50% HM across most strains (Doores, 2015; Go et al., 
2015; Pritchard, Vasiljevic, et al., 2015), suggesting that our gp140 did not form trimers and 
thus did not represent PSV functional Env. However, gel filtration of our purified gp140 
indicated monomers, dimers and trimers (Dr Van Ryk, Data not shown), confirming that mixed 
oligomerisation had occurred as previously reported (Beddows et al., 2006). But whether these 
dimers and trimers were functional, was not shown. EndoH digestion deglycosylated some 




uncleaved gp140 trimers enriched with oligomannose and the ratio of gp140 oligomers to 
monomers could influence the overall apparent mannosylation of each clone.  
 Table 3.4.1 Abundance of released N-linked glycans obtained from recombinant 
(monomeric), pseudoviral, and viral gp120  




relative to rgp120 
Recombinant monomer 293T 29 1.0 
Pseudovirus (pSG3Denv:pSVIII JRCSF, 2:1) 293T 98 3.4 
Pseudovirus (pSG3Denv:pSVIII JRCSF, 10:1) 293T 85 2.9 
Supernatant (pSG3Denv:pSVIII JRCSF, 10:1) 293T 73 2.5 
Virus (pLAI-JRCSF env) 293T 56 1.9 
Virus JRCSF (clade B) PBMC 79 2.7 
Virus 92RW009 (clade A) PBMC 64 2.2 
Virus 93IN905 (clade C) PBMC 62 2.1 
Edited from Bonomelli et al., (2011) 

















CHO N/A N/A 36.6 1 
C3 293T 6.8 0.2 N/A N/A 
C4 293T 35.5 1.0 N/A N/A 
C7 293T 28.7 0.8 N/A N/A 
C8 293T 23.4 0.6 N/A N/A 
C12 293T 42.9 1.2 N/A N/A  
C13 293T 35.2 1.0 46.6 1.3 
C14 293T 39.7 1.1 49.6 1.4 
C15 293T 40.3 1.1 50.4 1.4 
C16 293T 34.3 0.9 36.5 1.0 
 
If gp160 cleavage is required for functional trimers (McCune et al., 1998), trimerisation 
sterically hinders trimming of oligomannose moieties (Bonomelli et al., 2011) and uncleaved 
gp140 trimers carry higher levels of complex-type N-glycans (Pritchard, Vasiljevic, et al., 
2015), we hypothesised that glycosylated gp120 of C13, C14, C15 and C16 were likely derived 
from fully processed trimers and thus enriched with oligomannose when compared to gp140. 




mannosylation were very similar differing 0.6- to 1.2-fold, except for C3 which had very low 
levels of HM/H (Table 3.4.2). Mannosylation of gp120 ranged from 37 to 50%, marginally 
higher than that of gp140 and the positive control (1.0 – 1.4-fold) but still much lower than 
virion- or PSV-associated Env (1.9 – 3.4-fold) (Table 3.4.1), suggesting that the source of 
gp120 was monomeric cleaved gp140. The presence of only monomers was surprising as 
gp140 constructs with intact cleavage sites have been shown to form oligomers including 
trimers although with poor stability (Jeffs et al., 2004; Beddows et al., 2006). However, 
oligomerisation varied according to Env clone, suggesting that the extent of trimerisation and 
thus mannosylation could be variant specific (Jeffs et al., 2004; Beddows et al., 2006).  
Mannosylation of virus-associated gp120 from different variants ranged from 56 – 79% (Table 
3.4.1). As some Envs have been shown to trimerise much more efficiently than others and 
studies have only characterised one or two variants at a time, Env mannosylation levels, 
whether monomeric or virus-associated trimers, might be more heterogeneous than previously 
reported (Bonomelli et al., in press; Jeffs et al., 2004; Beddows et al., 2006; Go et al., 2015).  
Furthermore, other factors have also been shown to influence Env N-glycosylation including 
the cell type used to express the recombinant protein, cleavage efficiency of gp160 and level 
of Env expression (Table 3.4.1) (Bonomelli et al., 2011; Binley et al., 2002; Raska et al., 2010). 
We showed that expression of Env in the absence of pSG3ΔEnv, the pseudovirion backbone 
vector, was much lower than when pseudovirus was being prepared although relative 
expression remained the same (Appendix I Figure A1). Therefore, N-glycosylation analysis, 
preferably using mass spectrometry comparing virion-associated gp120 to gp140 is required of 
all eighteen clones to confirm whether gp140 mannosylation represents PSV-associated 
functional Env and thus determine whether mannosylation plays a role in Env entry efficiency. 
However, PSV mannosylation could be similar to that of recombinant gp140 as we found a 
statistically significant correlation between PSV DC-SIGN binding and gp140 mannosylation, 
supporting previous findings that DC-SIGN interactions with Env favours mannose type N-
glycans (Geijtenbeek, Torensma, et al., 2000; Lin et al., 2003; Montfort et al., 2011). 
Furthermore, both Raji-DC-SIGN and MDDCs were found to transfer PSVs to TZM-bl cells, 
confirming previous findings by Geijtenbeek et al. (2000) (Geijtenbeek, Torensma, et al., 
2000).  A correlation was found between DC-SIGN binding and DC-SIGN-mediated trans-
infection further confirming studies by Geijtenbeek et al. (2000) that DC-SIGN is involved in 




used for capture probably because MDDCs express not only  DC-SIGN but other CLRs and 
non-CLRs (heparin sulphate proteoglycans, CD169, GarCer) which are also involved in HIV 
trans-infection (Saphire et al., 2001; Turville et al., 2002; Magerus-Chatinet et al., 2007; 
Lambert et al., 2008; Izquierdo-Useros, Lorizate, Puertas, et al., 2012; Puryear et al., 2012). 
Eggink et al. (2010) proposed that HIV-1 LAI, enriched with HM residues, bound weakly to 
iMDDCs due to the presence of receptors other than DC-SIGN that recognised Env complex 
glycans (Eggink et al., 2010).  
Despite the lack of correlation between DC-SIGN binding and MDDC-mediated trans-
infection, there was a highly significant correlation between the two trans-infection methods 
using Raji and MDDCs (p < 0.0001, r = 0.8762), suggesting that the overall mechanism was 
similar for both cell types. Trans-infection does not only depend on binding to MDDCS via 
DC-SIGN (and other receptors), it is also highly dependent on Env entry efficiency. There was 
a highly significant correlation between both DC-SIGN-mediated and MDDC-mediated trans-
infection with entry efficiency confirming the role of Env entry in trans-infection.   However, 
MDDC-mediated trans-infection seemed more sensitive to changes in Env entry efficiency 
than when Raji-DC-SIGN cells were used for capture and trans-infection was more efficient 
at infecting TZM-bl cells than direct infection in the absence of Raji-DC-SIGN cell capture. 
This suggested that binding to Raji-DC-SIGN and not MDDCs, enhanced the entry efficiency 
of Env, confirming previous suggestions that DC-SIGN binding may lead to trans-
enhancement of HIV infection (Appendix I, Figure A2) (Cameron et al., 1992; Kwon et al., 
2002; Reyes-Rodriguez, Reuter & McDonald, 2016). Previous studies have suggested a change 
in Env conformation or increased affinity following interaction with DC-SIGN that rendered 
the virus more infectious by stabilising the gp120-CD4 complex  (Geijtenbeek, Kwon, et al., 
2000; Kwon et al., 2002; Hijazi et al., 2011).  
The differences in trans-infection of TZM-bl cells by the two cell types could be due to multiple 
factors. The concentration of DC-SIGN on the cell surface is different between MDDCs and 
Raji-DC-SIGN cells (data not shown) and trans-infection is highly dependent on DC-SIGN 
expression levels (Pöhlmann et al., 2001). Low levels of DC-SIGN were also shown in another 
study to enhance CD4+ cell trans-infection possibly because steric hindrance due to high levels 
of DC-SIGN interfered with gp120 binding to CD4  (Hijazi et al., 2011). DC-SIGN binds with 
high affinity to gp120 (Curtis, Scharnowske & Watson, 1992) and thus higher concentrations 




However, another study suggested that enhanced DC-SIGN expression would favour HIV 
trans-infection because trans-infection efficiency was shown to increase with an increasing 
number of cell surface DC-SIGN molecules until a plateau was reached (Pöhlmann et al., 
2001). MDDCs do not only express  DC-SIGN,  but also other CLRs and non-CLRs that could 
all play a role in capture/transferring PSV to TZM-bl cells and thus influence PSV dissociation 
from MDDCs, CD4 binding due to steric hindrance and stabilisation of the CD4-gp120 
complex. The mechanism whereby DC-SIGN might enhance HIV-1 trans-infection might also 
depend on the strain of virus. DC-SIGN enhanced trans-infection of CD4-independent viruses 
by concentrating virus at the cell surface and also by stabilising the CD4-gp120 complex 
(Hijazi et al., 2011). Therefore, studies into the nuanced variation between the capture of PSVs 
using Raji-DC-SIGN cells and MDDCs could provide a novel understanding of the molecular 
mechanism of HIV-1 trans-infection.  
Variable loop length and N-glycosylation have been suggested to influence the interaction of 
Env with DC-SIGN on MDDCs (Nabatov et al., 2006) and given that PNG number and variable 
loop length increases over the course of infection (Chohan et al., 2005),  DC-SIGN could play 
a role in selection of variants during transmission and disease progression.  Supporting this 
suggestion was our finding that TFs had a significantly lower number of PNGs than matched 
chronic infection Envs (p = 0.009), confirming previous findings (Derdeyn et al., 2004; Chohan 
et al., 2005). Comparison of the number of Env PNGs with gp140 mannosylation showed a 
significant association (p = 0.017), suggesting that as the number of PNGs increase, so does 
the level of mannosylation.  Furthermore, Env mannosylation levels correlated with DC-SIGN 
binding, which was significantly associated with Raji-DC-SIGN-mediated trans-infection. 
Therefore, based on these findings, TF Envs carry fewer PNGs should be less mannosylated, 
and by extrapolation, bind more weakly to DC-SIGN and have less efficient trans-infection 
than variants in chronic infection. However, it seems that specific PNGs and not only Env N-
glycan content influences DC-SIGN mediated trans-infection as this association was not 
significant for MDDC mediated trans-infection. This would suggest that Env mannosylation 
is not the only determinant of HIV-1 transmission via DC-SIGN binding.  
Alternatively, specific PNGs could be important for interaction of Env with DC-SIGN (Hong 
et al., 2007; Liao et al., 2011) and with CD4 and co-receptors (Pollakis et al., 2001; Clevestig 
et al., 2006). PNGs at positions 241, 262, 386, 392 and 448 of C15 and C16 were deleted to 




were matched Envs from the same participant, carried all 5 PNGs and had similar binding to 
DC-SIGN. Mutation of specific PNGs previously profiled as carrying HM residues in subtypes 
B and C TF Envs (Go, Hewawasam, et al., 2011) confirmed that N241, N262, N386 and  N392 
were very important for entry efficiency and most likely Env structure (François & Balzarini, 
2011; Wang et al., 2013; Mathys et al., 2014; Pritchard, Spencer, et al., 2015). N448Q was 
found to enhance antigenicity by another study without affecting Env CD4 binding capacity 
(Kumar et al., 2011). N448 and N356 had also been suggested to be potentially important for 
CCR3 co-receptor interaction (Cenci et al., 2014), protection of the V3 loop from nAbs, while 
promoting  processing and presentation of T helper epitopes (Li, Chien  Jr., et al., 2008; Li, 
Xu, et al., 2009). N448 deletion was found to increase entry efficiency, decrease Env 
incorporation and lower the abundance of oligomannose type N-glycans (Wang et al., 2013; 
Pritchard, Spencer, et al., 2015). We found a non-significant decrease in infectivity in one PSV 
clone and a non-significant increase in entry of the other relative to WT. This suggests that 
N448 may be important for Env function but in a clone dependent manner. Although some 
PNGs influenced binding to DC-SIGN and trans-infection in a clone dependent manner, C15, 
a TF Env was on the whole more affected by N241, N262, N386, N392 and N448 deletions 
than its matched chronic infection clone. This could suggest that not only does the number of 
PNGs differ over the course of infection but also the role they play in Env function. Whether 
or not the increased sensitivity of the TF to N-glycan deletion is related to HIV-1 transmission 
requires further investigation using a larger sample size. 
PNG deletion analysis did not identify N-glycans important for DC-SIGN binding and trans-
infection as these mutants had either no or greatly reduced entry efficiencies. Further 
characterization of the Envs was done based on the presence or absence of PNGs that varied in 
frequency between 33 – 67 % in the constant regions. This method confirmed the results of the 
mutational analysis that the PNG at N392 was important for Env entry efficiency and showed 
that N392 might also influence Raji-DC-SIGN-mediated trans-infection. The impact that a 
PNG at N392 might have on Raji-DC-SIGN-mediated trans-infection, could be due to their 
influence on PSV entry efficiency. The lack of a PNG at position 674, located between heptad 
repeat 2 (HR2) and the TM domain was significantly associated with increased trans-infection 
by Raji-DC-SIGN cells. PSVs that tended to have higher DC-SIGN binding also tended not to 
carry a PNG at 674. It is possible that N-glycans located close to the membrane might sterically 
hinder proper gp120 interaction with DC-SIGN. Mathys and Balzarini (2014) reported that 




binding as well as transmission efficiency. This same study found that N674 had a frequency 
of approximately 15 % in A2, CRF04-cpx and CRF14-BG HIV-1 subtypes whereas a PNG at 
N674 was present in 33 % of the 18 Env clones studied and 24.8 % in the subtype C database, 
suggesting that it is under negative selection.  
Previously Parrish et al. (2013) showed that TFs are better at infectivity, DC-SIGN binding 
and trans-infection than chronic infection variants (Parrish et al., 2013) and another study 
suggested that viral fitness is an important determining factor in HIV transmission (Carlson et 
al., 2014). Although our sample size was too small to accurately compare TF (n = 5) to matched 
chronic infection controls (n = 13), our analysis suggests that specific PNGs could be important 
for transmission and not Env mannosylation. This study has identified PNGs that could be 
involved in HIV pathogenesis and screening a larger cohort can confirm the association 
between PNGs and Env function. This study has shown that PNGs can either enhance or 
compromise Env function, depending on their absence or presence. Escape from autologous 
antibodies could require the introduction of a PNG that comes with a fitness cost. It is possible 
that evasion from vaccine-induced bnAbs could rely on the introduction of an additional PNG 
with concomitant loss of the original PNG involved in escape from autologous antibodies. The 
loss of this PNG will enhance infectivity, resulting in a fitter virus and potentially increased 
disease progression. 
Conclusion 
In conclusion, we identified PNGs that could be important for Env entry efficiency and trans-
infection of CD4+ cells using both mutational and sequence analysis. The effect of N-glycans 
on entry efficiency, DC-SIGN binding and trans-infection was highly clone-dependent. With 
the recent findings that N-glycans form epitopes for potent bnAbs (McLellan et al., 2011; 
Moore et al., 2012; Kong et al., 2013; Pritchard, Spencer, et al., 2015), one of the key aims in 
HIV vaccine research is the design of Env immunogens with an N-glycosylation profile that 
represents that of transmitted founder-associated, native functional trimers (Sattentau, 2013). 
Vaccines that include N-glycan-containing epitopes could generate bnAb that prevent 
productive clinical HIV infection but they could also drive the rapid loss or gain of PNGs due 
to selective pressure on the virus to escape neutralisation. These PNG variations could either 
drive the emergence of fitter and more pathogenic variants or abrogate viral infectivity. We 
identified N356 as a potential fitness determinant. Therefore, if an epitope carrying a PNG at 




loss of a PNG at this site, significantly decreasing the fitness of the virus. However, as 
previously shown for N332, evolution of neutralising antibody responses can occur via loss of 
other PNGs that may be associated with enhanced infectivity. Therefore, the impact of N-
glycans on Env function and potentially HIV replication fitness must be tested in a range of 
phylogenetically distinct viruses to not only ensure the safe outcome of an Env N-glycan-
targeted vaccine but also as a means to drive the emergence of less fit variants. 
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Productive HIV infection requires dissemination and systemic spread. As DCs have a 
migratory nature, they are able to carry the virus to the lymphoid organs (Banchereau & 
Steinman, 1998; Banchereau et al., 2000), where they can infect T cells in trans. Therefore, 
although DCs may not be the primary target for HIV infection, they may play a more important 
role in viral dissemination. A murine knock-out study showed that autocrine IL-10 inhibited 
DC immune responses by down-regulating the translocation of DCs to lymphoid tissues and 
by locally regulating DC IL-12 production in the draining lymph nodes (Demangel, Bertolino 
& Britton, 2002). Therefore, as IL-10 has been shown to slow the migration of DCs infected 
with M.tuberculosis to lymph nodes, this suggests that it might also play a very important role 
in autocrine modulation of DC responses to HIV infection. 
IL-10 has been found to play a critical role in modulating immunopathology related to 
exacerbated immune responses (Couper, Blount & Riley, 2008) and dampens the development 
of Th1 responses while encouraging Th2 development (Fiorentino et al., 1991; Dong & Flavell, 
2001). As it limits inflammation and Th1 cytokine activity in response to viruses and other 
intracellular pathogens (like Leishmania, Mycobacterium avium), IL-10 encourages the 
establishment of chronic infections. High expression levels of IL-10 in human viral infections 
like Hepatitis B and C (HBV and HCV) infections correlated with poor T cell immune 
responses, and hence a failure to control viral replication (Spellberg & Edwards, 2001; Couper, 
Blount & Riley, 2008; Flynn et al., 2011; Redford, Murray & O’Garra, 2011; Singh & 
Thirumalapura, 2014). Studies in mouse models of Lymphocytic Choriomeningitis virus 
(LCMV) have also shown the role of IL-10 in limiting the T cellular immune response, 
permitting the virus to establish infection. Interventional interference with IL-10 activity in  
this model enhanced viral clearance (Brooks et al., 2006; Ejrnaes et al., 2006).  
IL-10 immune regulation involves the suppression of MHC class II and costimulatory 
molecule, B7-1/B7-2 expression and restricts proinflammatory cytokine production. This 
includes IL-1, IL-1, IL-6, IL-12, IL-18, and TNF- and chemokines such as MCP-1, MCP-
5, RANTES, IL-8, IP-10, and MIP-2. Furthermore, IL-10 has a negative feed-back loop where 
it inhibits DC chemokine production, preventing migration to lymph tissues for recruitment 
and induction of Th1 responses (Couper, Blount & Riley, 2008). Production of IL-10, IL-4, IL-
5 and IL-13 by APCs drives naïve (Th0) T cells differentiation into Th2 cells, enhancing B cell 




function and is also immunoregulatory; promoting differentiation of Th0 cells into regulatory 
T cells (Treg) whichs cause induction of tolerance (Espir et al., 2014). The delicate balance of 
pro- and anti-inflammatory cytokines can drive naïve T cell differentiation towards either, Th1, 
Th2, Th17, Th22 or T regulatory pathways through the secretion of required cytokines and 
chemokines like IL-1β, TNF-α, IL-6, IL-8, IL-12, MIP-1α, and MIP-1β. These are either 
important for enhancing the immune response, preventing immune related pathologies or 
stimulating tolerance to a pathogen in order to protect the host from tissue damage caused by 
an excessive immune response (Kitagishi et al., 2012). In persistent viral infections, these 
regulatory functions of DCs could contribute to the establishment of infection and also 
determine the disease severity as they dampen the immune response (de Waal Malefyt, Haanen, 
et al., 1991), reviewed in (Espir et al., 2014).  
Due to the immune modulation function of some cytokines, such as IL-1β and TNF-α, they 
have been coined immune modulatory cytokines. TNF-α has been shown to enhance HIV 
replication in cell line models (Finnegan et al. 1996) especially under immunosuppressive 
conditions. Thus DCs do not only initiate an adaptive immune response, they also maintain and 
modulate immune responses through cytokine secretion. Understanding the interplay between 
the host immune response and the role of APCs, such as DCs, in viral pathgenesis would 
provide not only valuable insight into HIV transmission and persistence, but also contribute to 
the search for more improved treatment and prevention methods 
IL-12 production by DCs and other APCs causes polarization of the Th0 cells to Th1 cells, 
which further produce more IL-12 and IFN-γ and causes up-regulation of both co-stimulatory 
and maturation markers of DCs (Trinchieri, Pflanz & Kastelein, 2003). IL-12 acts directly on 
T cells, enhancing proliferation, IFN-γ production and increasing cytolytic activity of both cell 
types (Clerici & Shearer, 1993; Kennedy et al., 1994; Wolf, Sieburth & Sypek, 1994; 
Kedzierska & Crowe, 2001; Trinchieri, 2003; Trinchieri, Pflanz & Kastelein, 2003; Watford et 
al., 2003; Hamza, Barnett & Li, 2010). IL-12 thus has a critical role in regulating the 
development of native CD4+ T cells into Th1, while impairing the Th2 pathway and production 
of associated cytokines (Dong & Flavell, 2001). IL-12 and IFN-γ act on macrophages and 
natural killer cells (NK) to enhance their phagocytic activity against viruses and other 
intracellular pathogens. Therefore, differentiation of Th0 into either Th1 or Th2 responses is 




 In HIV infection, a dysregulation of cytokine production has also been reported, with impaired 
IL-12 secretion by PBMCs from HIV infected patients in response to stimulants (Clerici et al., 
1993; Chehimi et al., 1994; Daftarian et al., 1995; Marshall et al., 1999; Bal et al., 2005), 
suggesting that there is impairment of the Th1 pathway (Marshall et al., 1999). IL-10 levels 
were found to be elevated in the plasma of HIV infected patients (Stylianou et al., 1999). While 
it was found that IL-10 increase was mostly associated with acute infections (AI) (Norris et al., 
2006), other studies showed that its levels increased with disease progression and were partially 
resolved following HAART (Stylianou et al., 1999; Norris et al., 2006; Roberts et al., 2010).  
While Brockman et al. (2009) found that all cell types except DCs produced higher levels of 
IL-10 in HIV positive subjects compared to negative subjects (Brockman et al., 2009), another 
study couldn’t differentiate the source of IL-10 when HIV infected DCs were co-cultured with 
T cells (Granelli-Piperno et al., 2004). Most of these past studies presupposed that viral 
replication in the cells was the cause of IL-10 production. It took many more studies to find 
that gp120 induced IL-10 expression but whether T cells and/or APCs were the initial sources 
remained unclear (Ameglio et al., 1994; Schols & De Clercq, 1996; Taoufik et al., 1997; 
Mellado et al., 1998). Some of these studies nevertheless found that the increase in IL-10 levels 
in HIV infected individuals indirectly impaired T cell responses by suppressing APC 
production of IL-12 and IFN-γ production (Clerici et al., 1993; Chehimi et al., 1994; Daftarian 
et al., 1995; Herbein, Montaner & Gordon, 1996; Taoufik et al., 1997; Marshall et al., 1999). 
Further research later found that interaction between gp120 and mannose C-type lectin 
receptors (MCLR) on MDDCs was enough to induce IL-10 production in culture (Shan et al., 
2007). Moreover, IL-10 expression was accompanied by poor MDDC maturation and impaired 
ability of these MDDCs to stimulate T cells in mixed leukocyte culture (Fantuzzi et al., 2004; 
Shan et al., 2007). This suggested that induction of DC IL-10 secretion in the female genital 
tract could be a potential mechanism whereby HIV-1 is able to modulate immune responses 
which favour transmission as well as disease progression. 
However, longitudinal follow-up of HIV-infected participants showed that there was a distinct 
pattern of expression of cytokines over time following infection (Stacey et al., 2009). Initially, 
there was a sharp increase in IFN- and IL-15, then IP-10 followed by a protracted increase in 
TNF- and MCP-1. This was followed by the pro-inflammatory IL-6, IL-8, IL-18 and IFN- 
and then IL-10 (Stacey et al., 2009), suggesting that HIV induced inflammation cytokines 




of the IL-10. As IL-10 is expressed by a wide range of cells, its differential regulation depends 
on cell type and environment and this will results in the fine balance between effective immune 
responses and immunopathology (Saraiva & O’Garra, 2010). In this study we stimulated 
purified MDDCs with HIV-1 and gp140, which can induce the production of pro-inflammatory 
cytokines via CLRs, TLR2 and/or TLR4 (Thibault et al., 2009), and IL-10 expression by both 
TLRs and DC-SIGN binding to gp120 (Shan et al., 2007; Saraiva & O’Garra, 2010). As HIV 
infection is associated with inflammatory responses, we wanted to understand how IL-10, an 
immunesuppresor might influence this relationship. We hypothesised that instead of 
inflammation triggering IL-10 responses, HIV-1 binding to DC-SIGN induced IL-10 
production and autocrine IL-10 deregulated DC anti-HIV activity locally during early HIV 
infection. 
 Due to the relationship between Env mannosylation and MCLR DC-SIGN mediated 
stimulation of IL-10 in MDDCs (Shan et al., 2007), and the specific N-glycan features 
associated with TF Env (Chohan et al. 2005; Derdeyn et al. 2004; Sagar et al. 2006; Go et al 
20011), we hypothesised that either the number of PNGs, type of N-glycans and/or specific 




4.2 Aim and Objectives 
Aim: Understand how HIV-1 Subtype C Envelope N-glycosylation impacts dendritic cell 
immune response to favour viral transmission. 
Rationale: 
Dendritic cells are important players in tailoring the immune response to specific pathogens 
via the secretion of pro-inflammatory and immune-suppressive cytokines. DCs are one of the 
first cells to encounter HIV within the genital mucosa and thus should play an important role 
in preventing productive HIV-1 infection. However, HIV seems to be able to circumvent DC-
mediated viral clearance potentially by preventing DC maturation and immune responses. Env 
N-glycans stimulate MDDC release of IL-10 which then in turn regulates MDDC function as 
well as the course of pathogen clearance. Thus, changes in IL-10 levels could play an important 
role in persistent HIV infection. As the number of PNGs has been found to change over the 
course of infection and mannose type N-glycans are involved in the interaction between DC-
SIGN and gp120, N-glycosylation might facilitate HIV transmission by modulating immune 
responses in the genital tract. Therefore, this study hypothesises that Env N-glycosylation is 
involved in stimulating the differential secretion of cytokines by DCs. 
4.2.1 Specific objectives: 
1. Determine whether differentially N-glycosylated Envs differ in their ability to 
induce IL-10 secretion by MDDCs from healthy blood donors. 
2. Determine if Env PNGs at specific positions impact the induction of IL-10 secretion 
by MDDCs.  
3. Determine whether differentially N-glycosylated Envs influence MDDC secretion 







4.3.1 Pseudovirus stimulation of MDDCs to secrete IL-10 
Chapter 3 showed that entry efficiency, DC-SIGN binding and trans-infection of CD4+ cells 
varied across Env clones, suggesting a wide range in phenotypic properties. We therefore 
determined whether the clones also varied in their ability to stimulate MDDC secretion of 
cytokines which could suggest that Envs influence immune responses in the genital tract. Nine 
HIV-1 subtype C Envs (C1, C2, C7, C8, C12-C16) (Figure 3.2.1 & Table 3.2.1) were selected 
that varied in PNG number and location to determine whether HIV-1 subtype C Env N-
glycosylation influenced MDDC secretion of cytokines following stimulation with pseudovirus 
(PSVs) and purified soluble Env (gp140).     
When PSVs were used to stimulate MDDCs, IL-10 levels in the culture supernatants varied 
from 15-725 pg/ml (Figure 4.3.1) for 7 healthy donors. The majority of PSVs (C1, C2, C8, 
C13, C15 and C16) induced low levels of IL-10 secretion, 1.2- to 2-fold above the negative 
control. Only C7 and C12 induced significantly higher MDDC IL-10 secretion (9.5- and 9.1-
fold, respectively) than the negative control (p = 0.04 and p = 0.013, respectively). C14 induced 





































Figure 4.3.1 Pseudovirion stimulation of MDDC IL-10 release. PSVs from nine participants 
with varying PNG patterns were used to stimulate MDDCs from seven healthy blood donors and the 
release of IL-10 was measured by Luminex assay. PSVs generated using pSG3∆Env and empty vector 
was used as a negative control (Ctrl). Mann-Whitney test was used to compare IL-10 levels in the 
supernatants to the negative control. Bar graphs represent mean IL-10 (pg/ml) from 7 biological repeats 
with error bars showing +/-SEM (SEM). *, ** and *** represent p values less than 0.05, 0.01 and 0.001, 
respectively. MDDCs from the same donor were used to compare the induction of cytokine production 





4.3.2 Induction of MDDC IL-10 secretion by gp140 
To confirm that Env was responsible for the variation in IL-10 secreted by MDDCs, gp140 was 
generated for three env clones (C12, C13 and C14) that differed at N448, N397 and N674 
(Table 3.3.1), induced variable levels of IL-10 release (Figure 4.3.1) and  had different binding 
efficiencies  to DC-SIGN (Figure 3.3.5). When purified gp140 was used to stimulate MDDCs, 
all three clones differentially induced the release of IL-10 similar to PSVs. However, the 
hierarchy of clones was altered with C13 (6-fold) stimulating the release of more IL-10 than 
C14 (2.6-fold) albeit non-significantly (Figure 4.3.2). C12 and C13 induced significantly 
higher IL-10 levels than background with p values of 0.0001 and 0.047, respectively, while 
C14 did not have a statistically significant effect (p = 0.117). The difference in IL-10 levels 
induced by PSV and gp140 for C13 and C14 could be due to MDDC donor differences as 
secretion of IL-10 varied between donors (Figure 4.3.1). It is also possible that differences in 
cell line-specific N-glycosylation might have influenced whether PSVs and gp140 were 
similarly N-glycosylated. It has been shown that CHO and HEK293T cells N-glycosylate Env 
differently and altered Env N-glycan patterns of PSVs and gp140 could have impacted the 
stimulation of MDDC IL-10 release (Raska et al., 2010). Finally, gp140 expresion and 
purification resulted in monomers and dimers (data not shonw) and migh thus not represent 
natirve trimers of PSVs. Despite the variation between gp140 and PSVs, the release of IL-10 
in response to purified gp140 confirmed that Env is likely partly responsible for inducing IL-























Figure 4.3.2 Purified soluble gp140 stimulation of MDDC IL-10 release. Env (gp140) was 
generated by the introduction of a stop codon before the transmembrane domain of three env clones 
(C12, C13 and C14). The mutants were transiently expressed in CHO cells and purified by affinity 
chromatography and size exclusion chromatography. Day six MDDCs were stimulated with purified 
C12-C14 gp140 and IL-10 released into the culture supernatant was measured by Luminex assay. 
Means of at least 5 biological repeats using different MDDC donors are shown with SEM. Mann-
Whitney t-test was used to compare IL-10 levels in sgp140 stimulated samples to the negative control 
(no sgp140 added).  P values were represented as *, ** and *** for values less than 0.05, 0.01 and 
0.001, respectively. 
4.3.3 Evaluation of DC-SIGN involvement in inducing MDDC IL-10 secretion 
DCs express a range of PRR receptors on their surfaces including TLRs, CLRs and non-CLRs 
which have all been suggested to play a role in pathogen interaction with DCs. Although, CLRs 
and other non CLR receptors like Garcer and CD169 have been suggested to be involved in the 
transfer of HIV by MDDCs to T cells (Meng et al., 2002; Turville et al., 2002; Magerus-
Chatinet et al., 2007; Lambert et al., 2008; Izquierdo-Useros, Lorizate, Puertas, et al., 2012), 
DC-SIGN has been suggested to be the main candidate (Geijtenbeek, Kwon, et al., 2000; 
Geijtenbeek, Torensma, et al., 2000; Geijtenbeek et al., 2002; Kwon et al., 2002). We therefore 
investigated whether IL-10 release was inhibited when PSVs were pre-incubated with 
recombinant DC-SIGN before stimulating MDDCs. The presence of recombinant DC-SIGN 
reduced IL-10 release by 65.25% for C12 when compared to the control without DC-SIGN 
pre-incubation (p = 0.017) (Figure 4.3.3), suggesting that DC-SIGN-Env interactions are 
important for MDDC IL-10 secretion. However, the inhibition was not as apparent for C13 as 
MDDC IL-10 secretion decreased by only 25.43%. C13 PSV induced MDDCs to release only 
1.2-fold higher IL-10 compared to the background control. It is thus possible that as C13 PSV 

















Figure 4.3.3 Pseudovirion stimulation of MDDC IL-10 release in the presence of 
recombinant DC-SIGN. Two PSV clones (C12 and C13) were pre-incubated with and without 
recombinant DC-SIGN to block DC-SIGN binding sites on Env prior to stimulation of MDDCs to 
release IL-10. The induction of IL-10 in the absence (denoted C12 & C13) and presence (C12+ and 
C13+) of recombinant DC-SIGN protein was measured in the culture supernatants by Luminex assay. 
Results shown are 3 biological repeats from three different donors expressed as a percentage of 
uninhibited PSVs and compared to the uninhibited control using one way ANOVA. *, ** and *** 
represent p values less than 0.05, 0.01 and 0.001, respectively. 
 
4.3.4 Determine whether CD4 receptor is involved in induction of MDDC IL-
10 secretion 
As recombinant DC-SIGN did not completely inhibit IL-10 release and MDDCs express CD4, 
we blocked CD4-gp120 interactions by either pre-incubation of PSVs with recombinant 
soluble CD4 (sCD4) to block CD4 binding sites of Env or pre-incubation of MDDCs with 
Leu3A, an anti-CD4 monoclonal antibody to block CD4 receptors. sCD4 and Leu3a did not 
lower IL-10 levels, suggesting that Env-CD4 interactions are not involved in inducing MDDC 
IL-10 release (Figures 4.3.4 A and B). Although, only two donors were tested, one for sCD4 
and the other for Leu3A inhibition, the analysis confirmed findings by previous groups and it 
is thus highly unlikely that the induction of MDDC IL-10 release is via CD4 (Ji et al., 2005; 











































Figure 4.3.4 Stimulation of MDDC IL-10 release in the presence of CD4 receptor binding 
inhibitors. Env-CD4 interactions were blocked by pre-incubating A) PSV with sCD4 (+) and B) 
MDDCs with Leu3A (+) before stimulation of MDDC with C1, C2, C7, C8, C12 and C13 PSVs. IL-10 
secretion was measured by Luminex assay and compared to PSVs not pre-incubated with inhibitors. A 
single donor was used for each inhibitor. 
 
4.3.5 Importance of Env N-glycosylation in MDDC IL-10 release  
4.3.5.1 Effect of Env PNG deletions on MDDC IL-10 release 
Next we determined whether the variation in IL-10 release in response to different Env clones 
was due to differences in Env PNGs. There was no significant relationship between MDDC 
IL-10 secretion in response to PSVs and PNG number or level of gp140 mannosylation (Data 




interact with DC-SIGN or shown to carry high mannose sugars (Hong et al., 2007; Go, 
Hewawasam, et al., 2011; Liao et al., 2011) were deleted in C15 and C16. These two clones 
carried all five PNGs but C15 had higher mannosylation than C16 (47% compared to 33%). 
These clones also differed in entry efficiency but they bound DC-SIGN trans-infected TZM-
bl cells (Figures 3.2.5 3.2.7 and 3.2.9) and induced IL-10 release with similar efficiency (Figure 
4.3.1).  
C15 WT induced MDDC IL-10 secretion 1.5-fold higher than background in these donors and 
deletion of PNGs at N241 and N448 led to a statistically significant decrease (p = 0.045 and p 
= 0.047, respectively). Deletion of N386, N392, N241-448 and N386-392 also led to decreased 
IL-10 secretion relative to the WT but did not reach significance although this could be due to 
MDDC donor variation.  
Similar to what was apparent in Chapter 3, deletion of the PNGs did not affect the ability of 
C16 to induce MDDC IL-10 secretion to the same extent as observed for C15 (Figure 4.3.5). 
IL-10 induction by the C16 mutants either remained the same as WT (N241 and N262) or 
increased non-significantly (N448, N386, N241-262, N241-448, N262-448, N386-392). 
However, the negative control induced nearly as much MDDC IL-10 secretion as WT, 
suggesting non-specific stimulation might have influenced the outcome of the experiment. As 
deletion of all the PNGs significantly reduced the ability of C15 to infect TZM-bl cells, these 
sites are likely to be essential for Env structure and function. This is corroborated by the high 
population frequency (Table 3.3.1) observed for these PNGs in subtype C sequences. 
Therefore, we were unable to conclude whether the presence of PNGs at N241, N262, N448, 
N386 and N392 are important determinants of MDDC IL-10 secretion as deletion seemed to 
disrupt the overall structural integrity of Env. Interestingly, there was no statistically significant 
correlation between IL-10 levels and PSV entry efficiency, DC-SIGN binding or trans-
infection and despite the inability of C15 N386/N392 and C16 N241/N262 to enter TZM-bl 
cells (Figure 3.3.11); they were able to induce MDDCs to release IL-10. These findings suggest 























































































Figure 4.3.5 Impact of deletion of Env Potential N-Glycan sites (PNGs) on MDDC IL-10 
release. Env PNGs at N241, N262, N448, N386 and N392 were deleted by site-directed mutagenesis 
of A) C15 and B) C16. PSVs of wild-type and mutants were compared for stimulation of MDDC IL-10 
secretion to the negative control (Ctrl). PSVs generated using pSG3∆Env and empty vector was used 
as a negative control.  The graph shows the mean of 3 biological repeats using 3 different donors plotted 
as percentage of WT (Error bars represent SEM). Means were compared using paired t test. *, ** and 
*** represent p values less than 0.05, 0.01 and 0.001, respectively. 
 
4.3.5.2. Identification of Env PNGs that influence MDDC IL-10 release 
The majority of sites deleted in C15 and C16 were highly conserved and thus their deletion led 
to reduced entry efficiency, suggesting that these sites were important for overall Env structure 




of bystander PNG processing (Pritchard, Spencer, et al., 2015). The secretion of IL-10 varied 
greatly across MDDC donors, with some secreting very low levels of cytokine irrespective of 
Env clone. Therefore, to identify Env PNGs associated with the ability to induce IL-10 
secretion irrespective of donor, we compared PSVs that differed in the presence and absence 
of PNGs for all donors tested. Mann-Whitney test showed that the presence of PNGs at 
positions 130, 332 and the lack of a PNG at 674 had a significant impact on the induction of 
IL-10 release by MDDCs (Figure 4.3.6). When median or mean IL-10 levels were compared, 
statistical significance was lost most likely due to extreme variability between donors and small 
sample size (data not shown). However, even with these limitations, the trend was mainatained 
indicating that N130, N332 and N674 could be important in stimulating MDDCs to release IL-
10.The frequency of the PNGs at position 130, 332 and 674 were 67%, 56% and 33%, 
respectively in our sequences and 55%, 77% and 25%, respectively in the subtype C 












































        
Figure 4.3.6 Identification of PNGs associated with IL-10 release irrespective of donor 
MDDC. Analysis of eighteen Env sequences identified PNGs that varied by 33 % - 67 % between 
sequences. Variable domains were excluded from the analysis.  PSVs were grouped on whether the Env 
clones carried a specific PNG or not and the level of IL-10 secreted by each of seven MDDC donors 
was compared between the two groups using a Mann-Whitney test. In order to directly compare IL-10 
levels between experiments with different donors, IL-10 levels were calculated as a percentage of 





Either the presence of a single PNG (or lack in the case of N674) or combination of N130+, 
N332+ and N674- N-glycans could be required to interact with DCs via DC-SIGN, triggering 
the release of IL-10. We hypothesized that if the potential IL-10 induction motif (N130+, 
N332+, and N674-) was essential for optimal MDDC stimulation then its presence would be 
significantly associated with increased MDDC IL-10 release irrespective of donor. MDDC IL-
10 release was compared between PSVs that carried either 0, 1, 2 or 3 PNGs comprising the 
induction motif. PSVs that carried either 1 or all of the PNGs significantly induced the release 
of higher levels of IL-10 (p = 0.0335 and 0.030 respectively) compared to when the motif was 
absent or only 2/3 PNGs were present (Figure 4.3.7 A). This suggests that the presence of one 
of the PNGs might be sufficient to stimulate the release of IL-10 in most donor MDDCs. 
The presence of N674 was significantly associated with reduced entry efficiency, disruption of 
DC-SIGN binding and a drop in trans-infection. This could suggest that an N-glycan at this 
position disrupted the structure and function of Env similar to the deletion of conserved PNGs 
in the previous experiments. It was previously shown that the introduction of a PNG at N674 
facilitated escape from carbohydrate binding agents with concomitant reduced viral fitness 
(Mathys & Balzarini, 2014). Furthermore, as N674 is likely under negative selection with a 
frequency of only 25% in subtype C viruses we repeated the analysis excluding N674 (Figure 
4.3.7 B). PSVs with PNGs at both N130 and N332 stimulated significantly higher IL-10 release 
than those that had either none or one of these sites (p = 0.0053). As a PNG at 674 could be 
influencing Env structure and function, site-directed mutagenesis of this site needs to be carried 









































Figure 4.3.7 Evaluation of the relationship between PSV carrying specific PNGs (+N130, 
+N332 and –N674) and MDDC IL-10 secretion. Nine PSVs were grouped on whether Env had 
A) 0 (–N130, -N332, +N674), 1 (e.g. –N130, -N332, -N674), 2 (e.g. –N130, +N332, -N674) or 3  
(+N130, +N332, -N674) and B) 0 (-N130, -N332), 1 (e.g.+N130, -N332) , or 2 (+N130, +N332) PNGs 
making up the potential IL-10 induction motif: PNGs at positions 130 and 332 and lack of a PNG at 
position 674.  IL-10 values obtained from the stimulation of seven MDDC donors with each PSV were 
normalised to background and groups were compared using a Mann Whitney t-test with two tailed 
comparison. Significance was not upheld after adjusting for multiple comparisons. 
 
4.3.6. Comparison of MDDC IL-10 induction between transmitted founder 
and chronic infection PSVs. 
Previous studies of HIV transmitted variants indicated that subtypes C and A TF viruses tended 
to carry fewer PNGs with shorter variable loops when compared to those from chronic stages 
of infection. Viruses identified years post-infection tended to have increased number of PNGs 
with insertions and deletions contributing to shifting positions that facilitated escape from 
immune pressure (Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006). These 
differences between viruses from acute and chronic stages of infection suggested that Env N-
glycosylation might play an important role in transmission. We grouped PSVs based on time 
















    
Figure 4.3.8 Comparison of multiple donor MDDC IL-10 secretion in response to 
stimulation by PSVs from acute and chronic stages of infection. PSVs were grouped on 
whether they were sampled 2-3 wks or 80-173 wks (2-3 years) post-infection. PSVs were used to 
stimulate up to seven donor MDDCs and IL-10 secretion was compared between matched acute and 
chronic infection pairs using a Wilcoxon matched pairs test, using A) all donors for each PSV and B) 
medians of IL-10 all donors stimulated with a single PSV. A) Each line connecting two points represents 
the data from one MDDC donor stimulated by one matched PSV pair, while for B), each bar represent 
median values of IL-10 released from all donors stimulated with either TF or chronic infection variants.  
 
PSVs from acute infection stimulated significantly higher MDDC IL-10 secretion (p = 0.0039) 
than those from chronic infection irrespective of MDDC donor (Figure 4.3.8).   
As N130+, N332+ and 674- were identified as associated with increased MDDC IL-10 release; 




infection Envs. We hypothesised that acute infection variants, if enriched with the induction 
motif might stimulate the release of higher MDDC IL-10 than those from chronic infection 
thus dampening the immune response and facilitating HIV transmission. Comparison 
suggested that the putative IL-10 induction motif was marginally more frequent in sequences 
from acute infection than chronic infection (Figure 4.3.9). However, when N674 was excluded 
from the analysis, the frequency of both N130 and N332 in acute infection PSVs was only 
higher by one participant and acute infection variants tended to not carry either N130 or N332 
compared to chronic infection viruses. It is thus possible that N130 and N332 are important for 
inducing MDDCs to release IL-10 but that these are not enriched in TFs. However, the sample 
size is too small to make this conclusion and further analysis is required. 
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Figure 4.3.9 Comparison of the frequency of PNGs in sequences from acute and matched 
chronic infection controls. The frequency of the potential induction motif: A) +N130, +N332 and -
N674 and B) +N130 and +N332  was compared between 18 sequences from acute infection (TF) and 
18 matched sequences representing the consensus virus circulating during chronic infection (CC).   
 
4.3.8 Influence of PSV stimulation on MDDC secretion of TNF-α, IL-6, IL-1β, 
IL-12, IL-8, MIP-1α and MIP-1β. 
HIV-1 infection does not only deregulate IL-10 levels, but also other pro-inflammatory and  
anti-inflammatory cytokines (Breen et al., 1990; Chehimi et al., 1994; Daftarian et al., 1995; 
Taoufik et al., 1997; Marshall et al., 1999; Narimatsu, Wolday & Patterson, 2005; Roberts et 
al., 2010; Shah et al., 2011; Borges et al., 2014, 2015). IL-10 was initially said to inhibit the 
production of pro-inflammatory cytokines like TNF-α, IFN-γ, IL-1β, IL-6, IL-2 and IL-12 
(Clerici & Shearer, 1993; Clerici et al., 1993; Borish & Steinke, 2003; Steinke & Borish, 2006; 
Villinger & Ansari, 2010). This was supported when Chehimi et al. (1994), Trinchieri et al. 
(2003)  and Marshall et al. (1999) found that HIV infection was associated with increased 
lymphocytic IL-10 production while IL-12 expression was impaired (Chehimi et al., 1994; 
Marshall et al., 1999; Choi, Fallert, et al., 2003). However, whole blood from HIV-positive 
individuals showed deregulated IL-12 expression independent of IL-10 levels, suggesting that 
under certain conditions other cytokines might be influenced directly by HIV (Meyaard et al., 
1997). Bebell et al. (2008) found that acutely HIV infected women had significantly higher IL-
6, IL-10 and lL-12 levels in CVLs and higher plasma IL-1β, IL-8 and IL-10 compared to HIV 




(Bebell et al., 2008). Roberts et al. (2010) also confirmed this finding when they showed that 
IL-1α, IL-1β, IL-6, TNF-α, IL-8, Fractalkine, IP-10 and IL-10 were significantly elevated in 
plasma of HIV-1 acutely infected women (Roberts et al., 2010, 2012). To determine whether 
exposure to HIV-1 influenced the release of cytokines other than IL-10, we measured the 
release of TNF-α, IL-1β, IL-6, IL-8, IL-12, MIP-1α, and MIP-1β, by MDDCs in response to 
PSVs. 
4.3.8.1 Impact of PSV stimulation on TNF-α secretion by MDDCs  
Levels of TNF-α, a pro-inflammatory cytokine which stimulates the production of free radicals 
has been reported to increase during HIV infection, correlating with increased viral load set 
point and hence disease progression (Bahia & Silakari, 2010; Vaidya et al., 2014). TNF-α has 
also been found to enhance HIV infection in women with bacterial vaginosis (BV) (Sturm-
Ramirez et al., 2000; De Jong et al., 2008) while high plasma levels were associated with 
increased risk of HIV acquisition (Roberts et al., 2012). TNF-α induced the production of other 
pro-inflammatory cytokines like IL-6 and IL-8 and also stimulated the production of IL-10 by 
monocytes (Platzer et al., 1995). While some studies have suggested TNFα inhibits HIV entry 
into tissue culture differentiated macrophages (Herbein, Montaner & Gordon, 1996; Lane et 
al., 1999), other studies found that it cooperated with IL-10 to enhance HIV replication (Poli 
et al., 1990; Finnegan et al., 1996). When MDDCs were stimulated with PSVs the differential 
release of TNF-α was similar to that of IL-10 with C7, C12 and C14 inducing significantly 
higher TNF-α secretion than the other clones when compared to the background control (p = 
0.0022, p = 0.0079 and p = 0.0087, 6-, 7- and 3-fold, respectively) (Figure 4.3.10). However, 
C15 that did not stimulate MDDCs to release high levels of IL-10 induced significantly more 
TNF-α than the control.  As C7, C12 and C14 both induced high levels of IL-10 and TNF-α, it 
is possible that the release of one cytokine induced the secretion of the other as suggested 
previously. However, IL-10 has been reported to repress TNF-α expression in activated 
macrophages (Zhang & An, 2007) by reduing myeloid differentiation primary response  protein 
88 (MyD88) expression and thus preventing NFκB activation in an LPS ch+allenged 
macrophage cell line (Dagvadorj et al., 2008). Furthermore, exogenous IL-10 inhibited TNF-
α, IL-6 and IL-8 secretion by mouse macrophages and human epithelial cells exposed to 
Chlamydia (Yilma et al., 2011). Thus, TNF-, like all pro-inflammtory cytokines initially 
induces IL-10 expression, but as part of its immune-suppressive function, IL-10 then inhibits 




suggests that either HIV has deregulated the ability of IL-10 to inhibit TNF- TNF- is 
enhancing the expression of IL-10 or HIV-1 is increasing the expression of both cytokines 






































Figure 4.3.10 Impact of PSV stimulation on MDDC secretion of TNF-α. Day six MDDCs 
from six different donors were stimulated with PSV in culture and the release of TNF-α in the culture 
supernatant was measured by Luminex assay. Results plotted are means of TNF-α (pg/ml) of six 
biological repeats from six different donors and the error bars represent SEM. Mann-Whitney test was 
used to compare TNF-α induction between PSV clones and between PSV and background. PSVs 
generated using pSG3∆Env and empty vector was used the negative control (Ctrl). *, ** and *** 
represent p values less than 0.05, 0.01 and 0.001, respectively. 
4.3.8.2 Impact of PSV stimulation on IL-6 secretion by MDDCs  
IL-6 is a pleotropic cytokine that has been described as a double edged cytokine (Zhang & An, 
2007). IL-6 is a special warning signal for the presence of pathogen. It has both pro- and anti-
inflammatory properties with several lines of evidence to suggest that it plays a vital role during 
the transition from innate to acquired immunity (Tanaka, Narazaki & Kishimoto, 2014). IL-6 
together with TGF-β participates in Th17 cell differentiation and these two cytokines are 
negatively regulated by IFN-γ, IL-2 and IL-27 (Ludewig et al., 2001).  Besides its crucial role 
in B and T cell differentiation, IL-6 is also known to promote CD4+ T cell  helper capacities 
through increased IL-21 production (Reviewed in (Deeks, Tracy & Douek, 2013), hence 
skewing Th0 differentiation towards Th2 and Th17 while inhibiting TGF-β driven 
differentiation of naïve CD4+ T-cells (Th0) towards regulatory T-cells. IL-6 serum levels were 




1990; Borges et al., 2014, 2015). There has been some contradiction to the role of IL-6 in HIV 
infection: while Poli et al. (1990) found that it synergizes with TNF-α to induce HIV 
replication, Rogez-Kreuz et al.(2005) showed that it enhanced the anti- HIV activity of IFN-τ 
in human macrophages (Poli et al., 1990; Rogez-Kreuz et al., 2005; Shah et al., 2011). In this 
study, C7, C12 and C14 PSVs stimulated MDDCs to release 8-, 9- and 4-fold increases in IL-
6 secretion relative to background (Figure 4.3.11) (p = 0.03, p = 0.031 and p = 0.05, 
respectively). This was a similar trend to that of IL-10 and TNF-α secretion (Figures 4.3.1 and 
4.3.10). The concomitant increase in IL-6, TNF-α and IL-10 in response to specific PSVs may 
induce chemokine expression which would in turn recruit target cells to the female genital tract, 




































Figure 4.3.11 Impact of PSV stimulation on MDDC secretion of IL-6. Day six MDDCs were 
stimulated with PSVs for 24 hours in culture and IL-6 levels were measured in the culture supernatants 
by Luminex assay. Bar graph shows mean IL-6 concentration (pg/ml) from five independent donor 
MDDCs stimulated with different PSV preparations. Error bars indicate +/-SEM. The control (Ctrl) is 
the HIV pseudoviral backbone without Env (pSG3). Mann-Whitney test was used to compare IL-6 
inductionbetween PSVs and control. * indicates p value less than 0.05. 
 
4.3.8.3 Impact of PSV stimulation on IL-1β release by MDDCs  
IL-1β is an important mediator of inflammation in many diseases. It has been shown that IL-
1β  synergises with IL-6 and IL-8 to upregulate the risk of HIV acquisition (Mlisana et al., 




(Masson et al., 2015). Levels of IL-1β together with IL-1α and IL-8 were high in BV which is 
associatd with increased risk of HIV infection (Sturm-Ramirez et al., 2000; Liebenberg et al., 
2016). In a cross sectional study, higher plasma IL-1β  was associated with  lower CD4+ T cell 
levels in acutely HIV infected women (Bebell et al., 2008). It has been reported that binding of 
IL-1β to its receptors activates NF-kB that induces secretion of IL-6, TNF-α and IL-8 in mice 
models (Nambu and Nakae, 2010). IL-1β and other cytokine levels including TNF-α and IL-6 
were elevated in the plasma of HIV infected subjects during early infection and in the 
supernatants of cells infected with HIV (Roberts et al., 2010). It was also suggested that 
infection of or exposure of macrophages to HIV induces secretion of these three cytokines, a 
trio which in turn increases HIV replication in these cells (reviewed in (Breen, 2002)), possibly 
by activating the NF-κB which in turn binds to the HIV promoter to directly enhance HIV 
replication. 
High variation between MDDC donors and low IL-1β levels made it difficult to identify a 
significant increase in IL-1β in response to PSV (Figure 4.3.12). Apart from C8 and C13, 
stimulation by all PSVs lead to at least 2-fold increase in MDDC secretion of IL-1β compared 
to the negative control (Figure 4.3.12) although the difference did not reach statistical 
significance. The increase in IL-1β did not follow the pattern observed for IL-10, TNF- and 
IL-6 and thus regulation of MDDC IL-1β release in the presence of HIV might differ to that of 
the other cytokines. However, the low levels of IL-1β released in response to PSV could be 







































Figure 4.3.12 Impact of PSV stimulation on MDDC secretion of IL-1β. Day six MDDCs 
were stimulated in culture with PSVs for 24 hours after washing to remove differentiation medium and 
the secretion of IL-1β was measured in the culture supernatants by Luminex assay. Graph presents the 
mean IL-1β (pg/ml) of 3 biological repeats each representing a different donor. PSVs generated using 
pSG3∆Env and empty vector was used as a negative control (Ctrl). Error bars are +/-SEM. Mann 
Whitney test was used to compare PSV induced secretion of IL-1β between PSVs and Ctrl. 
4.3.8.4 Impact of PSV stimulation on IL-12 secretion by MDDCs 
IL-12 is a heterodimeric pro-inflammatory cytokine with immune regulatory properties. It has 
been identified as the master switch leading to the differentiation of Th0 cells to Th1 as well 
as regulating T cell proliferation and cytotoxicity. It regulates its own secretion by DCs and T 
cells and induces IFN-γ production by T cells while inhibiting the development of tolerance 
(Chehimi et al., 1994; Marshall et al., 1999; Villinger & Ansari, 2010). IL-12 comprises of IL-
12p35 and IL-12p40 and a number of reviews have debated whether IL-12p40 dimers are 
agonists of IL-12 function  (Ling et al., 1995; Holscher et al., 2001; Abdi, 2002; Hölscher, 
2004; Khader et al., 2006; Abdi & Singh, 2015). Importantly, there was a positive correlation 
between the number of cells expressing IL-12 and IL-12p40, and we therefore used IL-12p40 
as a surrogate marker of IL-12 expression and function (Muller-berghaus et al., 2005). When 
we measured MDDC IL-12 secretion after stimulation with PSVs, there was a slight increase 
in levels relative to background, suggesting that HIV-1 interactions with DCs resulted in very 
little or no IL-12 release (Figure 4.3.13). This finding corroborated previous findings (Roberts 
et al., 2010) that didn’t identify increased levels of IL-12 in the plasma/CVLs of HIV-positive 
women. The pattern of IL-12 release did not match that of IL-10 secretion i.e. C7, C12 and 
C14 did not stimulate the secretion of higher IL-12 levels when compared to other clones. This 
could be due to PSVs directly preventing IL-12 release. Studies have shown that HIV and 
gp120 impair the secretion of IL-12 in response to stimuli. However, whether or not this is as 
a result of direct PSV stimulation or via PSV-mediated IL-10 secretion remains unclear 
(Chehimi et al., 1994; Daftarian et al., 1995; Taoufik et al., 1997; Marshall et al., 1999; Fantuzzi 
et al., 2004). Furthermore, we cannot exclude that IL-12p40 might be expressed differently 
from IL-12 in MDDCs in response to PSV. However, IL-12 levels are unlikely to be higher 












































Figure 4.3.13 Impact of PSV stimulation on MDDC secretion of IL-12. Day six MDDCs 
were stimulated in culture with PSV for 24 hours and the secretion of IL-12 was measured in culture 
supernatants by Luminex assay. PSV generated using pSG3∆Env and empty vector was used as a 
negative control (Ctrl). Results show mean IL-12 (pg/ml) +/-SEM from five donors stimulated on 
different days with different virus preparations. Mann Whitney test showed no significant difference 
between PSV induced IL-12 secretion and Ctrl.  
 
4.3.8.5 Impact of PSV stimulation of MDDCs on IL-8 secretion 
IL-8 is a chemokine (CXC) released by a number of cells and it is responsible for attraction of 
neutrophils to sites of infection and enhancing phagocytosis (Koch et al., 1992; Matsumoto et 
al., 1993). It has been shown to increase several folds in the serum of HIV infected subjects 
compared to their uninfected controls (Matsumoto et al., 1993) and to enhance HIV replication 
in both lymphocytes and macrophages (Lane et al., 2001). Narimatsu et al. and Masson et al.  
and Naranhhai et al. also found that elevated levels of IL-8 in cervical tissue explants, CVLs 
and plasma increased HIV transmission risk (Narimatsu, Wolday & Patterson, 2005; Naranbhai 
et al., 2012; Masson et al., 2015). This could suggest that increased levels of IL-8 at sites of 
HIV transmission attracts an increased number of target cells to the female genital sub-mucosa 
which then enhances HIV productive infection (Lane et al., 2001; Narimatsu, Wolday & 










































































Figure 4.3.14 Impact of PSV on MDDC secretion of IL-8. Day six MDDCs were stimulated 
with PSVs and the secretion of IL-8 measured in culture supernatants by Luminex assay. Due to high 
MDDC donor variation, IL-8 values (pg/ml) A) were normalised to that of C1 (%) B). then compared 
for four independent experiments each using a different MDDC donor and PSV preparation. Error bars 
represent mean +/-SEM. PSVs generated using pSG3∆Env and empty vector was used as a negative 
control (Ctrl). Mann Whitney test showed no significant difference between PSV induced IL-12 
secretion and Ctrl. * indicates p value less than 0.05. 
 
This is supported by findings that higher relative concentrations of IL-8 in the genital tract 
compared to plasma was associated with HIV acquisition risk in women (Liebenberg et al., 
2016).  Soluble IL-8 levels in response to PSV stimulation varied greatly between donors and 
some donor MDDCs did not release IL-8 above background (Figure 4.3.14, A). To circumvent 




donor (Figure 4.3.14 B) and the average percentages from five donors were compared between 
clones and the negative control. Similar to what was observed for IL-10, C7, C12 and C14 
induced IL-8 secretion 13-, 11-, and 5-fold, respectively above the negative control. However, 
only C12 induced IL-8 secretion that reached statistical significance (p = 0.05) (Figure 4.3.14) 
likely due to variation in IL-8 secretion across donors. Once again, the relative differences in 
IL-10 levels across clones was reflected in IL-8 which could suggest that pro-inflammatory 
cytokine production in response to PSVs resulted in IL-10 upregulation to reduce tissue damage 
in response to inflammation. Alternatively, early studies showed that under normal 
circumstances, IL-10 inhibited IL-8 expression in neutrophils to prevent immunopathology 
(Wang et al., 1994) and limited the expression of most pro-inflammatory cytokines and 
chemokines (Moore et al., 2001; Couper, Blount & Riley, 2008) after LPS but not PHA 
stimulation (de Waal Malefyt, Abrams, et al., 1991). As IL-8 levels were increased similarly 
to IL-10, PSVs might have impaired IL-10’s ability to inhibit pro-inflammatory cytokines. 
4.3.8.6 Impact of PSV stimulation of MDDCs on MIP-1α and MIP-1β secretion 
MIP1-α and MIP-1β are pro-inflammatory chemokines produced by pDCs in response to 
infection that attract CD4+ T cells to sites of infection (Li, Estes, et al., 2009). Peripheral blood 
cells from HIV positive subjects lacked the ability to secret MIP-1α and MIP-1β into culture 
supernatants despite high intracellular levels. However, the elevated intracellular levels of 
MIP-1α and MIP-1β in CD4+ T cells correlated with plasma viral load, suggesting that it played 
a role in HIV disease progression (Jennes et al., 2002, 2004). MIP-1α and MIP-1β levels were 
also shown to be elevated in CVLs of women with BV and associated with risk of HIV 
acquisition, with levels higher in women who later sero-converted than those who did not 
(Masson et al., 2015; Liebenberg et al., 2016). 
Most of the PSVs stimulated the release of MIP-1α and MIP-1β only 1.5-fold above the 
background control. Although  three PSVs (C7, C12 and C14) induced higher levels of MIP-
1α and MIP-1β levels (2.7-, 3.3- & 2-fold and 4-, 5- & 2-fold respectively for MIP-1α and  
MIP-1β) compared to background (Figure 4.3.15 A & B), only C12 stimulation resulted in a 
significant increase (p = 0.05) for MIP-1α.  However, when values were expressed relative to 
C1 to normalize for values from different donors, C7 and C12 induced significantly more 
MIP1-α and MIP1-β secretion than the controls(Figure 4.3.15 C & D). 
IL-10 has been said to inhibit MIP1-α and MCP-1 in human blood monocytes and alveolar 




concentrations during early HIV infection which correlated with plasma viral load set (Roberts 
et al., 2012). Our data shows that in most donors PSVs did not stimulate MDDCs to release 
much MIP1-α, MIP1-β (Figure 4.3.15) and MCP-1 (data not shown) compared to the 
background control. However, C7, C12 and C14 induced higher levels of MIP-1α and MIP-1β 
consistent with what was observed for IL-10, TNF-α, IL-6 and IL-8. It is therefore possible 
that either PSV stimulation was responsible for the changes in the cytokines and chemokines 













































































































































Figure 4.3.15 Impact of PSV MDDC stimulation on the release of A) MIP-1 α and B) 
MIP-1 β. Following differentiation MDDCs were stimulated with PSV in culture and the induction of 
A) MIP-1α and B) MIP-1β release by the PSV measured in culture supernatants by Luminex assay. The 
values of A) MIP-1α and B) MIP-1β (pg/ml) from three and four donors respectively, were expressed 
relative to C1 (C & D) to normalize cytokine variation between independent donor and the means +/- 
SEM are shown in bar graphs. ANOVA was used to calculate statistical differences between means 
from PSV stimulated donors and pSG3ΔEnv stimulated control. *, ** and *** represent p values of < 
0.05, 0.01 and 0.001, respectively. 
 
To summarize the effects of Env PSV on MDDC secretion of IL-10 and inflammatory 
cytokines, a hierarchical clustering of all cytokines was plotted. The plot showed the inter-
relatedness between MDDC IL-10 secretion with that of the other cytokines and whether some 




C7, C12 and C14 tending to stimulate the release of IL-10 together with TNF-α, IL-6, MIP-1α 




Figure 4.4.16: Potential association between MDDC secretion of IL-10 and pro-
inflammatory cytokines and chemokines. IL-10, TNF-α, IL-6, MIP-1α, IL-8, IL12, IL-1β 
and MIP-1β levels were measured following stimulation of MDDCs with PSVs and were 
clustered by unsupervised hierarchical clustering (using R).  C13, C8, C1, C16, C2, C15, C14, 
C7 and C12 are represented on the e y-axis and cytokines on the x-axis.  
 
4.4 Discussion  
An ideal environment for HIV-1 survival would include dampened phagocytic and cytotoxic 
activity with increased influx of immune cells to sites of infection. Viruses and intracellular 




10 levels as IL-10 inhibits IL-12 production, allowing pathogens to establish infection or 
enhance persistence (Brooks et al., 2006; Finlay & McFadden, 2006; Hamza, Barnett & Li, 
2010; Redford, Murray & O’Garra, 2011; Wilson & Brooks, 2011).  
There is an apparent interdependent relationship between HIV-1 infection and inflammation as 
the one seems to exacerbate the other: inflammation is associated with increased risk of HIV-
1 infection (Masson et al., 2015) and disease progression (Roberts et al., 2010, 2012) while 
HIV-1 replication and resultant immune dysfunction increases inflammatory responses.   
Inflammation is likely to enhance heterosexual HIV transmission by increasing the number of 
DCs, macrophages, and CD4+ T cells in the female genital tract, providing HIV-1 with target 
cells for replication (Miller & Shattock, 2003; Miller, 2007; Li, Estes, et al., 2009), reducing 
epithelial barrier integrity (Nazli et al., 2010) or directly promoting HIV-1 replicaiton (Osborn, 
Kunkel & Nabel, 1989). Therefore, understanding how HIV-1 manipulates inflammatory 
immune responses to favour its own survival will provide vital information for the design of 
HIV preventive, treatment and cure strategies.  
 IL-10 has been suggested to be the key cytokine involved in tissue repair during an 
inflammatory response as well as an initiator of Th2 type responses (Hazlett, Jiang & 
McClellan, 2014). While earlier studies stated that the principle function of IL-10 is to limit or 
terminate inflammatory responses, Trinchieri et al. pre-supposed that viral products may 
suppress IL-12 production directly (Trinchieri, 1997; Moore et al., 2001). Corinti et al., (2001) 
found that autocrine IL-10 decreased DC function and Aimaniandra et al. (2009) suggested the 
role IL-10 to enhance Tregs so as to impede maturation, IL-12 secretion and protective immune 
response (Corinti et al., 2001; Aimanianda et al., 2009). In Epstein Barr virus, IL-10 is not only 
produced to limit inflammation but it is produced very early to blunt immune response 
development (Redford, Murray & O’Garra, 2011). This could suggest that IL-10 can be 
produced together with or in the absence of IL-12 and/or other pro-inflamamtory cytokines 
following exposure of DCs to pathogen or pathogenic product. The fine balance of the cytokine 
profile produced by DCs determines the Th0 differentiation (Kennedy et al., 1994; Trinchieri, 
1997; Romagnani, 2000; Watford et al., 2003). Other inflammatory cytokines like TNF-α, IL-
6, IL-1 IL-9 and IL-17 are also made by immature DCs, and these serve to expand other 
subsets of T cells like the Treg and Th17 which help either in the control of the immune 

















Figure 4.4.1 Variation in the cytokine interactions network focussed on the role of IL-10 
as a modulator. The simplified diagrams represent only a subset of cytokine interactions specific to 
the immune modulators discussed in this study with the aim of highlighting the interconnectedness and 
complexity of the interactions. A) Literature discussed in this chapter was used to map out interactions 
between IL-10, IL-12, IL-1β, TNF-α, IL-8, IL-6, MIP-1α and MIP1β. Concentrations of cytokines were 
not taken into consideration nor were the outcome of Th0 differentiation into Th1 or Th2. B) Map of 
cytokine interactions if IL-10 levels were elevated. C) Studies on plasma, CVL and whole blood of 
HIV-positive individuals indicated that IL-10, IL-8, IL-6,TNF-α IL-1β, MIP1α and MIP1β levels were 
all increased compared to HIV-negative controls. When this data was included into Map A, 
inflammatory responses were increased. D) Map of the results of MDDC cytokine release in response 
to pseudovirus. The interactions and the consequences are nearly identical to that of Map C: 
inflammatory responses increased. Blue (+) and red (-) lines indicate increase/positive effect and 
decrease/negative effect, respectively. Green lines (?) indicate inconclusive findings. *Conflicting 
results on whether IL-12 levels were decreased or increased in HIV-infected samples. Figure based on 
literature from (Chehimi et al., 1994; Marshall et al., 1999; Choi et al., 2003; Meyaard et al, 1997; 
Bebell et al., 2008).  
We found that stimulation of MDDCs with PSVs carrying Env with variable number, position 
and mannosylation of PNGs induced the secretion of varying levels of IL-10 for most of the 
donors tested, indicating that some Envs are better inducers than others. PSVs C7, C12 and 
C14 induced significantly greater IL-10 production than both the background control and the 
other Env clones (Figure 4.3.1), while other clones induced IL-10 secretion only slightly above 





PSV-stimulated MDDC IL-10 release, it is likely that gp120-DC-SIGN interactions were 
involved in the release of this cytokine (Figures 4.3.2 & 4.3.3). However, inhibition with 
recombinant DC-SIGN did not reach 100% suggesting that other receptors could also play a 
role as previously suggested (Turville et al., 2001; Shan et al., 2007; Lambert et al., 2008). 
Non-CLRs like Galcer, CD169 or heparan sulfate might also be involved as they capture HIV 
and trans-infect CD4+ T cells (de Witte, Bobardt, et al., 2007; Magerus-Chatinet et al., 2007; 
Izquierdo-Useros, Lorizate, Puertas, et al., 2012). Binding of HIV to TLR2 and TLR4 
stimulated IL-10 expression, suggesting that TLR responses could also account for the release, 
in part of IL-10 (Figure 5.1.1) (Saraiva & O’Garra, 2010).   
Env-DC-SIGN interactions are likely via high mannose as Shan et al. (2007) found that 
removal of mannose residues from gp120 abrogated their ability to induce MDDC IL-10 
secretion (Shan et al., 2007). As the nine clones differed in number, position and level of 
mannosylation, we determined if there was a relationship between the level of gp140 
mannosylation and the ability of PSVs to stimulate the release of IL-10. Even though C7, C12 
and C14 were amongst the clones with the highest mannosylation and induction of IL-10 
release, C13, one of the weaker IL-10 inducers also had approximately 40% mannosylation. 
There was thus no overall relationship between Env mannosylation and IL-10 secretion. This 
could be because sgp140 and PSVs are processed slightly differently, or Env activation of other 
receptors (e.g. TLR2 or TLR4) than DC-SIGN whose interaction with DC might not depend 
entirely on the number of high mannose residues could also contributes to induction of the IL-
10 release seen. 
 As other studies have identified PNGs involved in DC-SIGN binding and/or carried high 
mannose residues, we deleted PNGs at positions 241, 262, 386, 392 and, 448 to determine 
whether these putative N-glycans played a role in inducing IL-10 secretion by MDDCs (Hong 
et al., 2002, 2007; Go, Hewawasam, et al., 2011; Liao et al., 2011). However, deletions of most 
PNGs had deleterious effects on Env function and are more likely essential for maintaining 
native Env structure rather than IL-10 secretion. In order to circumvent the risk of disrupting 
Env structure and function we took an alternative approach. PSVs were grouped based on the 
presence or absence of PNGs that varied between 33 - 67% within the cohort sequences and 
IL-10 secretion in response to PSVs of the two groups was compared. Each TF and matched 
chronic infection pair was used to stimulate MDDCs from the same donor multiple times. The 




background, indicating that MDDC response to HIV was highly donor-specific. We thus 
compared the level of IL-10 released by each donor stimulated by Envs PSV that carried 
specific PNGs.  Statistical analysis of IL-10 secretion data indicated that the presence of PNGs 
at N130, N332 and absence at N674 could be important for the induction of MDDC IL-10 
release by PSVs irrespective of the donor. When IL-10 levels released by 7 donors stimulated 
by a single Env were averaged and a similar anlaysis was carried out, statistical significance 
was lost although the presence of PNGs at N130, N332 and absence at N674 were still 
associated with increased IL-10 levels. Therefore, the majority of MDDC donors are more 
likely to release IL-10 when stimulated with Envs that carry PNGs at N130 and N332 but not 
N674. As N674 was previously suggested to be important for Env structure and/or function, 
we excluded this PNG from the analysis. PSVs that carried both PNGs at N130 and N332 
stimulated MDDCs to release higher levels of IL-10 than those that lacked all of the PNGs or 
only carried one of the two. This suggested that PNGs at position 130 and 332 of gp120 could 
interact with DC-SIGN in such a way as to stimulate the release of IL-10 by MDDCs. However, 
we cannot discount the importance of these N-glycans in binding to alternative DC receptors 
As we had identified N130 and N332 as comprising a potential IL-10 inducing motif, we 
determined whether these PNGs were enriched in acute infection (AI) sequences. However, 
N130 and N332 were only marginally enriched in Envs from the acute stage of infection 
although this finding was possibly due to the small sample size of the study (18 matched AI vs 
18 CI Env sequences). Furthermore, some sequences were sampled before 2 years post-
infection and thus comparison of TF to later samples (more than 3 years) might detect a greater 
difference in the frequency of N130+ and N332+ between AI and chronic infection variants. 
To further investigate whether AI PSVs were better able to induce MDDC IL-10 secretion, 
matched PSVs were grouped on whether they were sampled 2-5 weeks or 80–173 weeks post-
infection. Comparison of IL-10 levels in the culture supernatants of 7 MDDC donors after 
stimulation with PSVs showed that the AI clones induced significantly more MDDC IL-10 
secretion than their matched CI pairs irrespective of MDDC donor. This could suggest a role 
of IL-10 in HIV transmission. Early IL-10 responses have been previously suggested to impair 
specific CD4+ T cell expansion, function and secondary recall in intracellular endosomal 
bacteria (Singh & Thirumalapura, 2014) and facilitated disease progression in HCV infection 
(Flynn et al., 2011). Norris et al. (2006) and Borghi et al. (1995) found IL-10 levels elevated 
in plasma at acute  HIV infection(Borghi et al., 1995; Norris et al., 2006)  whereas other studies 




However, as this study focussed on nine matched Env pairs, a larger sample size must be 
evaluated to confirm the relationship between IL-10 release and HIV transmission.  
IL-10 has been found to limit T cell, macrophage and NK activity via limiting MHC class II 
molecules, co-stimulatory molecules and changing the profile of pro-inflammatory and anti-
inflammatory cytokines produced by APCs (de Waal Malefyt, Haanen, et al., 1991; Fiorentino 
et al., 1991; D’Andrea et al., 1993). Thus, to confirm whether PSV stimulation of MDDCs also 
resulted in differential release of other pro-inflammatory cytokines and chemokines, IL-12p40, 
IL-6, IL-8, IL-1β, MIP1α, MIP1β and TNF-α levels were measured in the supernatants of PSV-
stimulated MDDCs. PSVs induced MDDCs to release very low levels of IL-12p40, suggesting 
that viral stimulation was not resulting in a Th1 response (Figures 4.3.13). This finding was 
similar to previous studies that found impaired IL-12 production with increased IL-10 levels 
(Shan et al., 2007) in MDDCs and some suggested that aberrant IL-12 expression was an 
indirect effect of IL-10 (Chehimi et al., 1994; Daftarian et al., 1995; Marshall et al., 1999) or 
failure to detect IL-12 using an anti-IL-12p40 detection system. It was also suggested that 
aberrant IL-12 expression was independent of IL-10 (Meyaard et al., 1997), although Bebell et 
al. (2008) found increased levels of both IL-10 and IL-12 in CVLs in acute HIV infection 
(Bebell et al., 2008). Despite contrary reports, PBMCs and MDDCs from HIV infected persons 
produced more IL-10 and less IL-12 than those from negative controls (Buisson et al., 2009) 
and autocrine IL-10 impaired IL-12 release and DC migration to lymph nodes in response to 
M. tuberculosis (Demangel, Bertolino & Britton, 2002).  
This suggests that HIV-1 could prevent Th0 cell differentiation into Th1 subtype by favouring 
the expression of IL-10 over IL-12, halting an adaptive immune response and thus protecting 
the virus from immune clearance (Mosmann & Coffman, 1989; Pulendran, 2001). Brooks et 
al. (2008) suggested that blocking IL-10 enhanced the efficacy of a DNA vaccine to induce T 
cell responses to clear persistent for LCMV viral infection. This re-enforces the hypothesis that 
IL-10 impairs the Th1 pathway of the immune response which fights viral and intracellular 
pathogens (Brooks et al., 2006, 2008; Ejrnaes et al., 2006). 
Studies have suggested that IL-10 represses expression of TNF-α, IL-1β and IL-8 in activated 
macrophages (Zhang & An, 2007), suppresses the expression of IL-1α, IL-1β, IL-6, IL-8 and 
TNFα in human monocyte (de Waal Malefyt, Abrams, et al., 1991) and inhibits MIP-1-α, MIP-
1-β and MCP-1 production by human blood monocytes (Berkman et al., 1995)., although this 




When we investigated whether PSVs induced secretion of other immune modulators, we also 
found that the same PSVs (C7, C12 and C14) that induced MDDCs to release high levels of 
IL-10 also stimulated the release of higher concentrations of IL-6, IL-8, MIP1α, MIP1β and 
TNF-α than all other clones. Longitudinal and cross-sectional cohort studies of HIV infected 
women showed that HIV infection is associated with elevated levels of IL-1β, IL-6, IL-8, MIP-
1-α, MIP-1-β and TNF-α, in CVL and plasma (Bebell et al., 2008; Stacey et al., 2009; Roberts 
et al., 2010) resulting in heightened inflammatory responses (Figure 4.4.1C). However, 
identification of increased IL-10 levels was done within the context of increased concentrations 
of these inflammatory cytokines. These studies, therefore suggested that HIV infection resulted 
in a robust inflammatory response that initiated the production of high levels of IL-10 (Stacey 
et al., 2009). Despite evidence that IL-10 reduces the expression of IL-6, IL-8 and TNF-α, the 
longitudinal study of Stacey et al. (2009) did not show a decrease in inflammatory cytokines 
over time in response to IL-10, highlighting the complexity of in vivo models (Stacey et al., 
2009).  
Further experiments in the presence of IL-10 inhibitors will be able to evaluate the relationship 
between IL-10 and the expression of IL-8, IL-6, TNF-α, MIP-1α, MIP-1β, and IL-1β by DCs 
in the presence of HIV or gp120. Despite opposing hypothesese as to whether IL-10 deregulates 
a Th1 response or inflammation leads to high IL-10 levels, both in vivo HIV-1 infection and in 
vitro PSV stimulation of MDDCs resulted in enhanced expression of the same cytokines. 
Therefore in vitro stimulation of MDDCs inflammation responses mimic the effect observed 
in HIV-infected individuals when they first come in contact with the virus. The overall outcome 
of the “cytokine storm” is increased inflammatory responses that could favour HIV 
transmission and survival by activating large numbers of target cells at sites of infection and 
promoting viral establishment probably by modualtion of the immune response by IL-10 
together with the activation of the NF-KB. 
N-glycans around the N332 and V3 loop of gp120 have been found to be very immunogenic 
and form epitopes for some of the most potent nAbs (Garces et al., 2014; Pritchard, Spencer, 
et al., 2015). Potentially, the PNG at N332 might be included in a vaccine cocktail to help the 
development of nAb response. However, this study has shown that the Env PNG at N332 could 
be involved in inducing MDDCs to release high levels of IL-10 and pro-inflammatory 
cytokines in a potentially deregulated Th1 response. An immunogen including N332 might 




deregulated inflammatory signals. This study highlights the need to understand how HIV 
modulates the immune response to safeguard its survival to inform vaccine design. 
In conclusion, our findings supported studies that looked at inflammatory responses in HIV 
infected women as PSV stimulated MDDCs to secrete increased levels of IL-10 and pro-
inflammatory cytokines and chemokines. Inflammation was previously shown to increase the 
risk of infection although the cells responsible were not identified. Here we show that DC-
mediated inflammation might be very important to HIV acquisition. Furthermore, acute 
infection PSVs stimulated higher levels of IL-10 than those from chronic infection, suggesting 
that it could play a role in HIV transmission. The proposed model therefore is that the secretion 
of IL-10, TNF-α, IL-6, IL-8, IL-1β, MIP-1 α and MIP-1β by DCs after binding HIV in the 
female genital tract attracts T cells, DCs and macrophages into the sub-mucosal, lamina propria 
and epithelium where they become infected. IL-10 could prevent DC maturation (Fantuzzi et 
al., 2004) and under these conditions enhance migration of DCs carrying virus to the lymph 
nodes where more CD4+ T cells are trans-infected. As IL-10 causes immunosuppression, a 
cytotoxic immune response may be impaired, while TNF-α, IL-6 and IL-8 may enhance the 
replication of the virus enough for effective dissemination and productive clinical infection 
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HIV Envelope (Env) N-glycosylation plays an important role in the host immune response to 
HIV infection (Binley et al., 1998; Scanlan et al., 2002; Calarese, 2003; Koch et al., 2003; Shan 
et al., 2007; Banerjee et al., 2009; McLellan et al., 2011; Moore et al., 2012).  Like most 
pathogens or pathogen associated molecular patterns (PAMPs), Env N-glycans could alter 
immune responses by activating alternative signaling pathways in dendritic cells (DCs) 
(Geijtenbeek et al., 2003; Geijtenbeek & Gringhuis, 2009; Gringhuis et al., 2009). However, 
the mechanism whereby HIV-1 N-glycans could modulate DC signaling is not fully 
understood. 
Pathogens that activate DCs do so by triggering a series of complex intracellular signals leading 
to DC maturation, up-regulation of co-stimulatory molecules (Banchereau & Steinman, 1998; 
Banchereau et al., 2000) and production of cytokines and chemokines. NF-kB and other 
transcription factors are also required for expression of inflammatory cytokines (Osorio & Reis 
e Sousa, 2011).  
Earlier evidence has indicated an association between IL-10 and HIV infection. The  level  of 
IL-10 is elevated at the earliest time post-infection, increases with disease progression and is 
said to impair IL-12 production, hence dysregulating Th1/Th2 responses during HIV infection 
(Clerici & Shearer, 1993; Stylianou et al., 1999; Norris et al., 2006; Brockman et al., 2009). 
More specifically, Env mannose type N-glycans were found to stimulate MDDC IL-10 
production (Shan et al., 2007) via DC-SIGN. Furthermore, as we have identified potential 
PNGs that could play a role in regulating MDDC IL-10 release and that TFs might induce 
MDDCs to release higher levels of IL-10 (Manuscript in preparation), we wanted to investigate 
if Env N-glycans activated alternative DC signaling pathways.  
Although C-type lectin receptors (CLRs) are antigen capture receptors that help induce 
effective immune responses, pathogens like Mycobacterium tuberculosis, HIV and hepatitis C 
virus  (HCV) subvert DC function when they interact with DC-SIGN (Geijtenbeek et al., 2003; 
van Kooyk & Geijtenbeek, 2003; Van Kooyk et al., 2004; van Vliet et al., 2007; Den Dunnen, 
Gringhuis & Geijtenbeek, 2009; Geijtenbeek & Gringhuis, 2009). Pathogen interaction with 
DC-SIGN has been reported to activate signaling via Raf-1. Raf-1 activation is central to 
modulating toll-like receptor (TLR) -mediated NF-κB activation and enhancing IL-10 
production (Figure 5.1.1) (Geijtenbeek et al., 2003; Gringhuis et al., 2007, 2009; Den Dunnen, 




acetylation of the p65 subunit of NF-κB at Ser276. In response to M. tuberculosis infection, 
acetylation of NF-κB p65 leads to transcription of Il-10, Il-6 and Il-12 (Gringhuis et al., 2007, 
2010; Sancho & Reis e Sousa, 2012). Although fucose-containing pathogens don’t activate 
Raf-1, they also induce IL-10 while down-regulating the expression of IL-6 and IL-12 (Figure 
1.4). It is possible that different PAMP-associated N-glycans can either activate Raf-1 or 
downstream effectors of Raf-1 (Geijtenbeek et al., 2003; Geijtenbeek & Gringhuis, 2009; 
Gringhuis et al., 2009, 2010), reviewed in (Sancho & Reis e Sousa, 2012). Mitogen activated 
protein kinases (MAPKs) are well established downstream effectors of the Raf-1 kinases in the 
Raf-Ras-MEK pathway (Wellbrock, Karasarides & Marais, 2004). As carbohydrate 
components of PAMPs influence Raf-1 activation, it is possible that carbohydrate content could 
also influence the MAPK kinases. 
MAPKs that regulate some of the most critical functions (growth, differentiation and apoptosis) 
of the immune response and could play a role in the pathogenesis of a variety of human diseases 
(Johnson & Lapadat, 2002; Kim & Choi, 2010)  (Shaul & Seger, 2007). The major groups of 
MAPKs include the extracellular regulated kinases (ERK), the c-Jun N-terminal kinase (JNK) 
[also known as the stress activated protein kinases (SAPK)] and p38 MAP kinases (Zhang, Wei 
, Tu Liu, 2002; Shaul & Seger, 2007). The relative importance of ERK, JNK and p38 in an 
immune response is dependent upon both the stimulating agonist and the target TLR. JNK and 
p38 are mainly stimulated by environmental stress and inflammatory cytokines (Wagner & 
Nebreda, 2009; Liu et al., 2016). The ERK pathway is involved in the control of cell growth, 
proliferation and cell survival in response to mitogens and growth factors (Lu & Xu, 2006; 
Boutros, Chevet & Metrakos, 2008). ERK activation leads to expression of cytokines necessary 
for the balance between cell expansion and survival (Lu & Xu, 2006; Shaul & Seger, 2007). 
Previous studies by Shrefler et al. (2006),  Caparros et al. (2006) and Hsu et al. (2010) showed 
that DC-SIGN ligands activate ERK phosphorylation in DCs (Caparros et al., 2006; Shreffler 
et al., 2006; Hsu et al., 2010; Zhao et al., 2013). Hsu et al. (2010) and Zhao et al. (2013) found 
that the Bermuda grass protein, BG60 and E2 protein (one of the viral envelope glycoproteins 
of HCV) activated Raf-1 and ERK  signalling (Hsu et al., 2010; Zhao et al., 2013) of MDDCs 
















Figure 5.1.1 DC-SIGN modulation of TLR signaling. Signaling via DC-SIGN modulates TLR 
dependent signalling. Binding of HIV to DC-SIGN activates Raf-1 and modulates crosstalk between 
TLR and CLR-dependent activation of NF-KB, tipping the balance between immunopathology and 
innate immune response in its favour to establish infection.  Simplified from (Hajishengallis & Lambris, 
2011; Biasin et al., 2014).  
Shan et al. (2007) found that Env mannose type N-glycans activated MDDC ERK to produce 
IL-10 and we showed that Env clones induced varying levels of IL-10 release, suggesting that 
some HIV variants might stimulate ERK better than others due to differences in Env N-
glycosylation (Shan et al., 2007). The impact of differential N-glycosylation of HIV-1 gp120 
on MAPK activation is not known. Given that some of these PNGs are important epitopes for 
broadly neutralising and potent Abs (Sanders et al., 2002; Scanlan et al., 2002; McLellan et al., 
2011; Pejchal et al., 2011; Walker et al., 2011; Pritchard, Spencer, et al., 2015) and may be 
considered as components of HIV-1 vaccines, understanding their impact on DC CLR-





5.2 Aims and Objectives 
Aim: Understand how HIV-1 Subtype C Envelope N-glycosylation impacts dendritic cell 
signaling. 
Rationale:  
Shan et al. (2007) showed that gp120 high mannose residues were involved in inducing DCs 
to secrete IL-10 and that not all Env clones were able to activate this pathway (Shan et al., 
2007). Fucose-containing pathogens bind DC-SIGN but do not activate Raf-1 although they 
induce IL-10 secretion (Sancho and Reis e Sousa, 2012), suggesting that DC-SIGN-mediated 
signaling pathways are differentially activated depending on N-glycosylation of ligand. In 
Chapter 4 we showed that Envs stimulated MDDCs to release different levels of IL-10 and 
other cytokines. As N-glycan patterns differ between Envs, we hypothesise that differential N-
glycosylation between Envs could activate alternative DC signaling pathways. This could 
result in the expression of different inflammatory cytokines that then shapes the immune 
response and potentially HIV-1 survival.  
5.2.1 Specific Objectives: 
1. Determine if differentially N-glycosylated Env PSV differ in their activation of the 
MAPK signaling pathway. 
2. Determine if interactions between Env (gp140) and DC-SIGN are responsible for 
activating the MAPK signaling.  






5.3.1 Optimisation of experimental conditions to determine the 
phosphorylation of ERK, JNK and p38 using flow cytometry 
In chapters three and four, we showed that Env N-glycosylation could be important for Env 
structure and function, PSV entry efficiency, DC-SIGN binding, trans-infection and 
stimulating MDDCs to secrete IL-10. Next we determined if differences in Env PNGs impacted 
their ability to activate MAPK signaling as it is associated with MDDC release of IL-10. 
Phosphorylation and activation of the MAPK, ERK, leads to phosphorylation of the NF-KB 
p65 unit resulting in the activation of promoter regions for inflammatory cytokines genes 
(Dhillon et al., 2007). The ERK signaling pathway negatively regulates IL-12 production but 
enhances production of IL-10 and other inflammatory cytokines (Nakahara et al., 2006). Since 
we found that the production of IL-10, TNF-α, IL-6, IL-8 and IL-1β was enhanced by some 
PSVs and IL-12 was apparently not affected, we investigated whether Env with different PNG 
patterns differentially stimulated the phosphorylation of ERK. JNK and p38 were included in 
the study as they also differentially regulate MDDC cytokine production and  p38 has been 
suggested to positively regulate DC maturation (Zhang & Kaplan, 2000; Kim et al., 2005).  
5.3.1.1 Pseudovirion stimulation of MDDC MAPK phosphorylation 
 
 
Figure 5.3.1 Flow cytometry analysis of MDDC ERK and JNK phosphorylation in 
response to stimulation with pseudovirus. Equal amount of pre-titered C12 and C13 PSV were 
added to day six MDDCs and incubated for 5, 15 and 30 minutes (min) at 37oC and the phosphorylation 
of JNK (pJNK) A) and ERK (pERK) B) was measured by flow cytometry. pSG∆Env was used to 
control for the effect of other HIV-1 proteins on ERK and JNK phosphorylation (pSG3). Results were 
analysed by Flowjo software and the mean fluorescence intensities (MFIs) of the phosphorylated cells 
were plotted in GraphPad Prism 5.0. pJNK antibody was conjugated to phycoerythrin (PE) and pERK 






Hsu et al. (2010) was able to detect ERK phosphorylation following 5 and 15 min stimulation, 
Gringhuis et al. (2009) detected phosphorylated Raf-1 after 10 minutes of stimulation and 
Caparros et al. (2006)  and Olsnes  et al. (2011) detected pERK following 15 minutes of 
stimulation (Caparros et al., 2006; Gringhuis et al., 2009; Hsu et al., 2010; Olsnes, Olofsson & 
Aarstad, 2011) Therefore, phosphorylated ERK and JNK (pERK and pJNK) were detected by 
flow cytometry using fluorescent conjugated antibodies to phospho- ERK and JNK following 
stimulation of MDDCs for 5, 15 and 30 min with C12 and C13. PSVs lacking Env (pSG∆Env 
control) were used to control for the effect that other viral proteins might have on MDDC 
stimulation. After 5 min stimulation, pSG∆Env stimulated the phosphorylation of both ERK 
and JNK better than C12 and C13. After 15 min, there was a slight increase in pERK and pJNK 
in response to C12 and C13 relative to pSG∆Env although this slight increase (1.2-fold) only 
remained apparent for C13 (1.4-fold) after 30 min. The relative pattern of phosphorylation of 
both ERK and JNK in response to C12 and C13 were similar at each time-point, suggesting 
that Env was activating the MAPKs. However, the high signal across all pSG∆Env controls 
suggested that other viral proteins were also stimulating the phosphorylation of ERK and JNK 
especially at 5 minutes followed by a drop in activation over time (Figure 5.3.1). The reduced 
signal of the pSG∆Env control at 15 and 30 min could also represent background ‘noise’, suggesting 
that Env-specific stimulation could be detected at these time points. 
5.3.1.2 gp120 stimulation of MDDC MAPK phosphorylation 
To eliminate the background signal, cell fixation was done immediately following stimulation 
to avoid further phosphorylation occurring during the staining process as well as to inactivate 
cellular phosphatases. Multiple factors present in the fetal calf serum used in the pseudovirus 
preparation may activate TLRs non-specifically, leading to non-specific phosphorylation of 
ERK. Therefore, MDDCs were stimulated with purified gp120 (gp120) to see if the absence of 
serum would reduce the background signal to detect Env-specific stimulation of MAP 
stimulation. We included LPS as a positive control and for a negative control; stimulation 








Figure 5.3.2 Determine the effect of purified gp120 on ERK and JNK phosphorylation 
over time. Day six MDDCs were washed with pre-warmed PBS and stimulated with 2 µg/mL of 
purified gp120 [CAP88 acute infection (AI) [isolated 1 month post infection, 88 1m and CAP88 chronic 
infection (CI), isolated 12 months post infection [88 12m] clones (Gift from Dr. J Arthos)] and the 
phosphorylation of A) JNK (pJNK) and B) ERK (pERK) was measured by flow cytometry. LPS at 500 
ng/mL) was used as a positive control and culture medium was used as a negative, unstimulated control 
(U). Mean fluorescence intensity (MFI) was expressed as the percentage of unstimulated controls (U).  
 
Five and thirty minute stimulation with gp120 did not eliminate background signal as the MFI 
of the unstimulated control was equal to MDDCs stimulated by LPS and gp120. LPS stimulated 
an approximately 2-fold increase in pJNK levels after 15 min of stimulation relative to the 
unstimulated control. Furthermore, pERK levels did not change in response to LPS which was 
contrary to the 5.5-fold and 1.4-fold increase above unstimulated controls previously reported 
(Emre et al., 2007; Olsnes, Olofsson & Aarstad, 2011). The variation between the studies could 
be due to different experimental conditions and varying basal phosphorylation of MAPKs 
between donors (Olsnes, Olofsson & Aarstad, 2011). After 15 min incubation with gp120 
(CAP88 CI), pJNK levels increased approximately 2.5-fold, suggesting that activation had 
occurred at this time-point (Figure 5.3.2). However, this apparent increase was not observed 
for pERK and we thus tried to optimize the experiment further to reduce basal phosphorylation.  
5.3.1.3 Effect of serum deprivation on MDDC ERK phosphorylation in response to 
PMA 
Hamdorf et al. (2011) found high basal phosphorylation of ERK following differentiation of 
DCs from hematopoietic (CD34+) cells and they suggested that this basal activation was caused 
by IL-4 and GM-CSF in the differentiation medium (Caparros et al., 2006; Hamdorf et al., 
2011). Furthermore, CSF has been shown to activate the MAPK pathways in mice (Smith et 





differentiation for 24 hours before stimulation to remove the effect of IL-4 and GM-CSF 
(Caparros et al., 2006). Therefore, after differentiation for 6 days, MDDCs were washed with 
pre-warmed PBS to remove all differentiation medium and were then rested O/N in serum-free 
medium before stimulation with phorbol 12-myristate 13-acetate (PMA), an activator of 
protein kinase C which results in phosphorylation of phosphotyrosine kinase and ERK (Chang 
et al., 2005). Irrespective of whether the MDDCs were rested or not the unstimulated control 
MFI did not change (735 Vs 763) whereas resting the MDDCs before PMA stimulation resulted 
in a 4-fold increase in MFI (2812 vs 633) (Figure 5.3.3). This could suggest that factors in the 
differentiation medium inhibited phosphorylation of ERK. 













Figure 5.3.3 Phosphorylation of phosphotyrosine kinase after depriving MDDCs of 
serum. Day six MDDCs were either rested or not in serum-free medium for 24 hour before stimulation 
with phorbol 12-myristate 13-acetate (PMA) for 30 min and stained for phosphotyrosine-PE (pT-PE). 
Red histogram is unstimulated control and blue histogram indicates stimulated MDDCs from one donor. 
Each histogram was scaled up to the percentage of the maximum number of cells in each bin (denoted 
% of Max).  Representative of two rested donors, one stimulated with PMA and the other stimulated 





5.3.1.4 Stimulation of rested MDDCs with LPS for varying lengths of time.  
As resting MDDCs in serum-free medium led to phosphorylation of phosphotyrosine kinase in 
response to PMA, we stimulated rested MDDCs with LPS and determined pERK levels at 
different times. As LPS (500 ng/mL) stimulation did not result in robust stimulation of MAPK 
signal above that of background, IL-1β and TNF-α were included in these experiments to 
amplify the response. Levels of pERK increased with increasing time of stimulation with 30 
minutes showing a 6.7-fold increase compared to unstimulated control (16000 vs 2365) (Figure 
5.3.4). We then tested whether higher concentrations of LPS alone would also result in 
detectable increases in MAPK phosphorylation. We increased LPS concentration to 1 mg/ml 
and stimulated MDDCs for 5, 15 and 30 min to determine the best duration of stimulation 
(Figure 5.3.5). A fluorescent minus one (FMO) control was included to ensure that there was 
no spread of fluorescent signals from other channels. Auto florescence of unstained cells was 












Figure 5.3.4 Phosphorylation of ERK after stimulating rested MDDCs with LPS, IL-1 
and TNF-α. Day six MDDCs were either rested or not rested in serum-free medium for 24 hour before 
stimulation with LPS + IL-1 + TNF-α for various times and stained for pERK. The red histogram 
represents unstimulated controls, the blue histogram is 1 min stimulation, the green histogram is 5 min 
stimulation, the orange histogram indicates 15 min stimulation and the turquoise is 30 min stimulation. 
MFI is plotted and overlayed as the histograms. 
The background was too high after 5 min of LPS stimulation to distinguish an increase in pJNK, 
pERK and p-p38 (Figure 5.3.5 A and D). However, after 15 mins of LPS stimulation MFI 




5.3.5 B and D). Similarly, there was an increase in MFI for both pJNK and pERK after 30 min 
LPS stimulation. Although, there was an increase in MFI at 15 min (1.6-fold), LPS stimulation 
did not lead to phosphorylation of p38 at 30 min (Figure 5.3.5 B, C and D). The FMO control 
indicated that there was spill-over of pJNK-PE and pERK-PAC blue signals into the p-p38 
channel, which might make it difficult to discriminate between positive versus negative signals 








Figure 5.3.5 Optimising the duration of MDDC stimulation with LPS (1mg/mL). Day six 
MDDCs were washed and rested O/N in serum-free medium and stimulated with LPS at 1 mg/mL for 
A) 5, B) 15 and C) 30 min. Phosphorylation was measured by flow cytometry using antibodies to pJNK, 
pERK and pP38 conjugated to phycoerythrin (PE), pacific blue (Pac-Blue) and peridinin chlorophyll-a 
Protein-Cy5.5 (PerCP) fluorescent dyes, respectively. D) Mean florescent intensity (MFI) was plotted 
vs time for pJNK (diamond), pERK (star) and pP38 (circle) with (green lines) and without (blue lines) 
LPS.  
5.3.2. Flow cytometry analysis of MDDC MAPK phosphorylation in response 
to pseudovirus  
C12 and C13 PSVs were used to stimulate MDDCs and the effect of these Envs on 
phosphorylation of ERK, JNK and p38 were evaluated using flow cytometry. C12 and C13 
were selected as they differed significantly in their ability to induce the secretion of IL-10 by 
MDDCs (Figure 4.3.1) (Manuscript in preparation) and also in their PNG profiles. Therefore, 
this study aimed to determine whether differences in genotype and phenotype influenced 













Figure 5.3.6 Impact of C12 and C13 on ERK, JNK and p38 phosphorylation. Day six 
MDDCs rested O/N in serum-free medium were stimulated for 15 min with C12 and C13 PSVs and the 
phosphorylation of ERK, JNK and p38 was measured by flow cytometry. Results are indicated as mean 
fluorescence intensity (MFI) and a representative of two experiments for pERK, pJNK and pP38 
following 15 min of stimulation is shown. LPS was added as a positive control. The background control 
was HIV-1 backbone only (pSG3) to determine whether any increase in phosphorylation was due to the 
presence of other viral proteins present in the pseudovirus. Unstimulated control was MDCs to which 









Mean <Pac blue> 
pP38 
Mean <perCP> 
  C13 15 min 71.6 6197 3457 980 
  C12  15 min 67.6 6118 3263 1113 
  pSG3 15min 75.9 3785 1905 801 
 LPS 15 min 75.8 8830 3346 1820 
    Unstimulated 
15 min 





The effects of both negative (unstimulated and pSG3) controls on MDDC stimulation were 
nearly identical for both pERK and pJNK and thus fold-increase in MFI for LPS and PSVs 
were calculated relative to the pSG3 control (Figure 5.3.6). LPS stimulated a 1.8-, 2.3- and 2.3-
fold increase in MFI for pERK, pJNK and p-p38, respectively, indicating that signaling 
pathways involving activation of ERK, JNK and p38 were stimulated as expected. These results 
were similar to a previous study, which showed that LPS increased phosphorylation of pERK, 
JNK and p38 approximately 2-fold, 4-fold and 2.5-fold, respectively after 15 min stimulation 
of immature MDDCs (Fairman & Angel, 2012). C12 and C13 induced a 1.8-fold and 1.7-fold 
increase above the pSG3 control for pERK, respectively, and both PSVs stimulated a 1.6-fold 
increase in MFI for pJNK. This suggests that there was no difference between these two Envs 
in activation of ERK- and JNK-mediated signaling pathways.  Despite an increase in p-p38 in 
response to C12 and C13 relative to the pSG3 control (1.4- and 1.2-fold), this apparent increase 
was lost when calculated relative to the unstimulated control (1-fold), suggesting that 
phosphorylation of p38 was not stimulated by PSV. However, the FMO control did suggest 
that spillover between channels could influence the detection of p-p38 by flow cytometry and 
we were thus unable to conclude whether p38 was activated in response to Env or not.   
5.3.3 Western blot analysis of MDDC ERK phosphorylation in response to 
pseudovirus 
To confirm our results obtained using flow cytometry, we also used western blotting (WB) to 
test MDDC ERK and JNK phosphorylation in response to C12 and C13 PSVs (Figure 5.3.7). 
However, pJNK was not detected using WB most likely due to poor antibody specificity. For 
pERK analysis, unstimulated and pSG3 controls were very similar and LPS stimulated a 2-fold 
increase in pERK above background similar to that observed with flow cytometry (1.8-fold), 
indicating that LPS activated ERK to the same extent (Figure 5.3.7). C12 and C13 were 
previously tested for MAPK phosphorylation by flow cytometry and the results of the WB 
were identical with a 1.8-fold increase in pERK MFI for both clones, confirming that C12 and 
C13 were both equally able to stimulate the activation of ERK-mediated signaling pathways. 

















Figure 5.3.7 Western blot analyses of MDDC MAPK phosphorylation following 
stimulation with PSVs. Day six MDDCs were stimulated (after serum depriving O/N) with PSVs 
(C15, C16, C3, C4, C12, C13, C14, C7, C8 and C9) for 15 minutes, the cells were lysed and pERK 
measured by Western blotting using phosphor-p44/42 MAPKs and total ERK (ERK1/2) (Cell 
Signaling, Cat#9101/ #9102). C12 and C7 PSV were also used to stimulated MDDCs pre-incubated 
with anti-DC-SIGN Mab (Clone DCN46, ARP 7682) (denoted C7+ and C12+) to measure pERK with 
and without DC-SIGN inhibition. Representative Western blots of pERK and total ERK for two donors 
A), five donors B) and two donors C) are shown. Gene tool (Image J) was used to quantify band 
intensities and the ratios of pERK to total ERK densities were calculated relative to the unstimulated 
control for each donor. The mean pERK relative to Unstimulated controls was plotted in GraphPad 
prism 5.0 (D) with error bars indicating SEM. Mann Whitney test showed no statistically significant 
difference between pERK levels between different PSVs.  
Due to limited access to a flow cytometry facility, other Env clones were compared for MAPK 
phosphorylation using WB to determine if ERK activation could be associated with clone-
specific N-glycosylation, DC-SIGN binding and Env entry efficiency. ERK phosphorylation 
differed across the clones from 1- to 2-fold with C7 and C8 similar to the unstimulated control 
and C9 and LPS both stimulating a 2-fold increase in pERK (Figure 5.3.7). C7 and C9 had the 
same TZM-bl entry efficiency, confirming that Env function is not a prerequisite for activating 
signaling pathways. This was supported by the lack of correlation between ERK activation and 
Env entry efficiency. C3, C4, C15 and C16, were selected as they differed in mannosylation as 
well as number and position of PNGs. There was no difference in the phosphorylation of ERK 
when MDDCs were stimulated with C15, C16, C4 and C3 (Figure 5.3.7 A and D) even though 
C15 had more HM/H type N-glycans than C16 and C4 was more mannosylated than C3. 
Similarly, correlation analysis did not support a relationship between Env mannosylation and 







5.3.4 Inhibition of MAPK phosphorylation by recombinant DC-SIGN 
DC-SIGN binds HIV via Env N-glycans, is involved in trans-infecting CD4+ T cells and 
stimulating MDDCs to release IL-10 (Geijtenbeek, Kwon, et al., 2000; Kwon et al., 2002; Shan 
et al., 2007); (Figure 4.3.3; Manuscript in preparation). To investigate whether DC-SIGN was 
involved in MAPK phosphorylation in response to PSV stimulation, MDDCs were stimulated 
with C12 and C13 PSVs after inhibiting DC-SIGN interaction using recombinant DC-SIGN 
protein and pERK and pJNK were measured by flow cytometry. Pre-incubation of C12 with 
recombinant DC-SIGN lowered fluorescent signal by apparently 30.9% and 31.04% for ERK 
(2075 to 1438 MFI) and JNK (15579 to 10743 MFI), respectively indicating that preventing 
PSVs from binding MDDC DC-SIGN influenced MAPK phosphorylation levels (Figure 
5.3.8). However, when background was subtracted from the C12 _DC-SIGN values, there seem 
to be a 100% inhibition of pERK and pJNK for C12, but considering the background variatons 
across donors it was compared to unstimulated control. Stimulation with C13 resulted in only 
a 12.9% reduction (data not shown), much lower than C12. The difference between C12 and 
C13 mimicked IL-10 secretion when C12 was more sensitive to inhibition by recombinant DC-
SIGN than C13 (Figure 4.3.3). Complete inhibition of pERK and pJNK by recombinant DC-
SIGN was not observed, suggesting that other receptors are also involved in MDDC MAPK 
signaling activation. However, LPS barely stimulated the phosphorylation of JNK and ERK 
(1.3-, and 1.2-fold, respectively), contrary to what was previously observed, suggesting that 
MDDC donor variation might have influenced the outcome of the experiment.  
The data observed for flow cytometry analysis was confirmed using WB. When anti-DC-SIGN 
Mab (Clone DCN46, ARP 7682) was pre-incubated with MDDCs, there was a 42.7% reduction 
in ERK phosphorylation in response to C12 PSVs, (Figure 5.3.7), confirming that DC-SIGN-
Env interactions are in part responsible for ERK activation. C7 PSVs were also pre-incubated 
with recombinant DC-SIGN which resulted in 18.6% decrease in ERK phosphorylation most 
likely because C7 was a poor activator of ERK phosphorylation (Figure 5.3.7). CD4 receptor 
is not involved in phosphorylation of pERK as addition of soluble CD4 to C7 PSVs before 
adding to the MDDCs had no effect on ERK phosphorylation (Appendix I, Figure A3). Despite, 
partial inhibition of ERK phosphorylation following DC-SIGN inhibition, there was no 






Figure 5.3.8 MAPK phosphorylation in the presence of soluble DC-SIGN. Day six MDDCs 
were stimulated with C12 pre-incubated with (blue line) and without (red line) recombinant DC-SIGN) 
for 15 minutes and pERK, pJNK and p-p38 measured by Flow cytometry. A representative results of 
two donors (from two independent experiments) stimulated with C12 is shown here with histograms 
generated by Flowjo analysis following stimulation with PSV. Controls included a medium only 
(unstimulated) control (green line) and LPS (black line). 
 
5.3.5 Phosphorylation of ERK and JNK by Env protein 
Env mediates first contact with target cells during HIV infection and is thus the preferred 
vaccine immunogen.  As PSVs comprise not only Env but also other viral proteins, we tested 
purified soluble Env protein, gp140 to activate MAPK phosphorylation and flow cytometry 
was used to detect pERK and pJNK.  C12 and C13 gp140 were used to stimulate MDDCs 
following triton extraction of all endotoxins. Similar to previous experiments LPS increased 
the MFI of pERK and pJNK by 1.7-fold and 2.6-fold compared to the unstimulated control. 
Compared to the unstimulated control, there was an increase in signal when C12 gp140 was 
used to stimulate MDDCs for 15 min (Figure 5.3.9) and the pattern was similar for both ERK 
(1.5-fold) and JNK (1.7-fold), suggesting that C12 gp140 was stimulating the phosphorylation 
of these two kinases. However, C13 gp140 did not seem to have the same effect as C12 on JNK 
(1.3-fold) and ERK (1.1-fold) although the difference between the two clones did not reach 
significance (Figure 5.3.9). C12 was also a much better inducer of MDDC IL-10 secretion than 




IL-10 release for this clone. However, the increase in pERK and pJNK required for changes in 









Figure 5.3.9 MAPK phosphorylation by purified gp140 protein. Day six MDDCs were rested 
O/N at 37oC in serum free medium and stimulated with gp140 protein  for 15 min before  A) pERK or 
B) pJNK was measured by flow cytometry. The acquired flow cytometry data was analyzed using 
Flowjo software and the MFI from two biological repeats expressed as a percentage of the unstimulated 
control is shown with error bars indicating standard error of the mean (SEM). ANOVA showed no 
significant difference between C12 and C13. 
 
5.3.6 Impact of specific Env N-glycans on the phosphorylation of ERK and 
JNK 
We were unable to determine conclusively whether C12 and C13 differentially stimulated ERK 
and JNK phosphorylation as a result of their N-glycosylation differences as stimulation with 
PSVs and gp140 yielded differing results. Therefore, to determine if N-glycans are important 
for MAPK phosphorylation, we deleted PNGs at positions N241, N262, and N448 of Env and 
investigated whether or not the loss of these PNGs affected the ability of C15 and C16 PSVs 
to activate ERK and JNK. Previously, we showed that deletion of individual PNGs had varying 
effects on C15 and C16 function, suggesting that they influenced Env structure and function 
and that some clones were more sensitive to mutation than others. Deletion of the PNGs at 
N262 and N448 lead to a decrease and an increase in C16 entry efficiency, respectively (Figure 
3.3.11). The C16 N262 PNG mutant decreased the MFI of pERK compared to WT whereas 
N448 PSV increased pERK and pJNK after 15 min stimulation (Figure 5.3.10 A and C). The 
change in pJNK in response to C16 N262 was not as apparent, but this is likely due to the low 





deleted at N262 of C15, stimulation of MDDCs with this mutant resulted in lower pERK and 
pJNK compared to the WT. Deletion of N262 abrogated the entry efficiency of C15 and overall, 
these findings suggest that structural integrity of Env is required for activating JNK- and ERK-
mediated signaling pathways. This suggests that there are instances when non-functional Env 
(like C15 N262Q) is still able to activate signaling pathways of ERK and JNK although not as 
much as the functional Env. However, while deletion of the PNG at N241 significantly lowered 
entry efficiency of C15 it did not have a deleterious effect on the phosphorylation of ERK and 
JNK compared to WT (Figure 5.3.9 B and D), suggesting that both ERK and JNK 
phosphorylation was not influenced by the PNG at N241. 
Previously we showed that PNGs at N130 and N332 of gp120 could be involved in inducing 
MDDCs to release IL-10. As this study hypothesized that activation of ERK-mediated 
signaling pathways could be involved in activating IL-10 expression and release, we wanted to 
determine whether N130 and N332 was also associated with phosphorylation of ERK When 
we compared pERK levels between PSVs with and without N130 and N332, there was no 
correlation between the PNGs and phosphorylation of ERK. This supported the lack of 
association between pERK levels and IL-10 secretion and suggests that although the ERK-
mediated signaling pathway is differentially activated by Env clones, this does not translate 
into concomitant changes in IL-10 secretion. The lack of 100% inhibition by recombinant DC-
SIGN could suggest that receptors other than DC-SIGN are also involved and that activation 
of alternative signaling pathways masks the relationship between MDDC stimulation of pERK 
and IL-10 secretion. This could confirm previous findings by van Vliet at al. (2007) that the 
interaction of PAMPs with DCs leads to activation at times of multiple receptors and the effect 
on transcription factor and inflammatory gene expression is the outcome of the integration of 



















Figure 5.3.10 Impact of specific PNGs on the phosphorylation of MAPK in MDDCs. Day 
six MDDCs were stimulated with C16 (A and C) and C15 (B and D) and their mutant PSVs and the 
phosphorylation of JNK (A and B) and ERK (C and D) were measured by flow cytometry. PSG3 
pseudovirus lacking Env was used as a negative control and LPS as a positive control for MAPK 


























































































































Recombinant gp120 influenced the expression pattern of a number of surface DC proteins 
(Williams, Trout & Spector, 2002) and induced atypical maturation of DCs accompanied by 
functional changes (Fantuzzi et al., 2004). HIV-1 and M. tuberculosis have been shown to 
target DC-SIGN to suppress DC function and establish infection (Geijtenbeek et al., 2003; 
Cunningham, Harman & Donaghy, 2007; Den Dunnen, Gringhuis & Geijtenbeek, 2009; 
Gringhuis et al., 2009). The pathogenic products of M. tuberculosis and HIV-1 (ManLAM and 
gp120 mannose residues, respectively) induce Raf-1 phosphorylation and in the case of HIV-
1, activated Raf-1 promoting LTR activation and formation of full length HIV  transcript in 
DCs (Gringhuis et al., 2010). This suggests that signaling via Raf-1 might be important for 
pathogens that escape immune surveillance and subvert DC responses to establish infection. 
We hypothesized that to facilitate its transmission and survival, HIV-1 deregulates DC-
mediated innate immunity by activation of signaling pathways that result in the aberrant 
expression of cytokines that favour viral replication.  
Gringhuis et al. (2007) found that binding of ManLAM to DC-SIGN activated Raf-1 of the 
Ras-Raf-MEK-MAPK signaling pathway which resulted in NF-kB-stimulated expression of 
cytokines, including IL-10 (Gringhuis et al., 2007; Geijtenbeek & Gringhuis, 2009). As Env 
N-glycans interact with DC-SIGN, we determined if Env PNGs played a role in activating 
ERK, JNK and p38 (Johnson & Lapadat, 2002; Zhang, Wei , Tu Liu, 2002; Wellbrock, 
Karasarides & Marais, 2004). MAPKs have previously been targeted for immune-based 
therapies and could thus also be targeted for HIV-1 therapy (Johnson & Lapadat, 2002; 
Wellbrock, Karasarides & Marais, 2004). HIV-1 inhibits maturation of DCs; ERK 
phosphorylation, and to a lesser extent JNK phosphorylation, is said to inhibit maturation of 
DCs, whereas p38 phosphorylation is required for DC maturation (Nakahara et al., 2006). 
Therefore, other than stimulating the release of IL-10, Env could also modulate the maturation 
of DCs and thus the adaptive immune response. 
PSVs were used to induce phosphorylation of the MAPKs and pERK, p-p38 and pJNK were 
detected using flow cytometry. Flow cytometry experiments were optimised to improve 
detection of pERK, pJNK and p-p38. We determined that the optimum stimulation time was 
15 min and resting MDDCs in serum-free medium before stimulation with PSVs was required 




background in response to LPS was quite low, this was comparable to some studies (Emre et 
al., 2007; Olsnes, Olofsson & Aarstad, 2011). In some experiments PSVs from many 
participants were used to stimulate the same donor MDDC, but most comparisons used 
different MDDC donors per participant pair due to the limited amount of MDDCs produced 
from some donor PBMCs. Although variation between donors was taken into account when 
MFI values from each donor were normalized to the unstimulated control, we cannot discount 
the possible effect that donor variation could have in these experiments.  
HIV infection inhibited DC maturation (Fairman & Angel, 2012) and resulted in a transient 
increase in pERK levels and a sustained increase in p38 activation. Inhibition of p38 resulted 
in DCs unable to migrate along a chemokine gradient and the authors suggested that HIV-
induced p38 activation facilitated DC-mediated CD4+ T cell trans-infection (Wilflingseder et 
al., 2004). Phosphorylation of p38 above background was not observed for Env stimulation 
using flow cytometry despite increasing the length of stimulation, and buffer composition used 
for cell permeabilisation. Although, LPS is a well-known activator of p38, we were unable to 
show a robust response using flow cytometry. Previous studies showed that p38 was not 
activated in 30% DC donors in response to HIV (Wilflingseder et al., 2004) and that response 
to activators is cell-specific and varied according to physiological conditions (Zarubin & Han, 
2005). It is thus possible that the lack of apparent p38 activation could be due to donor 
variability or as previously discussed, overlapping signals in the p38 channel. However, a 
previous study found that cross-linking DC-SIGN with an antibody lead to enhanced il-10 
transcription and phosphorylation of ERK1/2 and Akt but not of p38 (Caparros et al., 2006). 
This suggests that DC-SIGN ligands could trigger alternative signaling pathways that lead to 
the phosphorylation of ERK but not p38.  
Flow cytometry and Western blotting indicated that C12 and C13 PSVs stimulated MDDC 
ERK and JNK phosphorylation equally. This was contrary to the observation that purified C12 
gp140 stimulated phosphorylation of ERK and JNK better than C13 gp140. The ratio of 
functional: non-functional trimers could differ between PSVs and purified gp140 with the latter 
more likely to be mostly monomers (Go et al., 2015; Pritchard, Harvey, et al., 2015), suggesting 
that PSVs would represent a more physiologically relevant model. However, as C12 and C13 
differed in mannosylation and PNG number and C12 also bound better to DC-SIGN, trans-
infected TZM-bl cells more efficiently and induced significantly more IL-10 secretion than 




phosphorylation because it was more heavily N-glycosylated and bound with higher efficiency 
to DC-SIGN. Furthermore, C12 represents a transmitted founder variant and C13 its chronic 
infection counterpart, suggesting that variants at transmission might be stronger activators of 
MDDC ERK signaling, leading to inhibition of DC maturation, immune deregulation and thus 
providing a fitness advantage. However, correlation analysis indicated that there was no 
relationship between ERK phosphorylation and Env mannosylation, entry efficiency, DC-
SIGN binding and trans-infection.  
Although, other viral proteins such as Tat have also been shown to activate the MAPK 
signaling pathway, these should not influence apparent differences between PSV clones as 
these proteins are identical in all pseudoviral preparations (Toschi et al., 2006). However, it is 
possible that the combined signal from gp120 and Tat might lower the sensitivity of the PSV 
induction assay so that small differences between C12 and C13 are less easily detected than 
when gp140 are compared. It was also shown that binding to CCR5 triggered signaling via 
Pyk2, p38 MAPK, and ERK1/2 signaling pathways (Wilflingseder et al., 2004), resulting in 
the activation of STAT3 involved in p38 MAPK–NF-B pathways and IL-6 secretion in DCs. 
it is possible that signaling via CCR5, and not only DC-SIGN regulates MAPK 
phosphorylation (Cornò et al., 2014). The authors suggest that increased expression of IL-6 
leads to constitutive activation of STAT3 which plays an important role in deregulation of DC 
immune function. However, DC-SIGN-gp120-induced IL-10 secretion down-regulated Nef-
stimulated IL-6 expression, suggesting that cross talk between signaling pathways activated by 
gp120 and Nef could further complicate the comparison between PSVs and gp140 (Sarkar, 
Mitra & Chakrabarti, 2013). In this study, soluble CD4 did not inhibit PSV-stimulated ERK 
phosphorylation, suggesting that CCR5-mediated signalling was not playing a role in ERK 
phosphorylation. 
Furthermore, DC-SIGN ligands stimulate alternative cellular responses:  the peanut allergen 
(Ara H1) and Schistosoma egg antigen caused ERK phosphorylation (Shreffler et al., 2006) 
that lead to impaired IL-12 production and a Th2 biased immune response whereas Salp15 
activated a Raf-1/MEK pathway that promoted TNF and IL-6 mRNA decay and decreased the 
production of IL-12 (Reviewed in (Sancho & Reis e Sousa, 2012).  An anti-DC-SIGN antibody 
stimulated ERK and impaired IL-12 production (Caparros et al., 2006). It was also shown that 
HIV-1 activated Raf-1 but instead of ERK this lead to the activation of scaffold proteins (LSP1, 




it is possible that DC-SIGN-dependent Raf-1 activation by PSVs leads to a signaling cascade 
that bypasses ERK. The lack of correlation between ERK phosphorylation and Env 
mannosylation, entry efficiency, DC-SIGN binding and trans-infection is most likely due to 
the highly complicated nature of HIV-1 activation of MDDC signaling pathways. 
It has been suggested that particular Env PNGs interact with DC-SIGN and therefore the 
presence or absence of specific N-glycans may be more important than overall levels of 
mannosylation for activating ERK-mediated pathways. Both Shan et al. (2007) and Nabatov et 
al. (2006) suggested that subtle differences in PAMPs might influence the interaction between 
DC-SIGN and its ligands (Nabatov et al., 2006; Shan et al., 2007) and thus DC signaling 
pathways. We had mutated Env at PNGs previously identified to play a role in DC-SIGN 
binding (Hong et al., 2007; Go, Hewawasam, et al., 2011; Liao et al., 2011),  but found that 
deletion of most sites reduced PSV entry efficiency.  In this study we tested PSVs with PNGs 
deleted at N241, N262, and N448 as these were not deleterious to all Envs and were shown to 
be enriched with high mannose type N-glycans (Go, Hewawasam, et al., 2011). Deletion of 
N262 in C16 reduced pERK levels and this corresponded to the drop in entry efficiency 
observed for the mutants. Similarly, deletion of N448 not only increased C16 entry efficiency, 
it also increased ERK phosphorylation. Together this would suggest that the native structure 
of Env is required for the activation of ERK-mediated pathways. However, deletion of N241 
which reduced C15 entry efficiency had no effect on pERK levels, suggesting that poorly 
functional Env (50 - 60% decrease in entry efficiency compared to WT) can still activate DC 
signaling pathways. Although, deletion of specific PNGs lead to changes in ERK 
phosphorylation, we cannot conclude that N241, N262 and N448 are essential for activation of 
ERK-mediated signaling pathways as the deletions also affected Env function. An HIV vaccine 
needs to comprise highly immunogenic molecules irrespective of whether it retains function or 
not. Therefore, as PNG deletions influence ERK activation, Env immunogens comprising N-
glycan motifs can thus be designed to elicit the most favourable DC-mediated immune 
responses for viral clearance.  
ERK phosphorylation induced via DC-SIGN lead to activation and expression of IL-10 
(Caparros et al., 2006; Shan et al., 2007), suggesting that those clones that induced higher levels 
of pERK should also induce the secretion of more IL-10. We did not find a statistically 
significant correlation between IL-10 secretion and ERK phosphorylation although C12, an 




phosphorylation and IL-10 secretion could be due to the small sample size as we only had 
overlapping data for seven clones. It is also possible that Env binds to DC surface receptors 
other than DC-SIGN and thus inhibition studies were carried out to determine the importance 
of DC-SIGN-Env interactions on MAPK phosphorylation. Stimulation of MDDCs with C12, 
C13 and C7 PSVs pre-incubated with recombinant DC-SIGN only partially inhibited MAPK 
phosphorylation, confirming that other receptors besides DC-SIGN, and thus signaling 
pathways, were involved. However, pre-incubation with soluble CD4 had no effect on MAPK 
phosphorylation (Appendix I, figure A3), ruling out this receptor as a potential player. 
Gringhuis et al (2007) suggested that DC-SIGN cannot activate NF-kB p56-mediated 
expression of IL-10, IL-12 and IL-8 in the absence of pre TLR triggering (Gringhuis et al., 
2007; Geijtenbeek & Gringhuis, 2009). Other PRRs such as CLRs like MR and DCIR of 
MDDCs have already been suggested to also play a role in binding HIV (Turville et al., 2001, 
2002; Lambert et al., 2008). As stimulation of IL-12 production was poor, dectin 1 or dectin 2 
might not be involved as these CLRs induce both IL-10 and IL-12 equally. Other non-CLR 
could also be important as they have been suggested to play a role in trans-infection (Saphire 
et al., 2001; Magerus-Chatinet et al., 2007; Izquierdo-Useros, Lorizate, Puertas, et al., 2012; 
Puryear et al., 2012; Izquierdo-Useros et al., 2014) The involvement of other receptors could 
also explain why there was no correlation between ERK phosphorylation and IL-10 secretion, 
mannosylation, entry efficiency, DC-SIGN binding and trans-infection.  
 
Conclusion  
We can conclude that Env triggers signal transduction in MDDCs that differentially activates 
and phosphorylates ERK and JNK. Some Env were better inducers than others, suggesting that 
vaccine design could utilise this approach to design highly immunogenic candidates. DC-SIGN 
is only one of the receptors involved in activating ERK and further study is required to identify 
any others. Changes in Env N-glycosylation seemed to be associated with ERK 
phosphorylation, although there was no clear relationship between overall levels of 
mannosylation or specific PNGs with ERK phosphorylation. Although PSVs differed in their 
ability to stimulate phosphorylation of ERK with C12 better at both IL10 and ERK 
phosphorylation, there was no association with their ability to induce IL-10 secretion. This is 
likely because PSVs activated more than one cross-linked signaling pathway so that IL-10 








Chapter 6: Conclusion 
Despite contradictory evidence, it is generally accepted that HIV infection is linked to aberrant 
cytokine expression and disruption of CD4+ T helper and CD8+ cytotoxic T cell function and 
that disease progression is mainly associated with a Th2 cytokine profile (Graziosi et al., 1994; 
Maggii et al., 1994; Sarih, Mabtaoui & Benslimane, 1996; Mellado et al., 1998). More recently, 
increased levels of genital tract inflammatory cytokines and chemokines such as MIP-1α, MIP-
1β, and IP-10, were associated with an increased risk of HIV acquisition, further suggesting 
that female genital tract inflammation is important for HIV infection (Masson et al., 2015). 
Inflammation could attract target cells to sites of HIV infection, facilitating replication.  
Modulation of immune responses by HIV could be mediated by Env N-glycans interacting with 
DC DC-SIGN (Hong et al., 2002, 2007; Lin et al., 2003; Liao et al., 2011; Montfort et al., 
2011) and inducing the release of IL-10 (Ameglio et al., 1994; Shan et al., 2007) that culminates 
in a shift from Th1 to Th2 adaptive responses (Gessani et al., 1997; Mellado et al., 1998). IL-
10, an anti-inflammatory cytokine plays a very important role in directing immune responses 
towards the Th2 route (Fiorentino et al., 1991; Fantuzzi et al., 2004; Singh & Thirumalapura, 
2014). Furthermore, inhibition of IL-10/IL-10R interactions enhanced T cell activity against 
HIV Env although this effect was lost upon depletion of CD4 T cells (Landay et al., 1996). 
These findings led to the hypothesis that for productive clinical infection to occur increased 
IL-10 levels down regulate the maturation, but allow migration of DCs with infectious virus to 
lymph nodes, enhance cell-cell viral transfer via virological synapses and stimulate aberrant T 
cell differentiation and proliferation. When TF Envs were discovered to: 1)  have fewer N-
glycan sites (Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006) 2) that were enriched 
with high mannose residues (Go, Hewawasam, et al., 2011), 3) mannose type N-glycans bound 
DC-SIGN (Lin et al., 2003; Montfort et al., 2011) and this interaction with DC-SIGN 
stimulated the release of IL-10 (Shan et al., 2007), we hypothesised that IL-10 could play an 
important role in HIV transmission and pathogenesis. However, these in vitro studies did not 
test whether inflammatory cytokines were also released by MDDCs in response to HIV 
stimulation. We found high levels of IL-8, IL-6, TNF-, MIP-1 and MIP-1 secreted in 
response to PSVs. To understand how PSVs manipulated the release of DC cytokines, we 
determined whether N-glycosylation influenced Env’s function, binding to DC-SIGN, ability 




We confirmed previous findings that the number of PNGs increased over the course of 
infection (Derdeyn et al., 2004; Chohan et al., 2005; Sagar et al., 2006), with sites carrying a 
heterogeneous mix of high mannose and complex-type N-glycans (Go et al., 2015). Although 
there was a positive correlation between PNG number and level of mannosylation the number 
of high mannose residues did not influence entry efficiency as reported in previous studies 
(Montefiori, Robinson Jr. & Mitchell, 1988; Binley et al., 2010; Eggink et al., 2010; van 
Montfort et al., 2011; Shen, Raska, et al., 2014). Mannosylation was associated with DC-SIGN 
binding  (Lin et al., 2003; Montfort et al., 2011), and with DC-SIGN mediated  trans-infection 
of TZM-bl cells, suggesting that the more high mannose residues, the better Env pseudovirus 
bound DC-SIGN and the more it was transferred to TZM-bl cells. The relationship was not 
apparent when MDDCs were used to trans-infect TZM-bl cells, probably because of the 
presence of other receptors on MDDCs which might have contributed to the process of trans-
infection.  
We deleted PNGs identified  to be involved in binding DC-SIGN and PNGs of TF Envs 
enriched with high mannose residues (Hong et al., 2007; Go, Hewawasam, et al., 2011; Liao 
et al., 2011) in two Env clones. We found that deletion of conserved PNGs was deleterious and 
that the effect was Env-specific, with one clone more sensitive to loss of PNGs than the other. 
Due to the loss or significant reduction of function, we were unable to identify PNGs that were 
essential for interaction with DC-SIGN or trans-infection using site-directed mutagenesis. 
Comparing Env phenotype based on the presence or absence of specific PNGs in their 
sequences proved a better approach at identifying potential PNGs essential for Env function.  
We confirmed that N392 was important for entry efficiency by both deletion and sequence 
analysis and N262 (which we identified by SDM) and N392 were important for Env structure 
(François & Balzarini, 2011; Wang et al., 2013; Mathys et al., 2014). Sequence analysis also 
showed that the presence of N356, and N392 were associated with enhanced Env entry 
efficiency, and N356, and lack of N674 for enhanced trans-infection. Moreover, a strong 
positive correlation was found between entry efficiency and trans-infection, supporting the 
rationale that the better the pseudovirus is able to enter TZM-bl cells, the better the trans-
infection. As entry efficiency of Env seemed to play a determining role in trans-infection, we 
normalised Raji-DC-SIGN-mediated trans-infection to direct infection before correlation 
analysis with DC-SIGN binding. Raji-DC-SIGN-mediated trans-infection remained 




al. (2000) of the importance of DC-SIGN in trans-infection (Geijtenbeek, Torensma, et al., 
2000).    
Similar to Shan et al. (2007), this project found that the interaction of gp120 with MDDC- DC-
SIGN induces IL-10 secretion and that levels of IL-10 released varied across Env clones. 
Despite the variation in IL-10 levels between Envs, there was no association with number of 
PNGs or Env mannosylation. This was surprising as PNG number and mannosylation 
correlated with DC-SIGN binding and blocking of DC-SIGN interaction using recombinant 
DC-SIGN protein inhibited MDDC IL-10 secretion. However, it was previously suggested that 
instead of Env mannosylation, differences in Env structure other than its N-glycosylation could 
also influence DC-SIGN-Env interaction (Nabatov et al., 2006) and could influence IL-10 
release. Alternatively, DC-SIGN binds to complex-type N-glycans (Liao et al., 2011) and/or 
N-glycans have to be spaced correctly within Env native structure for binding to DC-SIGN 
(Hong et al., 2007; Liao et al., 2011) in a specific way as to trigger IL-10 release.  
Further sequence analysis based on the presence or absence of specific PNGs identified that 
possession of PNGs at N130 and N332, with the latter forming part of the mannose patch close 
to the V3 loop were significantly more associated with Envs that induced more IL-10 secretion 
than those that did not, suggesting that PNGs at specific sites were important. Go et al. (2011) 
showed that N-glycans at N130 and N332 of subtype C Env were complex- and high mannose-
type, respectively (Go, Hewawasam, et al., 2011; Pritchard, Spencer, et al., 2015) and thus the 
mechanism whereby they might influence Env N-glycan-DC-SIGN binding and MDDC IL-10 
release remains unclear. Interestingly, N332 and other neighbouring PNGs have been found to 
be involved in immune escape in subtype C Envs (Moore et al., 2012; Krumm et al., 2016), 
suggesting that not only will the emergence of this N-glycan facilitate survival in the face of a 
neutralising immune response but could also stimulate the release of IL-10, and potentially 
other pro-inflamamtory cytokines. 
N130 and N332 were found to be marginally more represented in TF Envs (though not 
statistically significant), suggesting a role of these N-glycans in early infection or HIV 
transmission. Moreover, Envs from acute infection tended to induce higher levels of MDDC 
IL-10 release than those isolated at chronic infection. This was contrary to the finding that IL-
10 levels increased over the course of infection. However, cells other than DCs are known to 




to stage of HIV infection (Brockman et al., 2009; Hedrich & Bream, 2010; Saraiva & O’Garra, 
2010; Rutz & Ouyang, 2011). As DCs are most likely the first cells to encounter HIV, TF Envs 
able to induce MDDC IL-10 might be advantageous for sustained survival in the female genital 
tract whereas cells other than DCs are the main producers of IL-10 later in infection.  
Overall, we showed that TF Envs could carry PNGs that are involved in DC-mediated robust 
release of IL-10. Furthermore, as the pattern of secretion of IL-10 and inflammatory cytokines 
were the same, it is possible that their release are stimulated by the same cellular signaling 
pathway.  
We showed that TNF-α, IL-6, IL-8, MIP-1α, and MIP-1β levels were elevated compared to 
unstimulated control, albeit not consistently across all clones. A recent cytokinomic study 
suggested that elevated levels of IL-6 and IL-10 could be prognostic markers of HIV-1 
infection (Williams et al., 2013). When Li et al. (2009) inoculated macaques vaginally with 
SIV, MIP-1α, MIP-1β and IL-8 levels increased and was associated with an influx of CD4+ T 
cells to the site of infection and increased viral replication (Li, Estes, et al., 2009). C7, C12 and 
C14 PSVs were consistently better at stimulating MDDCs to secrete IL-10, IL-6, IL-8, TNF-
MIP-1and MIP-1 although the effect of C14 was not as apparent for all cytokines. 
Interestingly, C7 and C12 are TF Envs suggesting that successful transmission could rely on 
inflammation as previously suggested (Figure 6.1). Further investigation of the impact of Env 
N-glycans on its interaction with DC and resultant cytokine production in a larger cohort could 
provide valuable direction to the design of appropriate N-glycan-containing immunogens.  
In the absence of other predisposing inflammatory conditions there is paucity of HIV 
permissive cells in the genital mucosa. Immediately, after deposition of virus in the genital 
tract, secretion of immune regulators could elicit an inflammatory immune response that 
recruits target cells to the genital mucosa to establish viral replication. A model is therefore 
proposed that the secretion of TNF-α, IL-6, IL-8, MIP-1 α and MIP-1β by DCs after binding 
HIV attracts T cells, DCs and macrophages into the sub-mucosa, lamina propria and epithelium 
where they become infected, and DCs are induced by MIP-1α and MIP-1β to migrate to the 
lymphoid areas where CD4+ T cells are infected in trans. This results in high levels of 
inflammatory cytokines in the genital mucosa and rapid HIV dissemination. At the same time, 
as IL-10 causes immunosuppression of T cells by impairing IL-12 and the development of Th1 
response, it is possible that the host cannot mount an effective cytotoxic immune response, 




and productive clinical infection (Israel et al., 1989; Finnegan et al., 1996; De Jong et al., 2008) 
(Figure 6.1). Unlike systemic inflammation, which could involve multiple cell types, we would 
also like to suggest that when TF Env binds DCs in the female genital mucosa, it results in IL-
10 autocrine deregulation of DC maturation, and signaling. This localised, focused action thus 
















Figure 6.1 Model for HIV-1 deregulation of dendritic cell immune responses. When HIV 
Env binds DC-SIGN it does not culminate in an increase in IL-12 as expected to initiate a Th1 
cytotoxic CD8+ T cell immune response for the clearance of infected cells. Instead it results in 
an increase of TNF-α, IL-10, IL-6, IL-8, MIP-1αand MIP-1β which stimulates the influx of 
immune cells including CD4+ T cells for viral replication and a Th0 and Treg response which 
promotes tolerance and humoral immunity, ineffective against viral infections.   
 
Pathogens that use DC-SIGN have been found to subvert the immune response in DCs for their 
survival (Geijtenbeek et al., 2003; van Kooyk & Geijtenbeek, 2003; Van Kooyk et al., 2004; 
Den Dunnen, Gringhuis & Geijtenbeek, 2009). DC-SIGN has been suggested to modulate TLR 
induced activation of immune responses. Following DC-SIGN binding to Env, Raf-1 
(Gringhuis et al., 2010) and MAPKs such as ERK are activated resulting in the production of 





We showed that interactions of PSV and gp140 with DC-SIGN of MDDCs stimulated 
phosphorylation of ERK and JNK. ERK phosphorylation varied across clones, suggesting that 
activation of ERK-modulated pathways differed according to Env. However, there was no 
relationship between MDDC IL-10 secretion and ERK activation. It is possible that binding of 
Env PAMPs to TLR2 and TLR4 of mDCs induce IL-10 secretion via activation of multiple 
effectors: ERK, NF-KB, TRIF/TRAF3 and MSK1/MSK2 (Saraiva and O’Garra, 2010) so it 
will be difficult to detect a clear association between ERK activation and IL-10 release in 
response to DC-SIGN only. Therefore, to study DC-SIGN-Env mediated cytokine regulation, 
TLR signaling must be inhibited. 
In conclusion, Env interacts with MDDCs via DC-SIGN and those Env with high levels of 
mannosylation bind better to DC-SIGN with enhanced trans-infection efficiency than Envs 
with fewer high mannose residues. Env efficiency was a very important determinant of trans-
infection, supporting recent evidence that viral fitness is very important for variant selection 
during HIV-1 transmission (Carlson et al., 2014). Binding to DC-SIGN and other receptors 
activated MAP kinases, leading to the secretion of IL-10 and other inflammatory cytokines but 
did not increase IL-12 expression. Sequence analysis suggested that PNGs at N130 and N332 
could be important for IL-10 release although these sites were not associated with ERK 
phosphorylation. Overall, we can propose that PSV stimulation of IL-10 and other 
inflammatory cytokines but not IL-12  release  suggests that binding to DC-SIGN is sufficient 
for the deregulation of a Th1 response required for viral clearance and that aberrant signaling 
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Figure A1 Expression of Env clones in the absence and presence of the viral backbone 
(pSG3ΔEnv). A) HEK 293T cells were transfected with Env plasmid DNA (5 µg) and 60 µg of total 
protein was analysed by SDS-PAGE and Western blotting. B) HEK 293T cells producing pseudovirus 
were lysed and 60 µg of total protein was analysed by SDS-PAGE and Western blotting. Anti-gp120 
and anti-actin antibodies were used to detect gp120 and gp160 and the loading control protein β-actin, 
respectively. Env clones C1 – C4, C7, C8 and C12-C16 are indicated. Positions of the bands 
representing gp160, gp120 and actin were calculated using the standard curve of the molecular weight 
marker. The minus sign (-) represents cells transfected with an empty vector and the plus sign (+) 
represents 30 ng of recombinant purified HIV-1 gp120 (IIIB-CHO from the AIDS reagent programme). 
The molecular weight ladder is indicated in kilo-Daltons (KDa). A representative of three independent 



































































Figure A2 DC-SIGN mediated enhancement of trans-infection by Raji-DC-SIGN.  
Following trans-infection of TZM-bl cells using MDDC and Raji-DC-SIGN for capture of PSV at a 
concentration of 100 ng of p24 quantified by p24 ELISA, cell-associated luminescence (RLU) was 
compared between MDDC- and Raji-DC-SIGN-mediated trans-infection to direct infection of TZM-bl 
cells with same amount of PSV but without prior capture. Shown is a representative experiment for 
C12, C13 and C14 where D is direct infection of TZM-vl cells, MDDC refers to MDDC-mediated trans-
infection and DC-SIGN-Ra indicates Raji-DC-SIGN-mediated trans-infection RLU values. pSG3 is the 





                 
Figure A3. Determine the role of CD4 in ERK phosphorylation. Day six MDDCs were 
stimulated (after incubating in serum-free medium O/N) with PSVs (C7, C8 and C9) or Mannan (M) 
for 15 minutes before the cells were lysed and pERK levels were determined by Western blotting using 
phosphor-p44/42 MAPKs and total ERK (ERK1/2)  antibodies (Cell Signaling, Cat#9101/ #9102). C7 
was also pre-incubated with sCD4 (denoted C7+ sCD4) before stimulation to determine the effect of 
CD4 receptor inhibition on pERK levels. Mannan was used as a positive control for the activation of 
ERK via lectin receptors and the negative control (U) represents unstimulated MDDCs. Levels of pERK 
are indicated as the percentage densitometry of total ERK. This experiment represents a single 









Figure A4 Overview of stimulation of MDDCs to secrete IL-10.  PBMCs were isolated from 
whole blood by Ficoll gradient centrifugation and CD14+ cells were isolated by positive selection 
before differentiation by GM-CSF/IL-4 into immature monocyte derived dendritic cells. Cells were 
plated and stimulated with pseudovirus (or gp140) before supernatants were removed and Luminex was 

































Figure A4 Surface staining of monocyte post isolation. Monocytes isolation from PBMC by 
positive selection, were surface stained to verify the purity and yield and to make sure there was not 
lymphocyte contamination.  An aliquot of A) PBMCs, B) CD14- and C) CD14+ fractions were stained 
for expression of surface markers; CD4-PE, CD3-FITC and CD14-PE . A mouse Isotype control 
(IgG2b-PE) for CD14+ was added to exclude cell auto-flurorescence. Each population was sorted for 
forward and site scatter (FSC-A (x axis) and SSC-A (y-axis)) and the lymphocyte population, CD14- 
or CD14+ populations respectively for selected and stained for the CD3+, CD4 and CD14. Upper panel 
is PBMC before positive selection, where the y-axis is CD3-FITC and  x-axis IgG-FITC isotype control, or 
CD4-PE or CD14-PE, middle panel is CD14 negative fraction post positive selection and the lower panel 
is CD14 positive fraction, where the y-axis is CD3-FITC and x-axis is CD4-PE or CD14-PE as indicated  
 
Figure A5. Surface staining for characterisation of differentiated MDDCs prior to 
stimulation. Day six MDDCs were surface stained for maturation marker CD83, co-stimulatory 
marker, CD86 and DC-SIGN (CD209) expression using monoclonal antibodies for these markers and 
acquired using BD Facs Canto II flow cytometry. Flow data was analysed using Flowjo software 
(Treestar, USA) and an example from one donor is shown. Following staining, FSC (y-axis) and SSC-
A (x-axis) scatter, the MDDC population was analysed for the CD209-FITC (y-axis), CD86-Pacific 
blue (x-axis) and CD83-APC (x-axis). Upper panel represent unstained control showing negative for 
DC-SIGN receptor, CD209, while the lower panel represents a sample of MDDC stained which 
shows that DC-SIGN (CD209) was about 73% for this donor with some 23% activation as shown by 




Table A1. Primers used for mutation of potential N-glycan sites by site-directed mutagenesis  
 
Nucleotides mutated for N-Q conversion are in red and restriction enzyme sites introduced by silent sites are 
underlined. 
Reagents (per 
reaction) for PCR 
Volume(µl) 
Buffer (5x)                                          10
dNTPs (10mM)                                   2
DMSO (100%) 1.5 
For Primer (10uM) 2.5 
Rev Primer (10uM) 2.5 
High Fidelity DNA 
Polymerase(5U/µl)   
0.5 















C15 N241Q F 5’C AAT GGA GCA GGA CCG TGC ACT CAA GTC AGC ACA GTA CAA 3’ 
R 5’ TTG TAC TGT GCT GAC TTG AGT GCA CGG TCC TGC TCC ATT G 3’ 
AlW44I 
 N262Q F 5’  ACT CAA CTA CTG TTA CAA GGT AGC TTA GCA GAA GAG GAT A 3’ 






 N448Q F 5’ATA ACA TGT AAA TCA CAA ATC ACC GGA TTG CTC TTG ACA 3’ 
R 5’TGT CAA GAG CAA TCC GGT GAT TTG TGA TTT ACA TGT TAT 3’ 
BsaWI 
C16 N241Q F 5’  C AAT GGA ACA GGA CCG TGC ACT CAA GTC AGC ACA GTA CAA 3’ 
R 5’  TTG TAC TGT GCT GAC TTG AGT GCA CGG TCC TGT TCC ATT G 3’ 
ApaLI 
 N262Q F 5’ ACT CAA CTA CTG TTA CAA GGT AGC TTA GCA GAA GAG GAT A 3’ 





 N448Q  F 5’  ATA ACA TGT CAA TCA CAA ATC ACC GGA TTG CTC TTG ACA 3’ 






Appendix II  
 
Preparation of MACs beads (130-050-201, Miltenyi Biotec, USA) 
 It is essential to wash beads before use to remove Sodium Azide. This helps improve 
cell viability. 
 Mount an LS column (130-042-401, Miltenyi biotec) on a MidiMACS Separator (130-
042-302, Miltenyi biotec) (magnet) place on its Multi stand (130-042-303. Miltenyi 
biotec) as recommended by the manufacturer after taking out the plunger. 
 Prepare LS column by pre-wetting with 3 ml of cold (stored at 4oC) MACS buffer.  
 Beads are gently re-suspended and the entire volume transferred using a plugged 2 ml 
pipette into the column (it is advisable to take note of the exact volume, about 2 -2.2 
ml) to avoid losses following elution. 
 Add resuspended beads to column and allow buffer to flow through the column. 
 Rinse out original vial of beads with 3 mL wash buffer (MACs buffer) and add to the 
column. 
 Washes 3x with 3 ml wash buffer with each wash allowed to go through the column 
completely before the next volume is added. 
 Column is removed from the magnet and positioned over a 15 ml conical tube at least 
5 cm away from the magnet. MACs buffer is added to the column (100µl less than the 
original volume of beads) and liquid is forced through the column with a plunger. 
 1 ml aliquots of cells are made in 1.5 mls flat-bottom Eppendorf tubes, labelled with 
date and expiry date and stored at 4oC wrapped in aluminium foil to protect from light. 
 
MACs buffer 
1x PBS (10010049, Gibco) 
1 % Human serum AB (Sigma Cat # H1513) 
0.5 M EDTA 
This is pH to 7.2 -7.4, then filtered through a 0.22µm filter and stored at 4oC. Aliquots should 
be used within three months. 
 
 




1 mg/mL stock is made by injecting sterile TC grade dH20 into the vial using a sterile syringe and 
needle 
The 1 mg/ml stock has an activity of 15 x 106 IU/ml (international Units) 
Aliquots of 33µl are made and stored frozen at -20oC 
Working stocks of 5 x 105 U/ml are made by adding 967 µl of 0.1 % human serum albumin (HAS) in 
PBS. Working stock can be stored at 4oC. 2µl of this working stock can be added to 1 mL (dilution of 
1:500) of MDDC culture medium to get a final 1000 U/ml, which gives 60ng/ml. 
IL-4 (BioSource, PHC045), 100mg 
725 µl of PBS (-Ca2, -Mg2) containing 0.1 % HAS is added to the entire volume (100mg) to give an 
activity of 1 x 106 IU/ml. Aliquots of 25 µl each are made and stored at -20oC. Once each aliquot is 
thawed, it is stored at 4oC and used at 1 in 104 dilutions with differentiation medium (see material and 
methods) an activity of 100 U/ml or concentration of 30 ng/ml. 
 
